5’-Proximal cis-Acting RNA Signals for Coronavirus Genome Replication by Guan, Bo-Jhih
University of Tennessee, Knoxville
Trace: Tennessee Research and Creative
Exchange
Doctoral Dissertations Graduate School
8-2010
5’-Proximal cis-Acting RNA Signals for
Coronavirus Genome Replication
Bo-Jhih Guan
Microbiology, bguan1@utk.edu
This Dissertation is brought to you for free and open access by the Graduate School at Trace: Tennessee Research and Creative Exchange. It has been
accepted for inclusion in Doctoral Dissertations by an authorized administrator of Trace: Tennessee Research and Creative Exchange. For more
information, please contact trace@utk.edu.
Recommended Citation
Guan, Bo-Jhih, "5’-Proximal cis-Acting RNA Signals for Coronavirus Genome Replication. " PhD diss., University of Tennessee, 2010.
https://trace.tennessee.edu/utk_graddiss/802
To the Graduate Council:
I am submitting herewith a dissertation written by Bo-Jhih Guan entitled "5’-Proximal cis-Acting RNA
Signals for Coronavirus Genome Replication." I have examined the final electronic copy of this
dissertation for form and content and recommend that it be accepted in partial fulfillment of the
requirements for the degree of Doctor of Philosophy, with a major in Microbiology.
David A. Brian, Major Professor
We have read this dissertation and recommend its acceptance:
Chunlei Su, Gladys Alexandre, Albrecht von Arnim
Accepted for the Council:
Dixie L. Thompson
Vice Provost and Dean of the Graduate School
(Original signatures are on file with official student records.)
To the Graduate Council: 
 
I am submitting herewith a dissertation written by Bo-Jhih Guan entitled “5’-Proximal 
cis-Acting RNA Signals for Coronavirus Genome Replication.”  I have examined the final 
electronic copy of this dissertation for form and content and recommend that it be accepted 
in partial fulfillment of the requirements for the degree of Doctor of Philosophy, with a 
major in Microbiology. 
 
         David A. Brian, Major Professor 
 
We have read this dissertation 
and recommend its acceptance: 
 
 
Chunlei Su 
 
 
Gladys Alexandre 
 
 
Albrecht von Arnim 
 
         Accepted for the Council: 
                   
         Carolyn R. Hodges 
         Vice Provost and Dean of the Graduate School 
 
 
 
(Original signatures are on file with official student records.)
5’-Proximal cis-Acting RNA Signals for Coronavirus Genome Replication 
 
 
 
 
 
 
 
 
 
 
A Dissertation 
Presented for the 
Doctor of Philosophy 
Degree 
The University of Tennessee, Knoxville 
 
 
 
 
 
 
 
 
 
 
 
Bo-Jhih Guan 
August 2010 
 
  
 
 
 
 
 
 
 
 
 
 
 
Copyright © 2010 by Bo-Jhih Guan 
All rights reserved. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ii
ACKNOWLEDGEMENTS 
     I am heartily thankful to my major professor, Dr. David A. Brian, for his guidance, 
support, and encouragement from the initial to the final level enabled me to develop an 
understanding of the subject.  It is a great honor and pleasure doing research under Dr. 
Brian’s mentoring and supervision. 
     I am grateful to my committee members, Dr. Chunlei Su, Dr. Gladys Alexandre, and 
Dr. Albrecht von Arnim, for their enthusiasm, discussion, and inspiration.  I would also 
like to make a special reference to Dr. Ralph S. Baric who is a professor of the University of 
North Carolina.  Without his kindness I could not have gotten such relevant data. 
     In addition, this dissertation would not have been possible without the help of the 
current and past Brian lab’s colleagues, Kimberley Nixon, Kortney Gustin, Hung-Yi Wu, 
Yu-Pin Su, Yi-Hsin Fan, Agnieszka Dziduszko, and Tara Tucker.  I would like to show my 
gratitude to all their advices and friendships. 
     Lastly, I offer my regards and blessings to all of those who supported me in any 
respect during the completion of the dissertation research.  Thank you. 
 
 iii
ABSTRACT 
     RNA sequences and higher-order structures in the 5’ and 3’ untranslated regions 
(UTRs) of positive-strand RNA viruses are known to function as cis-acting elements for 
translation, replication, and transcription.  In coronaviruses, these are best characterized in 
the group 2a bovine coronavirus (BCoV) and mouse hepatitis virus (MHV), yet their precise 
mechanistic features are largely undefined.  Here, we use a reverse genetics system in 
MHV to exploit the ~30% nt sequence divergence between BCoV and MHV to establish 
structure/function relationships of 5’ UTR cis-replication elements.  It had been previously 
shown that a precise replacement of the 391-nt MHV 3’ UTR with the 288-nt BCoV 3’ UTR 
yields wt-like MHV.  Our attempts to replace the 209-nt MHV 5’ UTR with the 210-nt 
BCoV 5’ UTR, however, yielded a non-viable chimera.  Therefore, a systematic analysis of 
individual 5’-terminal structures was made to identify compatible elements.  By placing 
each of four putative cis-acting domains from the BCoV 5’ UTR into the MHV genome, we 
learned that (i) stem-loops (SLs) I & II and SLIII are functionally compatible, (ii) SLIV is 
compatible if it spans parts of the 5’ UTR and the nonstructural protein 1 (nsp1) cistron, 
thus identifying this part of ORF 1 as a component of the cis-replication signal, (iii) a 
relatively unstructured 32-nt region mapping between SLIII and SLIV defines a novel virus 
species-specific cis-replication element, (iv) spontaneous suppressor mutations within MHV 
SLI and nsp1 cistron compensated for growth defects arising from the BCoV 32-nt element 
in the MHV genome, (v) cross talk between the 32-nt element, SLI, and the nsp1 cistron 
appears essential for virus replication, (vi) the BCoV 5’ UTR and nsp1 cistron function 
together in the MHV genome to generate a wt-like MHV phenotype, and (vii) a functional 
5’ UTR-nsp1 domain in group 2a coronaviruses cannot be substituted by the corresponding 
genomic element from the group 2b SARS-CoV.  We postulate that the interaction between 
the 5’ UTR and nsp1 cistron (or possibly nsp1 protein) functions as a molecular switch 
between genome translation and ignition of negative-strand RNA synthesis. 
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CHAPTER I.  LITERATURE REVIEW 
 
BACKGROUND 
     What are coronaviruses?  Coronaviruses are a genus of animal viruses within the 
Coronaviridae, a family grouped with Roniviridae and Arteriviridae to form the Nidovirales 
order (22).  Coronaviruses infect primarily the respiratory and enteric tracts of numerous 
animal species, including humans, often causing clinically significant acute respiratory and 
gastrointestinal diseases.  Infections can be systemic or localized and can occasionally 
cause hepatitis, cardiovascular disease, or neurological illness (Table 1.1.) (118).  In 
human medicine it has been known since the 1960’s that coronaviruses cause ~10-20% of 
common colds and were not considered serious human pathogens until the outbreak of 
severe acute respiratory syndrome (SARS) in 2002-2003 which was a coronavirus infection 
characterized by a rapid spread and ~10% mortality rate.  Two new human coronaviruses 
associated with severe pneumonia in children, human coronavirus NL63 (HCoV-NL63) and 
coronavirus HKU1 (HCoV-HKU1), have also recently been found (29, 79).  In veterinary 
medicine, coronavirus infections in domestic animals are of major economic importance 
since mortality rates can reach 100% in newborns and weanlings.  Thus, coronaviruses are 
currently considered important viral pathogens in both human and veterinary medicine (75, 
116). 
     The Coronavirus Family.  Before 2003, coronaviruses were classified as three 
groups, 1, 2, and 3, based on serologic relationships.  Groups 1 and 2 comprised all 
mammalian coronaviruses and group 3 comprised the avian coronavirus (Table 1.1.) (52).  
In 2003 the sequences of only 10 complete genomes were known.  Since the discovery of 
the SARS coronavirus (SARS-CoV) a burst of research has taken place world-wide and 
many new coronaviruses from different species have been discovered and their genomes 
sequenced.  Currently, 26 complete genomes have led to a newly proposed sub- 
classification in each group based on the phylogenetic clustering of nucleotide sequences 
and genome organization (Table 1.1.) (52, 119, 164).  Group 1 coronavirus have been 
divided into subgroups 1a and 1b where the transmissible gastroenteritis virus (TGEV) and 
human enteric coronavirus strain 229E (HCoV-229E) respectively serve as prototypes.   
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  TABLE 1.1.  Representative coronavirus species and groups 
Group 
 
Designation Species Hosta Disease Cellular  receptor 
GenBank 
accession 
numberb 
TGEV Transmissible gastroenteritis virus Pig Gastroenteritis APN NC_002306 
FCoV Feline enteric coronavirus Cat Enteritis APN Y13921 
FIPV Feline infectious peritonitis virus Cat 
Enteritis, 
peritonitis APN AY994055 
CCoV Canine coronavirus Dog Enteritis APN D13096 
1a 
BtCoV＊ Bat coronavirus Bat Unknown Unknown NC_010437 
HCoV-229E Human enteric coronavirus strain 229E Human Nasopharyngitis APN NC_002645 
HCoV-NL63 Human coronavirus strain NL63 Human Pneumonia ACE2 NC_005831 
Group 
1 
1b 
PEDV Porcine epidemic diarrhea virus Pig Enteritis Unknown NC_003436 
MHV Mouse hepatitis virus Mouse Hepatitis, encephalitis CEACAM 1 NC_001846 
BCoV Bovine coronavirus Cow Enteritis 9-O-acetylated sialic acid U00735 
ECoV Equine coronavirus Horse Enteritis, diarrhea 
9-O-acetylated 
sialic acid NC_010327 
PHEV Porcine hemagglutinating encephalomyelitis virus Pig Encephalitis Unknown NC_007732 
Antelope 
CoV Sable antelope coronavirus 
Sable 
antelope Unknown 
9-O-acetylated 
sialic acid EF424621 
Calf-Giraffe 
CoV Calf-giraffe coronavirus Giraffe Unknown 
9-O-acetylated 
sialic acid EF424624 
CRCoV Canine respiratory coronavirus Dog Pneumonia Unknown CQ772298 
HCoV-OC43 Human coronavirus strain OC43 Human Nasopharyngitis 
9-O-acetylated 
sialic acid NC_005147 
HCoV-HKU1 Human coronavirus strain HKU1 Human Pneumonia Unknown NC_006577 
2a 
HECoV-4408 Human enteric coronavirus strain 4408 Human Enteritis Unknown FJ415324 
SARS-CoV Severe acute respiratory syndrome coronavirus Human Pneumonia ACE2 NC_004718 2b 
BtCoV＊ Bat coronavirus Bat Unknown Unknown NC_009696 
2c BtCoV＊ Bat coronavirus Bat Unknown Unknown NC_008315 
Group 
2 
2d BtCoV＊ Bat coronavirus Bat Unknown Unknown NC_009021 
IBV Infectious bronchitis virus Chicken Pneumonia Unknown NC_001451 
PhCoV Pheasant coronavirus Pheasant Pneumonia Unknown AJ618988 3a 
TCoV Turkey coronavirus Turkey Gastroenteritis Unknown AY342357 
3b SW1 Beluga whale coronavirus Whale Unknown Unknown NC_010646 
BuCoV Bulbul coronavirus Bulbul Unknown Unknown NC_011548 
ThCoV Thrush coronavirus Thrush Unknown Unknown NC_011549 
Group 
3 
3c 
MuCoV Munia coronavrius Munia Unknown Unknown NC_011550 
 
a Host denotes animals from which virus was first isolated. 
b One representative GenBank accession number is given for each species.  When available, a complete   
  genomic sequence is given. 
＊More than 60 bat coronavirus species have been identified and tentatively classified as members of group 1   
  or group 2.   
Abbreviations: APN, aminopeptidase N; ACE2, angiotensin-converting enzyme 2;  
            CEACAM 1, carcinoembryonic antigen adhesion molecule 1. 
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The best established sub-classification lies in group 2 coronaviruses where group 2a is 
considered to be one lineage harboring genes of hemagglutinin-esterase (HE) and two 
papain-like proteases (PL1pro and PL2pro) (164).  Two of the most extensively studied 
coronaviruses, mouse hepatitis virus (MHV) and bovine coronavirus (BCoV), belong 
to the group 2a and will be the focus of this dissertation.  The human SARS-CoV and 
other SARS-CoV-like viruses isolated from civets and bats are most likely an early split-off 
from the group 2a, and were classified as group 2b coronaviruses (140).  Group 2c and 2d 
are two additional subgroups of group 2 coronaviruses isolated from different genera of bats.  
Infectious bronchitis virus (IBV) and other avian coronaviruses comprise the group 3a and 
3c coronaviruses whereas the first non-avian coronavirus isolated from beluga whale is 
classified into group 3b (104, 165). 
     The striking diversity in species is one of the significant features of the coronavirus 
genus.  Most individual coronavirus species naturally infect only one or a few closely- 
related animal species due to receptor specificity or compatibility within another replication 
feature.  However, as the result of currently incompletely-understood attributes of the 
coronavirus RNA-dependent RNA polymerase (RdRp), an unusual mechanism of template 
switching during RNA synthesis (described below) occurs during coronavirus RNA 
replication and transcription such that homologous and heterologous recombination takes 
place at high rates leading to coronaviral diversity (39, 76, 115).  For the ~27-32 kilobase 
(kb) coronaviral genome, the largest known among all RNA viruses, the recombination rate 
has been measured at ~25% across the genome among all progeny of a double infection (8).  
Accordingly, it is tempting to propose that bats and birds are gene pools for coronavirus 
recombination in their respective viral subgroups (164).  The fact that bats and birds 
display species diversity, are able to fly long distances, are adaptable to a wide variety of 
environments, and roost and flock together probably promotes virus recombination and 
spreading to different hosts (160, 164).  Interspecies jumping and rapid adaptation by 
naturally-occurring recombinant coronaviruses could explain the observation that closely 
related coronaviruses were found from distantly related host species and thus may have 
been the cause of the disastrous SARS-CoV outbreak (166). 
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     Coronavirus Virion Morphology.  Coronavirus virions are spherical particles of 
medium size (80-120 nm diameters) with an endoplasmic reticulum (ER)-derived 
membrane envelope containing characteristic glycoprotein spike structures (peplomers).  
The spikes serve as the attachment protein for cell entry and cause the negatively-stained 
virus to appear to have a crown resembling the solar corona, hence the name coronavirus 
(Fig. 1.1. A) (77).  All coronaviruses possess four structural proteins: a spike glycoprotein 
(S), a small envelope glycoprotein (E), a membrane glycoprotein (M), and a nucleocapsid 
phosphoprotein (N).  The S, E, and M proteins are anchored in the viral envelope as 
transmembrane proteins.  The group 2a coronaviruses (e.g., all BCoV strains and some 
MHV strains) contain an additional shorter glycoprotein spike, HE, that, curiously, may 
have originated from the HE protein of the type C human influenza virus (72, 171).  The S 
protein is a large (150-200 kDa) transmembrane glycoprotein that assembles into trimers 
and projects 12-20 nm from the virion surface.  S mediates receptor attachment as well as 
viral-host cell membrane fusion (38).  M is a triple-spanning membrane glycoprotein and 
the most abundant of the envelope glycoprotein.  M together with the small, minor 
component E glycoprotein, determines the shape of virion (178).  N is a phosphorylated 
RNA-binding protein mainly responsible for the formation of the nucleocapsid.  N inside 
the cell also has a regulatory nonstructural function leading to an enhancement of viral 
genome replication.  While it is still being debated, a consensus seems to be emerging that 
coronaviruses have a helical rather than an icosahedral nucleocapsid structure inside the 
virion (126). 
     Coronavirus Life Cycle.  Coronavirus replication takes place exclusively within the 
cytoplasm (Fig. 1.1. B) (11, 97).  Most coronaviruses naturally infect epithelial cells of the 
respiratory or enteric tracts.  Viral infections are initiated by the binding of viral S proteins 
to specific cellular receptors (Table 1.1.) which triggers a major conformational change in 
the S molecule.  Changes in S protein structure following its attachment lead to entry of 
the viral nucleocapsid into the cytoplasm.  For MHV, entry is via virus-cell membrane 
fusion (147) whereas for the SARS-CoV, entry appears to be by receptor-mediated 
endocytosis (139).  After nucleocapsid entry the positive-strand viral RNA genome is 
released into the cytoplasm where the first open reading frame (ORF 1) is immediately  
 4
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FIG. 1.1.  Schematic depiction of coronavirus particle and life cycle.  (A)  A model of coronavirus 
particle (left) along with an electron-microscopic image of human SARS-CoV (right).  The coronavirus 
particle, called a virion, is organized with the spike (S), membrane (M), and envelope (E) glycoproteins.  The 
single-stranded positive-sense viral RNA genome is packaged into helical capsid with nucleocapsid (N) 
proteins.  (B)  Summary of the coronavirus life cycle as depicted in a review by Bergmann and colleagues 
(11).  The entire replication process takes place in the cytoplasm.  After attachment to the specific receptor, 
e. g., the CEACAM-1 molecule for MHV, the coronavirus enters host cells by membrane fusion or 
receptor-mediated endocytosis.  The positive-strand RNA genome is unpackaged and directly translated to 
make the replicase/transcriptase proteins.  The genome and replication/transcription complexes are located in 
a poorly understood membranous compartment where viral genome replication and transcription occur.  
After transcription, the nascent subgenomic mRNAs are transported to the cytoplasm or the endoplasmic 
reticulum (ER) where they are translated into structural (S, E, M, N) and accessory proteins (also called 
non-structural proteins or NSPs).  Genomic RNA is packaged by N protein and which later becomes 
assembled with structural proteins into a virion by budding into the ER or early Golgi compartments.  The 
mature virion then exits the cell via the exocytic pathway and is released. 
translated and processed into ~16 replicase/transcriptase proteins.  These include two kinds 
of proteases, an RdRp, a helicase, an exonuclease, an endonuclease, an N-methyltransferase, 
and a 2’-O-methyltransferase (described below).  The replicase/transcriptase proteins 
function for the synthesis of progeny genome (replication) and a 3’-coterminal set of 
subgenomic mRNAs (sgmRNAs) (transcription) (details described below).  Viral RNA 
synthesis are thought to occur on or within the cytoplasmic surface of double membrane 
vesicles derived from ER (73, 74, 141).  The sgmRNAs are translated into structural 
proteins or accessory proteins some of which are important pathogenic factors.  The newly 
synthesized genomes along with newly made structural proteins come together at the ER- 
Golgi intermediate compartment (ERGIC) where nucleocapsid formation (encapsidation) 
and virion assembly (packaging) occur by budding into the ERGIC (98).  Glycoprotein S, 
M and E are made by membrane translocation and are glycosylated within the lumen of the 
ER.  Encapsidation selectively incorporates only genomic RNA into nucleocapsid 
structures by means of unique packaging signals (95, 112).  Virion assembly is carried out 
through cooperative interactions among structural proteins, particularly the M and E (13, 
159).  Finally, the mature virions are transported to the plasma membrane in vesicles via 
exocytosis.  For some coronaviruses, such as MHV, a fraction of S protein incorporated 
into the ER at the time of synthesis is not packaged into virions but rather is carried to the 
plasma membrane where it protrudes from the cell surface and interacts with receptors of 
adjacent cells to cause cell fusion.  This gives rise to the formation of large, multinucleate 
syncytia (described in Chapter II, III, and IV).  Inactivated virus added externally to cells 
in culture can also cause cell fusion and syncytia formation (45). 
     Coronavirus Genome Organization and Gene Expression.  The coronavirus genome 
is a single-stranded, positive-sense RNA ranging from 27 to 32 kb in length that is 5’ capped 
and 3’ polyadenylated (Fig. 1.2).  Its coding region is flanked by terminal untranslated 
regions (UTRs) (77, 97).  The genomes of coronaviruses are structurally polycistronic 
containing 8~14 ORFs.  Gene 1, the 5’-most ORF, is functionally polycistronic as well 
(described below), but the remaining ORFs are functionally monocistronic since (in most 
cases) only the 5’-terminal ORF on each sgmRNA is translated.  Translation of genomic 
and subgenomic RNAs is presumably by a cap-dependent mechanism (77, 78).  When  
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FIG. 1.2.  Organization and gene expression of the MHV genome.  Adapted and modified from Sawicki 
and colleagues (130).  The organization of 31.3-kb MHV-A59 genome is shown at the top.  On the left, the 
positive-strand genomic RNA (gRNA) serves as a template for translation during which polyproteins (pp) 1a 
and 1ab are made from a single open reading frame 1 (ORF 1) as a result of a -1 programmed framshifting at 
the ORF 1a/1b junction.  The pp1a and pp1ab undergo proteolytic autoprocessing into 16 nonstructural 
proteins (nsps) with a number of confirmed and putative functional domains as depicted.  On the right, the 
gRNA also functions as a template for subgenomic mRNA (sgmRNA) transcription.  The structural 
relationship between genome and subgenomic mRNAs is shown.  A nested set of 3’ co-terminal sgmRNAs 
are synthesized by transcription, and then each sgmRNA is usually translated to produce only the protein 
encoded by the 5’ most open reading frame on the sgmRNA.  All of the structural proteins and accessory 
proteins are made by translation of the subgenomic mRNA.  Open box representing the translated ORF in 
each sgmRNA is denoted in gray.  Open circles at the 5’ termini of the gRNA and sgmRNAs identifies the 5’ 
methylated the cap structure.  PL1, papain-like proteinase 1; PL2, papain-like proteinase 2; 3CL, 3C-like 
proteinase; RdRp, RNA-dependent RNA polymerase; HEL, helicase; ExoN, 3’Æ5’ exoribonuclease; NeU, 
uridylate-specific endoribonuclease; MT, ribose-2’-O-methyltransferase; HE, hemagglutinin-esterase 
glycoprotein; S, spike glycoprotein; E, small envelope protein, M, membrane glycoprotein; N, nucleocapsid 
phosphoprotein. 
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genomic RNA is translated directly, the ORF comprising the 5’-proximal two-thirds of the 
genome is translated to make two polyproteins.  The first polyprotein (pp1a, ~500 kD) is 
translated from ORF 1a.  The second polyprotein (pp1ab, ~800 kD) is translated from ORF 
1ab by a mechanism of programmed ribosomal frameshifting at the ORF 1a/1b junction 
(108).  The pp1a and pp1ab are cotranslationally and/or posttranslationally processed by 
two or three internal-encoded viral proteases into 15~16 nonstructural proteins (nsps) that 
together make up the replicase/transcriptase (42, 54, 130).  The major structural proteins, S, 
E, M, and N, and several accessory proteins are translated from the 3’-proximal one-third of 
the genome by way of individually expressed sgmRNAs (115).   
     The nsps generated by translation of ORF 1 on genomic RNA are usually referred to 
as replicase/transcriptase proteins in recognition of their roles in viral RNA synthesis (Fig. 
1.2).  Both the precise arrangement of the nsps among themselves and with host factors to 
form the membrane-bound replication/transcription complexes (RTC), and the mechanisms 
by which the complexes lead to specific RNA synthesis, are currently unknown or poorly 
understood (16, 141, 158).  The recently developed reverse genetics systems for 
coronaviruses (described below) and the occurrence of the SARS-CoV epidemic have 
stimulated research that has begun to characterize the structural features and enzyme 
activities of many of the ORF 1 proteins.  In general, it is postulated that the products of 
pp1a (nsp1-11) function both to prepare a favorable cellular environment for viral 
replication and to assemble the RNA synthesizing machinery for carrying out the enzyme 
activities required for RNA synthesis (Fig. 1.2) (97).  Specifically, currently documented 
functional activities include suppression of host gene expression and cell cycle progression 
(nsp1) (26, 69, 70), protease activity (nsp3 and nsp5) (7, 91), anchoring transmembrane 
domains (nsp3, nsp4, and nsp6) (12, 137, 156), protein-protein interactions in complex 
assembly (nsp7 and nsp8) (120, 180), a putative RNA primase (nsp8) (66), single-stranded 
RNA (ssRNA) binding proteins of unknown function (nsp9 and nsp10) (41, 148), 
primer-dependent RdRp activity (nsp12) (152), 5’Æ3’ helicase activity (nsp13) (135), 
3’Æ5’ exoribonuclease and N7- methyl- transferase activity (nsp14) (28, 105), 
endoribonuclease activity (nsp15) (67), and a 2’-O-methyltransferase (nsp16) (34). 
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     Coronavirus RNA Synthesis.  The coronavirus RNA synthesis includes genome 
replication and transcription of sgmRNAs (Fig. 1.3).  By using the positive-strand viral 
genome as a template, both replication and transcription begin with the synthesis of 
negative-strand RNAs, which in turn serve as templates for the amplification of positive- 
strand virus genomes and subgenomes.  The mechanism of initiation of negative-strand 
and positive-strand syntheses for genomic and subgenomic mRNAs is presumably the same 
or very similar for both.  In addition, the ignition process possibly requires 5’-3’-end 
cross-talking that is guided by interactions between the distant segments of the genome, 
which may involve specific RNA signals and functional RTC (64, 77, 85, 185).  The major 
difference between replication and transcription is that during negative-strand synthesis to 
make the viral antigenome, RNA synthesis from the genomic RNA template continues for 
the full length of the template, whereas the RNA synthesis is discontinuous while making 
the viral anti-subgenomes (Fig. 1.3) (128, 129).  The discontinuous step is triggered by 
transcription regulating sequences (TRS) whereby the RdRp undergoes a template switch to 
a spot near the 5’ end of the genome where transcription continues on the leader sequence of 
the genome.  The TRS, including a core consensus (which is 5’-AAUCUAAAC-3’ for 
both BCoV and MHV) and nearby flanking sequences, are quite conserved within each 
coronavirus group.  The synthesis of negative-strand RNAs is initiated and elongated, 
along with consecutive events of scanning, reading through, and template switching, which 
requires interactions between TRS in the leader and TRSs in the body ahead of each ORF.  
Accordingly, continuous and discontinuous RNA syntheses occur and generate genome- 
length and a series of smaller, subgenome-length negative-strand RNAs, respectively (115, 
130).  The negative-strand RNAs all possess elements that are complementary to 
counterparts on the genome, i.e., a 5’ poly(U) tract and a 3’ anti-leader.  The complete 
negative-strand RNAs, probably in association with their positive-strand counterparts as 
double-stranded structures, then serve as templates for positive-strand RNA synthesis.  The 
positive-sense sgmRNAs are amplified to a level approximately ten to one hundred times as 
abundant as their negative-sense counterparts (60, 134).  Collectively, a 3’-coterminal 
nested set of six to nine sgmRNAs are made of which each sgmRNA contains an identical 
5’ leader sequence (65~93 nt, depending on viruses) derived from the 5’ end of the genome. 
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FIG. 1.3.  Model for coronavirus RNA synthesis.  Adapted and modified from Paul S. Masters (97).  
Using MHV as an example, the replication and transcription of coronaviruses are shown.  The positive-strand 
(solid line) genome serves as a template to be copied continuously or discontinuously into genome-length and 
subgenome-length negative-strand (broken line) RNAs, respectively.  The inset shows details of the 
arrangement of leader and body copies of the transcription regulating sequences (TRS).  The initiation for 
template switching possibly arises from the base-pairing between leader TRS and body TRSs, by which 
leading to the 3’-coterminal nested set of negative-strand subgenomic mRNAs.  Subsequently, the 
corresponding negative-strand RNAs are used as templates for synthesis of the progeny positive-sense genome 
(replication) and positive-sense subgenomic mRNAs (transcription). 
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     Cis-acting RNA elements in coronavirus defective interfering RNA replication.  
Viral cis-acting RNA replication elements are unique signals in the form of primary 
sequences or higher-order structures that lead to the replication of the viral genome (15).  
In coronaviruses, defective interfering RNAs (DI RNAs) have been used for over two 
decades to define the cis-acting elements specific for their replication.  Because DI RNAs 
are extensively deleted variants of the viral genome and are only able to replicate as 
molecular parasites in the presence of the RNA synthesizing machinery of helper viruses, 
they are used to identify the cis-replication elements which are postulated to function 
similarly in the virus genome.  By using DI RNAs as working molecules for identifying 
cis- replication elements, there can be a clear distinction from trans-acting factors that 
might be affected by any RNA structure mutations in analysis of the complete genome.  In 
DI RNA replication analyses, the required trans-acting elements are provided by the helper 
virus.  Naturally occurring and artificially constructed DI RNAs have been discovered and 
manipulated from all three groups of coronaviruses, and in most cases, the DI RNAs contain 
the entire terminal UTRs and a portion of the 5’ end of replicase 1a ORF (24, 92, 94, 103, 
117).  For BCoV, a naturally occurring 2.13 kb DI RNA has been cloned, modified, and 
studied by our laboratory for the identification and characterization of cis-acting replication 
elements (Fig. 1.4) (23-25).  The BCoV DI RNA is composed of the 5’ UTR of the viral 
genome, a contiguous ORF harboring the first 288 nt of the nsp1 gene, the intact N gene, 
and the whole genomic 3’ UTR plus a 68-nt poly(A) tail (24).  By using the BCoV DI 
RNA as a working molecule, along with closely related MHV DI RNAs, cis-acting 
replication signals have been best defined in the group 2a coronaviruses (Fig. 1.4). 
     To date, nine cis-replication elements have been identified for the replication of group 
2a coronaviruses.  Of these, three are in the 5’ UTR, two are in the nsp1 gene, and four are 
in the 3’ UTR (Fig. 1.4).  These are each described as follows:  (i) The BCoV 5’-terminal 
90-nt harboring stem-loop I (SLI) (nt 5-54) and SLII (nt 55-80).  These were demonstrated 
to be important as a primary sequence and/or structure for BCoV DI RNA replication (24, 
25).  Recently, the SLI region in MHV (homologous to that in BCoV) has been reanalyzed 
and is now described as being comprised of SL1 and SL2, of which SL1 was shown to be 
structurally labile for putative 5’ UTR-3’ UTR interaction in MHV replication and SL2 was  
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FIG. 1.4.  Structure of the BCoV DI RNA and some of the observations that led to this research.  
Shown below the genome is the structure of BCoV DI RNA relative to the BCoV genome.  Open boxes 
represent open reading frames (ORFs).  The solid line denotes the 5’ and 3’ untranslated regions (UTRs) 
where the common leader RNA sequence at the 5’ terminal is indicated by a hatched pattern.  Base 499 of the 
DI RNA is the first base in the ORF of N which forms a contiguous ORF with the 288 nucleotide (nt) of the 
nonstructural protein 1 (nsp1) gene.  Also shown are the 5’-proximal 421-nt region that provides cis-acting 
replication signals for the DI RNA, a sequence that differentiates the DI RNA molecule from the shortest 
subgenomic mRNA (sgmRNA 7).  Shown above the genome is a schematic depiction of current model for 
the cis-replication higher-order RNA structures postulated in the 5’ and 3’ UTRs.  Four stem-loops (I, II, III, 
and IV) are found in the 5’ UTR.  Two stem-loops (V and VI) map within the nsp1 coding region.  A bulged 
stem-loop (BSL) with overlapping pseudoknot (PK) and a hypervariable region (HVR) are demonstrated in 
the 3’ UTR.  Solid circles in the 5’ UTR indicate the AUG start codon of ORF 1 whose coding sequence is 
indicated by a thickened line.  The stop codon for the N-gene preceding the 3’ UTR is boxed.  All nt 
numbering is from the first base at the 5’ and 3’ end of the genome, respectively. 
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proposed to be a uYNMG(U)a-like tetraloop structure critical for stimulating sgmRNA 
negative-strand synthesis (83, 87, 88).  These same structures are predicted in the BCoV 
genome.  (ii) SLIII (nt 97-116).  SLIII has associated with it an internal translation start 
codon for a short intra-5’ UTR ORF (8 aa in BCoV) of unknown function.  Both SLIII and 
the short upstream ORF (uORF) are phylogenetically conserved structures in group 2a and 
possibly all coronaviruses (122).  (iii) SLIV (nt 186-215).  SLIV is located immediately 
upstream of the coding region of ORF 1, holds the start codon for genome translation, and 
appears to be conserved only within the group 2a coronaviruses (123).  (iv) SLV (nt 239- 
310) and (v) SLVI (nt 311-340).  SLV and SLVI map within the nsp1 coding region and 
both function as higher-order cis-acting signals for replication of BCoV DI RNA (19, 55).  
(vi) A bulged stem-loop (BSL) at the 5’ end of the 3’ UTR.  The BSL maps just 
downstream from the stop codon of the N gene.  It partially overlaps with an adjacent 
hairpin pseudoknot.  (vii) Hairpin-like RNA pseudoknot (PK).  The BSL and PK are 
shown to be mutually exclusive since they share a sequence and cannot simultaneously exist.  
Both structures, however, are required for the replication of group 2a DI RNAs and the 
MHV genome which has led to the idea of that they function together as a molecular switch 
modulating some features of RNA synthesis.  These two structures appear to be conserved 
in group 2a and group 2b coronaviruses (49, 51, 61-63, 163).  (viii) A complex octamer- 
associated BSL at the 3’ end of the 3’ UTR.  This BSL is poorly conserved in both 
sequence and secondary structure among closely related coronaviruses such as BCoV and 
MHV.  While this structure is viewed as a hypervariable region (HVR), an octanucleotide 
5’-GGAAGAGC-3’ harbored within this region is nearly conserved among all 
coronaviruses (89, 177).  Intriguingly, although the HVR has been demonstrated to be 
important for replication of MHV DI RNA, removal of this element from the MHV genome 
has little effect on virus replication in tissue culture but affects pathogenesis in mice (50).  
(ix) A 3’-terminal poly(A) tail.  The 3’ poly(A) tail has been shown to be a crucial 
cis-acting signal for BCoV DI RNA replication (143, 144). 
     Proteins identified to bind cis-replication elements.  Extremely little is understood 
about how these cis-replication elements function.  It has been generally presumed that 
RNA-protein interactions direct the various steps leading to RNA synthesis but RNA-RNA 
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interactions have never been ruled out (15).  Several viral proteins with RNA-binding 
activity have been described as the result of structural, biochemical, and genetic evidence.  
A majority of these are replicase/trancriptase gene products generated from ORF 1a and 1b, 
that include nsp1, nsp7, nsp8, nsp9 and nsp10 (41, 55, 68, 97, 148, 149, 180).  Plus, N, a 
structural protein, is also a RNA binding protein.  The nsp1 of BCoV has strong and weak 
binding affinity to the positive-strands of 5’ and 3’ UTRs, respectively (55).  Nsps 7-10 of 
MHV are implicated in interactions with the 3’ BSL-PK accounting for the potential 
molecular switch (190).  Specific cis-acting RNA substrates bound with N protein have 
mapped to positive-strand of TRS in the MHV 5’ UTR and in the IBV 3’ UTR (113, 182).  
Moreover, a number of host proteins have also been identified and postulated to participate 
in the connection between cis-acting signals and RNA synthesis.  Heterogeneous nuclear 
ribonucleoprotein A1 (hnRNP A1), synaptotagmin-binding cytoplasmic RNA-interacting 
protein (SYNCRIP), and polypyrimidine tract-binding protein (PTB, also known as hnRNP 
I) have been shown to strongly bind positive strand forms of SLI and SLII in the 5’ UTR of 
MHV.  In addition, hnRNP A1 and SYNCRIP also bind the negative strand of SLI and 
SLII (30, 81, 82).  For SLIV and SLV-VI of BCoV, six and two uncharacterized cellular 
proteins appeared to be UV cross-linked with their positive strands, respectively (55, 123).  
Additionally, a complex of proteins including hnRNP A1, mitochondrial aconitase and 
heat-shock protein 70 (HSP70), and chaperones HSP60 and HSP40 are demonstrated to 
bind the positive-strand form of the 3’ UTR in MHV (64, 109, 111) .  The negative strand 
of the 3’ UTR of MHV is bound with the PTB, specifically at the motif that is 
complementary to the conserved octanucleotide (65).  Finally, the binding ability of 
poly(A) binding protein (PABP) to the poly(A) tail is proportional to the rate of RNA 
replication and appears to be independent of its function on translation (143).  The precise 
role of the interactions between proteins (viral and cellular) and cis-replication elements 
remains to be determined. 
     Coronavirus Reverse Genetics.  While studies with DI RNAs have provided a 
foundation for approaching the molecular biology of coronaviruses, the availability of 
reverse genetics systems has enabled a more in-depth analyses of the mechanisms of RNA 
synthesis, viral protein functions, virus-host interactions, pathogenesis, and development of 
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recombinant vaccines (97).  Reverse genetics for positive-strand RNA virus is defined as 
the transcription of infectious RNA from a full-length cDNA clone.  It was established to 
investigate the correlation between artificial genetic modifications and consequential 
phenotypic effects by manipulating the real virus (121).  The reverse genetics for 
coronaviruses became possible only recently because of the historic difficulties in working 
with the huge genome size.  Remarkably, to date four different and independent strategies 
of coronavirus reverse genetics systems have been developed.  These are as follows:  (i) 
Targeted RNA recombination, the first-developed reverse genetics system for coronaviruses, 
was based on the rationale that a recombinant virus can be created and selected from cells 
infected with a recipient coronavirus carrying a selectable marker.  The mutation is 
introduced with a synthetic donor RNA bearing the mutation of interest (99).  The success 
of this method was made feasible by the exceptionally high rate of homologous RNA 
recombination in coronaviruses.  While so far applicable only in MHV, this system can be 
used for making mutations only in the downstream one-third of the genome.  (ii) The 
bacterial artificial chromosome (BAC) in a low copy number and with an upstream CMV 
promoter has been utilized to assemble a full-length cDNA copy of the coronavirus genome 
(43).  Full-length infectious viral RNA is produced in vivo by host RNA polymerase II 
after transfection of the BAC DNA into host cells.  Although to date engineered for only 
TGEV and HCoV-OC43, this strategy overcomes the low efficiency of RNA transfection, 
avoids the limitation of in vitro RNA preparation, and ensures complete 5’ capping of the 
viral RNA (2, 145).  (iii) Vaccinia virus cloning vectors have been used to assemble the 
entire coronavirus cDNAs by using enzyme-directed insertion methods (155).  
Coronaviruses are recovered from cells transfected with infectious RNA that is produced in 
vitro from recombinant vaccinia virus DNA supplemented with bacteriophage T7 RNA 
polymerase.  Alternatively, coronaviruses can also be rescued from cells transfected with a 
DNA mixture containing the vaccinia virus DNA and expression vector for T7 RNA 
polymerase.  This system was first applied to human coronavirus-229E, but the genomes 
of two other coronaviruses, MHV and IBV, have also been successfully used (21, 32, 153).  
(iv) Systematic assembly of a full-length infectious cDNA was designed and carried out by 
in vitro ligation of five to seven contiguous cDNAs that span the entire genome (10).  
 15
These cDNA fragments are arranged in such a way so as to interrupt the viral genomic 
regions that are toxic to the E. coli host in cloning vectors.  They are also engineered with 
unique flanking restriction sites such that only one precise assembly of the entire genome 
takes place.  The 5’-terminal fragment contains the T7 RNA polymerase promoter.  
Genome-length infectious RNAs made from in vitro transcription are electroporated into 
host cells where recombinant coronaviruses are produced and recovered.  One major 
advantage of this system is that it allows for simple, rapid, and straightforward site-directed 
mutagenesis of virtually any site in the genome with minimal chances of introducing 
unexpected mutations elsewhere.  This method enables the independent genetic 
manipulation of cDNA subclones.  This strategy is now widely applied in coronaviruses of 
all three groups.  Viruses in which it has been established include TGEV, HCoV-NL63, 
MHV, SARS-CoV, and IBV (37, 172-175). 
 
QUESTIONS THAT LED TO THIS DISSERTATION RESEARCH 
     With the BCoV and MHV DI RNAs as major working molecules, nine cis-replication 
RNA elements have been identified as described above.  Among these is a 421-nucleotide 
(nt) 5’ cis-acting replication region that is the only difference between the replicating BCoV 
DI RNA and the shortest subgenome that is incapable of replication (sgmRNA 7) (Fig. 1.4).  
This region therefore undoubtedly bears distinct signals specific for RNA replication and 
has been a focus of investigation in our laboratory in recent years (19, 24, 55, 122, 123).  It 
has been postulated that the 421-nt is providing signals for initiation of negative-strand 
RNA synthesis from the positive-strand or initiation of positive-strand from negative-strand.  
Interestingly, within the 421-nt region not only are the four higher-order structures 
(SLIII-SLVI) present, but so too is the translation of the contiguous ORF necessary for DI 
RNA replication (19, 23).  Additionally, deletion or mutation of the 5’-proximal region of 
the nsp1 coding region, but not the 3’-proximal region, have been demonstrated to be 
detrimental for virus replication in the context of the MHV genome (17).  It has also been 
shown that MHV nsp1 co-localizes and interacts with viral replication complexes, nsp7 and 
nsp10, during early times postinfection (18).  Accordingly, the mechanistic contribution of 
nsp1 has been speculated to be a dual function of RNA structures and protein product.   
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Therefore, question #1 was what RNA structures in the 5’-proximal 500-nt regulatory 
region of the genome (including the 5’ UTR) and the 3’ UTR does nsp1 bind?  Does 
this protein have a regulatory function in translation that can be determined by an in 
vitro assay?  The results of this part of my study have been published as a 
collaborative paper and make up part of the Appendix.  Other questions led to other 
components of the Appendix.  What 5’ and 3’ terminal RNA structures are bound by 
nsp16 and the N protein?  Might these be regulatory proteins? 
     Despite significant sequence divergence among group 2a coronaviruses, many of their 
putative cis-replication RNA elements have predicted or documented common higher-order 
structure and some are functionally interchangeable.  For instance, the BCoV 3’ UTR was 
found to be able to entirely replace the MHV 3’ UTR in the context of the MHV genome 
(62).  By contrast, neither the group 1 TGEV 3’ UTR nor group 3 IBV 3’ UTR was capable 
of substituting for MHV 3’ UTR.  Moreover, it was suggested that common RNA 
replication signals exist among group 2a coronaviruses as evidenced by support of 
replication of the BCoV DI RNA by all the other group 2a coronaviruses including MHV 
(169).  Yet little of the functional interchangeability of 5’-proximal cis-replication signals 
among coronaviruses has been examined in the context of the viral genome.  Therefore, 
question #2 was can it be determined whether the BCoV higher-order cis-acting 
structures within 5’ UTR function in the context of the MHV genome when analyzed 
by a reverse genetics approach?  If so, what are they?   The answers to this question 
led to Chapter II. 
     In the study described in Chapter II, it was learned that (i) SLIV of BCoV functioned 
as a cis-replication element in the MHV genome only after it was extended into the nsp1 
coding region, and (ii) a 30-nt region immediately upstream of the newly defined SLIV 
could not be supplied by the BCoV counterpart without severe detriment to MHV growth.  
It was noted that after two blind cell passages following transfection with chimeric virus 
genomes carrying the 32-nt BCoV element, wt plaques emerged.  Therefore, question #3 
was what potential suppressor mutations might have arisen to yield the wt-like 
phenotype?  Might the position and character of the suppressor mutations identify 
potential RNA-RNA, RNA-protein, or protein-protein interactions that would explain 
 17
the debilitated phenotype?  Could these interactions be established by reconstituting 
a wt MHV with compensatory mutations?   
 In attempts to recapitulate mutational distortions of SLIII structure that would impair 
MHV genome replication as they did for BCoV DI RNA replication (122), we learned that 
mutational distortions in the upper loop had little or no effect on MHV replication.  
Therefore, question #4 evolved that led to Chapter IV.  What are the limits to SLIII 
changes that would still enable MHV replication?  That is, can parts of SLIII be 
removed and still leave a viable virus? 
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CHAPTER II.  CIS-REPLICATION STEM-LOOP IV IN THE 
MOUSE AND BOVINE CORONAVIRUS GENOMES SPANS PARTS 
OF THE 5’ UNTRANSLATED REGION AND NONSTRUCTURAL 
PROTEIN 1 CISTRON 
 
INTRODUCTION 
     Cis-acting structures in positive-strand RNA virus genomes that function as signals 
for genome translation, transcription and replication are potential sites for antiviral drug 
design.  The fact that replication signals from evolutionarily divergent coronaviruses can 
be exchanged, for example between the 3’ UTR of the bovine coronavirus (BCoV) and 
mouse hepatitis coronavirus (MHV) (61, 62), or the SARS-CoV and MHV (51), would 
suggest that antiviral molecules designed against common signals might be broadly 
effective therapeutic agents.  Several studies have identified cis-replication structures in 
the 3’ UTR of MHV and BCoV that are likely to be involved in the initial steps of genome 
translation and initiation of negative-strand RNA synthesis (143, 190).  The 3’-proximal 
cis-replication elements in the positive-strand identified thus far, either in a helper virus- 
dependent DI RNA replicon of MHV or BCoV, or in the full-length MHV genome, are (i) 
the 3’ poly(A) tail (84, 143), (ii) the 3’-terminal 55 nt of the 3’ UTR (50, 84, 190), and (iii) 
an upstream bulged stem-loop (SL) and associated hairpin pseudoknot (49, 61, 62, 163).  
Curiously, a ~140-nt hypervariable region in the 3’ UTR that comprises part of a 3-proximal 
bulged stem-loop and harbors a coronavirus-universal octamer sequence (GGAAGAGC) in 
MHV is not required for virus replication but plays a role in pathogenesis (50). 
     Cis-replication structures have also been identified in the 5’-proximal region of group 
2 coronaviruses, but few studies have characterized their common signaling features among 
the viruses.  The higher-order RNA structures within the BCoV 5’ UTR were initially 
predicted by the Tinoco algorithm and more recently by the Mfold algorithm of Zuker (100, 
183).  They were characterized as helical SLs I-IV (Fig. 2.1 B) and their predicted 
structures were consistent with enzyme structure probing analyses (24, 25, 122, 123).  In 
the context of a BCoV DI RNA in helper virus-infected cells, the higher-order structure of 
SLIII and SLIV (identified by the shaded areas in Fig. 2.1 B) were shown by mutation  
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FIG. 2.1.  Comparison of RNA structures in the 5’-terminal regions of the mouse hepatitis coronavirus, 
A59 strain (MHV-A59) and the bovine coronavirus, Mebus strain (BCoV-Mebus).  (A)  Higher-order 
structures for MHV.  (B)  Higher-order structures for BCoV.  For both viruses, the structures of stem-loops 
I (comprised of two smaller stem-loops named SL1 and SL2), II, III, and IV, and a short piece of the nsp1 
ORF are shown.  The “short” forms of SLIII and SLIV, the previously-described SLIII and SLIV forms for 
BCoV (122, 123) are high-lighted in gray.  The start and stop codons for the SLIII-associated intra-5’ UTR 
upstream ORF and the start codon for the nsp1 ORF are boxed.  (C)  Aligned 5’ UTR and adjacent 28-nt 
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Vector NTI.  Identical regions are noted by shading.  Positions of the MHV and BCoV stem-loops are noted. 
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analyses to be required for DI RNA replication and were then identified as cis-replication 
signals (122, 123).  Similar analyses could not be carried out for SLI and SLII since SLI 
resides within the leader and SLII resides largely within the leader and also harbors the 
transcription regulatory core sequence (UCUAAAC) (Fig. 2.1 B) (168, 170).   The 
transfected DI RNAs mutated in the SLI and SLII regions rapidly acquired the leader 
sequence of the helper virus genome in a process known as “leader switching” (24, 25, 93).   
It was shown, however, that the 5’-terminal 13 nt of SLI are required for BCoV DI RNA 
replication (24).  The BCoV SLIII, and its predicted homologue in other coronaviruses, 
has associated with it the start codon for a short upstream open reading frame (uORF) also 
found in the 5’ UTR of virtually all coronaviruses (122).  The coronavirus uORF encodes 
typically 8-11 aa, but its function has not been determined.  Recent Mfold analyses have 
predicted the BCoV SLIII to be 46-nt in length (a “long” SLIII) (19) rather than 20-nt as 
previously predicted (Fig. 2.1 B) (122).  The BCoV long SLIII is equivalent to the SLIII 
predicted for MHV (Fig. 2.1 A) (19, 88).  Between SLIII and a predicted SLIV in both 
BCoV and MHV is a ~40-nt region which appears to be a relatively unstructured region by 
Mfold prediction (Fig. 2.1 A and B).  SLIV and its predicted homologue in other 
coronaviruses (123) has associated with it the start codon for ORF 1, an ~ 20-kilobase ORF 
encoding 16 nonstructural proteins that make up the replication/transcription complex (53).  
In BCoV cross linking studies have identified SLIV to be a binding site for cellular but not 
viral proteins (123).  Downstream of SLIV and within the partial ORF 1 found in BCoV 
DI RNA are SLs V and VI which were shown by stem disruption and restoration studies to 
be cis-replication structures for DI RNA replication (19, 55).    
     Recently, the SLI region in MHV (nt 1-56) has been analyzed by NMR spectroscopy 
and studied in the reverse genetics system of MHV and has been described as comprising 
SLs 1 and 2 (Fig. 2.1 A and B) (83, 88).  The terminal loop of SL2 has been shown to be a 
U-turn motif that behaves as a cis-replication signal in the MHV genome (88).  In the same 
study, the MHV homologue of BCoV SLII (nt 57-74 in MHV) was predicted to be single 
stranded or weekly folded structure (88).  In the study of Liu et al. (88), MHV SL4b, nt 
96-115, is equivalent to the higher-order structure we have named here and elsewhere as 
SLIII, nt 97-116, in BCoV (122).  All in all, the predictions in the 5’ UTR higher-order 
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structures in BCoV and MHV show similarities suggesting they might be functionally 
conserved among group 2a coronaviruses (24, 122, 123). 
     Here, we postulated that since the MHV and BCoV genomes are structurally similar, 
their 5’ UTRs would be interchangeable as was their 3’ UTRs.  An initial set of 
experiments, however, demonstrated that a precise replacement of the 209-nt MHV 5’ UTR 
with the 210-nt BCoV 5’ UTR yielded no viable chimeras.  We therefore made 
replacements of regionally-characterized cis-acting BCoV structures in an effort to more 
precisely define the required 5’-proximal elements for MHV genome replication.  For this, 
the BCoV 5’ UTR SLs I & II region, the SLIII region, a 32-nt unstructured region between 
SLIII and SLIV, and eventually a 16-nt-extended version of the short SLIV were used to 
replace the equivalent regions in the 5’ UTR of the MHV genome.  From this, we learned 
(i) that the SLs I & II region and the SLIII region can immediately functionally replace 
homologous regions in the MHV genome, (ii) that the BCoV 32-nt unstructured region 
produces virus with slow-growing small plaques after two blind cell passages, (iii) that only 
the 16-nt extended version of the intra-5’ UTR BCoV SLIV (the newly-described “long” 
SLIV) can replace the MHV long SLIV for virus replication, and (iv) that structure 
disruptions of SLV within the partial nonstructural protein 1 (nsp1) cistron did not hinder 
MHV replication indicating this structure may be less critical as a cis-replication element in 
the MHV genome than in the BCoV DI RNA replicon.  These results together establish (i) 
that the cis-replication SLIV of BCoV and MHV includes sequence from both the 5’ UTR 
and nsp1 coding region, and (ii) that a relatively unstructured 30 to 32-nt hypervariable 
region within the 5’ UTR strongly prefers the context of the parent genome for its function 
in virus replication, thus identifying a subgroup 2a-specific cis-replication element. 
 
MATERIALS AND METHODS 
     Cells and viruses.  Delayed brain tumor (DBT) cells (58), mouse L2 cells (47), and 
baby hamster kidney cells expressing the MHV receptor (BHK-MHVR) (175) were grown 
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% defined fetal 
calf serum (FCS) (Hyclone) and 20 μg/ml gentamicin (Invitrogen), and maintained at 37 °C 
with 5% CO2 for all experiments.  BHK-MHVR cells were maintained in selection 
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medium containing 0.8 mg/ml Geneticin (G418 sulfate; Invitrogen) (175). 
     Sequence alignment and GenBank accession numbers.  5’ UTR sequence 
alignments of group 2a coronaviruses were made with Vector NTI Suite 8 (Invitrogen).  
GenBank Accession Numbers were as follows: NC_001846 for MHV-A59, NC_006852 for 
MHV-JHM, AF201929 for MHV-2, NC_006577 for CoV-HKU1, NC_010327 for ECoV, 
U00735 for BCoV-Mebus, NC_003045 for BCoV-ENT, NC_005147 for HCoV-OC43, 
FJ415324 for HECoV-4408, NC_007732 for PHEV, EF424624 for Calf-Giraffe CoV, and 
EF424621 for Antelope CoV. 
     RNA structure prediction.  The Mfold program of Zuker 
(http://mfold.bioinfo.rpi.edu/) (100, 183) was used for RNA structure predictions. 
     Plasmid construction for mutations in fragment A of the infectious clone for 
MHV-A59.  Fragments A through G for the infectious clone of MHV-A59 (icMHV) (175) 
were a kind gift from Ralph Baric, University of North Carolina.  cDNA plasmid A 
(containing fragment A) which contains an upstream T7 promoter and nt 1- 4882 of the 
MHV genome was prepared in plasmid pCR-XL-TopoA (Invitrogen) and used to replace 
MHV sequences with homologous regions of the BCoV-Mebus.  Site-directed mutagenesis 
was carried out by overlap PCR with primers shown in Table 2.1.  All PCR reactions used 
AccuPrimeTM Taq Polymerase High Fidelity (Invitrogen) under conditions recommended by 
the manufacturer.  Briefly, the first PCR was done with primer T7startBCoV (or 
T7startMHV) and the designated reverse (+) primer, and the second PCR was done with 
primer MHV-ScaI and the designated forward (-) primer.  PCR fragments were 
chromatographically purified (QIAEX II; Qiagen) and used in the third PCR with primers 
T7startBCoV (or T7startMHV) and MHV-ScaI.  The resulting PCR fragments were TA 
cloned into pCR-XL-Topo followed by plasmid preparation and sequence confirmation.  
With purified cloned DNA, a restriction fragment exchange was performed to minimize 
unwanted mutations in the wt icMHV plasmid DNA.  Briefly, both wt icMHV plasmid A 
DNA and site-directed mutagenized TOPO plasmid DNA were digested with restriction 
enzymes SfiI and ScaI (New England Biolabs), whose sites are in the vector at nt 1616 
upstream from the T7 promoter and in the MHV genome at nt 910, respectively.  The ~2.5 
kb SfiI-ScaI fragment from TOPO clones were ligated with the ~6.5 kb SfiI-ScaI fragment 
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  TABLE 2.1.  Oligonucleotides used in Chapter II 
Oligonucleotidea Polarityb Sequence (5’Æ3’)c Binding region (nt) 
T7startMHV + gtcggcctcttaatacgactcactatagTATAAGAGTGATTGGCGTCCG T7 promoter MHV 1-21 
T7startBCoV + gtcggcctcttaatacgactcactataggattgtgagcgatttgc T7 promoter BCoV 1-17 
A59-Sca I - CGCCTTGCAGGAGTACTTACCCTTC MHV 899-923 
A59-BCoV(1-84)(-) + ctaaactttataaaaacatcCACTTCCTGCGTGTCCATGCCC MHV 83-104 BCoV 65-84 
A59-BCoV(1-84)(+) - gggcatggacacgcaggaagtgGATGTTTTTATAAAGTTTAG MHV 83-104 BCoV 65-84 
A59-BCoV(85-141)(-) + cttgtgggcgtagatttttcatagtggtgtctatattcaTTCCTTGACTTTCGTTCTCTGC 
MHV 141-162 
BCoV 103-141 
A59-BCoV(85-141)(+) - ctatgaaaaatctacgcccacaagcatagaatacagggagtgCCGTTTATAAAGTTTAGATTAG 
MHV 61-82 
BCoV 85-126 
A59-BCoV(142-210)(-) + gccagggacgtgttgtatcctaggcagtggcccacccataggtcacAATGGCAAAGATGGGCAAATAC 
MHV 209-230 
BCoV 164-209 
A59-BCoV(142-210)(+) - ctaggatacaacacgtccctggctgaaagctgttaacagcagaaaCTACAAATGTCAGCACTATGAC 
MHV 119-140 
BCoV 142-186 
A59-BCoV(142-226)(-) + cccacccataggtcacaatgtcgaagatcaacaAATACGGTCTCG MHV 226-237 BCoV 194-226 
A59-BCoV(142-226)(+) - CGAGACCGTATTtgttgatcttcgacattgtgacctatgggtggg MHV 226-237 BCoV 194-226 
A59-BCoV(174-226)(+) - gtgacctatgggtgggccactgcctaggatacaacaCGTCACTGGCAGAGAACG 
MHV 153-170 
BCoV 174-209 
A59-BCoV(142-173)(-) + tttctgctgttaacagctttcagaaagggacgTGTCCATTCGGCGCCAGCAG MHV 171-190 BCoV 142-173 
A59-BCoV(142-173)(+) - gctgttaacagcagaaaCTACAAATGTCAGCACTATGAC MHV 119-140 BCoV 142-158 
BCoV-SLIVtop(-) + gtggcccacccataggtcacaATGGCAAAGATGGGCAAATAC MHV 210-230 BCoV 190-210 
BCoV-SLIVtop(+) - tgtgacctatgggtgggccacTGGCGCCGAATGGACACG MHV 169-186 BCoV 190-210 
BCoV-SLIVmid(-) + GCAGCCCACCCATAGGTTGCATAatgtcgaagATGGGCAAATACG 
MHV 187-209, 
219-231 
BCoV 211-219 
BCoV-SLIVmid(+) - TATGCAACCTATGGGTGGGCTGCtgcctagGAATGGACACGTCAC 
MHV 187-209, 
165-179 
BCoV 183-189 
BCoV-SLIVbot(-) + GCCCACCCATAGGTTGCATAATGGCAAAgatcaacaAATACGGTCTCG 
MHV 190-217, 
226-237 
BCoV 219-226 
BCoV-SLIVbot(+) - TGCAACCTATGGGTGGGCTGCTGGCGCCgatacaacaCGTCACTGGCAG 
MHV 180-207, 
159-170 
BCoV 174-182 
BCoV-SLIVtop+mid(-) + gtggcccacccataggtcacaatgtcgaaGATGGGCAAATAC MHV 218-230 BCoV 190-218 
BCoV-SLIVtop+mid(+) - tgtgacctatgggtgggccactgcctagGAATGGACACGTC MHV 167-179 BCoV 183-210 
BCoV-SLIVmid+bot(-) + GCAGCCCACCCATAGGTTGCATAatgtcgaagatcaacaATACG 
MHV 187-209, 
226-231 
BCoV 211-226 
BCoV-SLIVmid+bot(+) - GCAACCTATGGGTGGGCTGCtgcctaggatacaacaCGTCACTGG 
MHV 187-206, 
162-170 
BCoV 174-189 
BCoV-SLIVtop+bot(-) + gtggcccacccataggtcacaATGGCAAAgatcaacaaatacg 
MHV 210-217 
BCoV 
190-210, 
219-232 
BCoV-SLIVtop+bot(+) - tgtgacctatgggtgggccacTGGCGCCGatacaacACGTCAC 
MHV 179-186, 
165-171 
BCoV 
190-210, 
175-181 
BCoV-SLIV-L(-) + GCCCACCCATAGGTTGCATAATG MHV 190-212 
BCoV-SLIV-L(+) - CATTATGCAACCTATGGGTGGGCcac MHV 190-212 BCoV 189-191 
BCoV-SLIV-R(-) + CAGCAGCCCACCCATAGGTcac MHV 185-203 BCoV 207-209 
BCoV-SLIV-R(+) - gtgACCTATGGGTGGGCTGCTG MHV 185-203 BCoV 207-209 
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         TABLE 2.1.  Continued. 
Oligonucleotidea Polarityb Sequence (5’Æ3’)c Binding region (nt) 
A59-BCoV(142-158)(-) + tttctgctgttaacagcTCTCTGCCAGTGACGTGTCC MHV 156-175 BCoV 142-158 
BCoV(122-158)(+) - gctgttaacagcagaaatgaatatagacaccactatg BCoV 122-158 
A59-BCoV(159-174)(-) + tttcagccagggacgtGTCCATTCGGCGCCAGCAG MHV 172-190 BCoV 159-174 
BCoV(140-175)(+) - cacgtccctggctgaaagctgttaacagcagaaatg BCoV 140-175 
A59-BCoV(176-192)(-) + ttgtatcctaggcagtgGCCCACCCATAGGTTGCATA MHV 190-209 BCoV 176-192 
BCoV(157-193)(+) - ccactgcctaggatacaacacgtccctggctgaaagc BCoV 157-193 
MHV-1094(+) - CGATCAACGTGCCAAGCCACAAGG MHV 1094-1117 
DI3(+) - cgggatccgtcgacacgcgtttttttttttttttttttt Poly(A) 
MHV-leader(-) + TATAAGAGTGATTGGCGTCCG MHV 1-21 
BCoV-leader(-) + gattgtgagcgatttgcgtgcg BCoV 1-22 
MHV(605-623)(+) - GTTACACAGGCAGACGCGC MHV 605-623 
MHV(261-284)(-) + CCATGGATGCTTCCGAACGCATCG MHV 261-284 
MHV(30811-30830)(-) + GGATGGTGGTGCAGATGTGG MHV 30811-30830 
MHV-NPol(A)(+) - ttttttttttttttttttttttttttACACATTAGAGTC MHV 31019-31033 
T7MHV-NATG(-) + gtaatacgactcactatagATGTCTTTTGTTCCTGGGC MHV 29669-29687 
MHV(31094-31122)(+) - CAGCAAGACATCCATTCTGATAGAGAGTG MHV 31094-31122 
 
a The positive and negative symbols in the oligonucleotide names indicate the polarity of the nucleic acids to     
  which the oligonucleotides anneal. 
b Polarity of the oligonucleotide relative to the positive-strand viral genome. 
c Lower-case bases represent non-MHV sequences.  Capitalized bases represent MHV sequences.  
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from the wt icMHV plasmid A DNA.  The BCoV/MHV chimeric plasmid A was then used 
to create a recombinant virus with fragments B through G in the MHV-A59 reverse genetics 
system. 
     Assembly of the full-length MHV-A59 infectious recombinant virus RNA.  
Wild-type (wt) and chimeric MHV viruses were produced as described by Yount et al. (175)  
and as modified by Denison et al. (35).  Briefly, plasmids containing the seven cDNA 
cassettes (A, B, C, D, E, F, and G) of the MHV-A59 genome were digested with the 
appropriate restriction enzymes (New England Biolabs) followed by gel electrophoresis 
purification of the fragments (QIAEX II; Qiagen).  In this study, fragment A was modified 
by RT-PCR mutagenesis to contain the described mutations using the appropriate primers 
(Table 2.1).  Gel purified DNA fragments were in vitro ligated with T4 DNA ligase (New 
England Biolabs) in a total reaction volume of 210 μl overnight at 4 °C.  Ligated cDNA 
was chloroform extracted, isopropanol precipitated, and size confirmed by electrophoresis 
in a 0.6 % nondenaturing agarose gel.  Infectious MHV genomic RNA was generated in 
vitro with the mMessage mMachine T7 transcription kit (Ambion) from the ligated cDNA 
in a total reaction volume of 50 μl supplemented with the addition of 7.5 μl of 30 mM GTP.  
In vitro transcription was done at 40.5 °C for 30 min, 37 °C for 60 min, 40.5 °C for 30 min, 
37 °C for 30 min, and 40.5 °C for 30 min.  In parallel, RNA transcripts encoding the MHV 
nucleocapsid (N) protein were generated from a cloned N cDNA plasmid containing an 
upstream T7 promoter using the mMessage mMachine in a total reaction volume of 25 μl at 
37 °C for 3 h.  Both icMHV genomic RNA and N RNA were treated with 5 μl Turbo 
DNAse (Ambion) at 37 °C for 30 min and mixed for electroporation.  To prepare for 
electroporation, BHK-MHVR cells were separated by trypsinization, washed twice with 
phosphate–buffered saline (PBS), and resuspended in PBS at a concentration of ~1×107 
cells/ml.  The RNA mixture was added to 650 μl of the resuspended BHK-MHVR cells in 
a 4-mm-gap cuvette (Phenix) and pulsed three times by 850 V at 25 μF with a Gene 
PulserTM electroporator (Bio-Rad).  Electroporated cells were then seeded on a layer of 
~1×106 DBT cells in a 75-cm2 flask and incubated at 37 °C.  Virus viability was 
determined by the development of cytopathic effect (CPE, syncytia) in cells in 72 h or less.  
Cultures that did not develop syncytia after 72 h were blind cell passaged at 48 h intervals 
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three times at 37 °C in a further attempt to recover infectious virus.  At least three 
independent experiments were done before a mutated MHV genome was claimed 
nonviable. 
     Characterization of viral mutants by RT-PCR and viral RNA sequence analyses.  
Cell cultures that developed complete CPE were freeze-thawed once and supernatant fluids 
were centrifuged at 5,000 × g for 10 min to clear cell debris.  Virus from cells that had 
been electroporated (i.e., virus passage 0 [VP0]) was passaged onto DBT cells (i.e. VP1), 
and the VP1 cells were lysed with Trizol reagent (Invitrogen) followed by RNA extraction 
in accordance with the manufacturer’s protocol.  To analyze the 5’ ~1000-nt and 3’ ~500-nt 
sequences of chimeric viruses, total cellular RNA harvested from VP1 cells was reverse 
transcribed with Superscript II reverse transcriptase (Invitrogen) using MHV-1094(+) and 
DI3(+) primers, respectively.  The cDNA was PCR amplified with primers MHV- leader(-) 
or BCoV-leader(-) and MHV-1094(+) for 5’ terminal sequences, and with primers DI3(+) 
and MHV(30811-30830)(-) for 3’ terminal sequences.  PCR products were gel purified 
(QIAEX II; Qiagen) prior to automated sequencing with primers MHV(261-284)(-) and 
MHV(605-623)(+) for the 5’ ~1000-nt fragment, and with primer MHV(30811-30830)(-) 
for the 3’ ~500-nt fragment.   
     To determine virus titers and plaque morphology, plaque assays were done on L2 
cells.  Briefly, L2 cells of ~80% confluence in 6-well flasks were inoculated with serial 
diluted viruses for 2 h at 37 °C, washed once with PBS, and overlaid with DMEM 
supplemented with 1% low melting agarose and 2% FCS.  After incubation at 37 °C for 
~60 h, the overlay were fixed with 10% formaldehyde at room temperature for 30 min, and 
then discarded.  The fixed cells were stained with 1% crystal violet for 10 min, washed 
with water, and air dried before plaques were counted.  Representative plaque images were 
taken with a Nikon digital camera and prepared using Adobe Photoshop CS. 
     Growth kinetics and sequence analyses.  To measure growth kinetics, DBT cells 
of ~80% confluence in 25-cm2 flasks (~4 × 106 cells) were inoculated with wt or chimeric 
MHV in DMEM at a multiplicity of infection (MOI) of 0.01 or 5.0 PFU/cell for 2 h at 37 °C.  
Inocula were removed, cells washed twice with DMEM, and 5 ml DMEM with 2% FCS 
were added and incubation was continued at 37 °C.  100 μl samples of supernatant fluid 
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were collected at the indicated times post-infection and viral titers were determined by 
plaque assays on L2 cells as described above.  To analyze sequence changes following 
viral passage, wt and chimeric MHV viruses were used to infect DBT cells of ~80% 
confluence in 25-cm2 flask at an MOI of ≤ 0.1 PFU/cell.  After complete CPE was 
observed (usually around 24 h post-infection), supernatant fluids were collected, clarified at 
5,000 × g for 10 min, and used for subsequent infections.  Intracellular RNA from infected 
cells was Trizol-extracted, RT-PCR amplified, gel purified, and sequences analyzed as 
described above.   
     Northern blot analysis of viral RNAs.  DBT cells of ~80% confluence in 25-cm2 
flasks (~4×106 cells) were infected with wt or chimeric MHV-A59 viruses at an MOI of 
0.01 PFU/cell.  At 20 hpi, cells were lysed with Trizol (Invitrogen) and intracellular RNA 
was isolated in accordance with the manufacturer’s protocol.  RNA (~6 μg) from one-tenth 
of each extraction was electrophoresed in a 1.0 % agarose-formaldehyde gel at 150 V for 4 
h.  RNA was transferred to HyBond N+ nylon membrane (Amersham Biosciences) by 
vacuum blotting for 3 h followed by UV cross-linking.  After pre-hybridizing the 
membrane with NorthernMax Prehybridization/Hybridization Buffer (Ambion) at 55 °C for 
4 h, the blot was probed with 20 pmol of γ-32P-end-labeled 3’ UTR-specific oligonucleotide 
MHV(31094-31122)(+) at ~4×105 cpm/pmol, at 55 °C overnight for detecting viral genomic 
and subgenomic RNAs.  Probed blots were exposed to Kodak XAR-5 film for 24 h at -80 
°C for imaging, and images were prepared using Adobe Photoshop CS. 
 
RESULTS 
     A precise 210-nt BCoV 5’ UTR failed to replace the 209-nt MHV 5’ UTR in the 
MHV genome.  Since the 288-nt 3’ UTR of BCoV can functionally replace the 301-nt 3’ 
UTR of MHV in the MHV genome (61, 62), and the BCoV DI RNA can replicate in 
MHV-infected cells indicating the BCoV cis-replication signals can be recognized by the 
MHV RNA replication machinery (169), we reasoned that a precise substitution of the 
BCoV 5’ UTR in the MHV genome might function for genome replication as well.  To test 
this, a 5’ UTR replacement was made by using the MHV reverse genetics system developed 
by Yount et al. (175).  The BCoV replacement of the MHV 5’ UTR, B1-210/M chimera, 
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yielded no viable virus as determined by syncytia formation in DBT cells and plaque assay 
in L2 cells following three blind cell passages (Fig. 2.2 A and B).  We therefore chose to 
separately analyze shorter domains of the 5’ UTR to determine which 5’ UTR components 
were compatible, if any, based on the identity of cis-replication elements described in the 
BCoV DI RNA. 
     The BCoV 5’ UTR stem-loops I & II region (nt 1-84) and stem-loop III region (nt 
85-141), but not the 5’ UTR-confined stem-loop IV region (nt 142-210), can 
functionally substitute for the homologous MHV region.  To test the hypothesis that 
individual parts of the BCoV 5’ UTR can functionally replace homologous regions in the 
MHV genome, the BCoV 5’ UTR was initially divided into three segments, SLs I & II (nt 
1-84), SLIII (nt 85-141), and SLIV (nt 142-210) as can be identified in Figs. 2.1 and 2.2 A, 
and each was tested separately or jointly in the MHV background as a chimeric BCoV/ 
MHV construct.  Virus-induced syncytia were detected within 24 h post-electroporation 
(hpe) from wt genomic RNA and within 24-48 hpe from cells electroporated with chimeric 
genomic RNAs containing BCoV SLs I & II (B1-84/M), BCoV long SLIII (B85-141/M), and 
BCoV SLs I & II & long SLIII (B1-141/M).  In each, plaques appeared similar in size and 
shape to wt MHV (Fig. 2.2 B).  RT-PCR and sequence analyses of RNA from virus 
passages 1 (VP1) and 10 (VP10) from all chimeras revealed no additional mutations within 
the 5’-1000 or 3’-500 genomic nt (data not shown).  Growth kinetics determined on DBT 
cells using MOIs of 5 PFU/cell and 0.01 PFU/cell (Fig. 2.2 C) revealed little difference 
between wt MHV and B85-141/M progeny during the early part of the growth curve (i.e., 
within 12 h), but the progeny from B1-84/M and B1-141/M replicated more slowly during 
these periods.  All three chimeras, however, reached a maximal viral titer of ~1.5×107 
PFU/ml, ~ ten-fold lower than wt, by 12 and 20 h for the MOIs of 5 and 0.01, respectively.  
These results demonstrated that while the BCoV SLs I & II and SLIII in chimeras are not 
identical to wt in structure and sequence, both supported replication of the chimera with 
near wt MHV-like properties. 
     The B142-210/MHV, B85-210/M, and B1-84, 142-210/M chimeras, on the other hand, failed to 
develop CPE by 72 hpe and no viable virus was recovered during three blind cell passages 
(Fig. 2.2 B and data not shown).  These results, therefore, identified one or more regions of  
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FIG. 2.2.  BCoV SLs I & II, and SLIII domains support virus replication in the MHV background.  (A)  
Scheme showing RNA domains in the BCoV 5’ UTR that were tested for supporting replication in 
BCoV/MHV chimeras.  Stem-loop structures coinciding with domains in MHV (solid line) and BCoV 
(stippled line) are depicted at the top and bottom, respectively.  Line lengths are proportional to the genetic 
distance.  Solid circles identify the AUG start codon for the nsp1 ORF.  (B)  Plaque phenotypes of wt 
MHV and BCoV/MHV chimeras described in (A).  Plaque assays were performed on monolayer mouse L2 
cells and stained with crystal violet.   Nonviable chimeras formed no visible plaques during 1-3 blind cell 
passages and were indistinguishable from mock-infected cells.  (C)  Single-cycle and multiple-cycle growth 
kinetics of the viable BCoV/MHV chimeras relative to those of wt MHV.  DBT cells were infected with the 
indicated viruses at an MOI of 5.0 or 0.01 PFU/cell.  At the indicated times post infection, aliquots of 
medium were removed and infectious titers were determined by plaque assays on mouse L2 cells.  Open and 
solid symbols represent results from two independent experiments. 
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incompatibility between the BCoV nt 142-210 sequence and the remainder of the MHV 
genome. 
     The BCoV stem-loop IV region (nt 142-210) when extended by 16-nt into the 
nsp1 cistron to form a longer stem-loop IV (nt 142-226) enabled recovery of MHV 
chimeras, but only after one blind cell passage.  A predicted long SLIV for BCoV after a 
16-nt extension into ORF 1 shows 12 base pairings within the 16-nt extension (Fig. 2.1 B), 
and the same for MHV SLIV (Fig. 2.1 A).  However, with the B142-210/M chimera, only 8 
base pairings are likely for the same region between the BCoV 5’ UTR and MHV ORF 1.  
Therefore, a chimera utilizing BCoV nt 142-226 in the chimera B142-226/M was tested (Fig. 
2.3 A).  Following electroporation, viral plaques became evident after one blind cell 
passage but these were small and grew to a much lower titer (1.5× 104 PFU/ml) than did wt 
(Fig. 2.3 B).  In addition, 5’ 1000-nt sequence analyses of isolated plaques revealed a 
mixed population of mutations mapping at nt 30, 162, 168, and 363 (data not shown).  
These results suggested that these mutations were compensatory and enabled the replication 
(data not shown).  Thus, the replicating but debilitated chimera indicated that either the 
32-nt unstructured BCoV region between SLIII and SLIV, or the long SLIV itself, or both, 
was not compatible with the rest of the MHV genome. 
     To further analyze the compatibility of BCoV sequences within these domains, the 
32-nt domain was divided into two parts and studied separately in new chimeras, and the 
long SLIV was studied separately in a chimera.  The results with the BCoV long SLIV 
alone are described first. 
     The BCoV long stem-loop IV alone (nt 174-226) is immediately fully functional 
within the context of the MHV genome.  A chimera with the BCoV long SLIV alone, 
B174-226/M (Fig. 2.3 A), formed plaques within 24 hpe and progeny from VP0 exhibited 
MHV wt-like plaques (Fig. 2.3 B).  Sequence analyses of progeny genomes demonstrated 
no additional mutations within the 5’ 1000-nt and 3’ 500-nt regions (data not shown).  In 
addition, growth kinetics with VP1 at low MOI was indistinguishable from wt MHV (Fig. 
2.3 C), and Northern blot analyses on RNA from infected cells displayed a wt-like pattern 
(Fig. 2.3 D).  These results together demonstrated that the long SLIV from BCoV is fully 
functional in the context of the MHV genome despite an 18-nt (33%) difference between  
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FIG. 2.3.  BCoV nt 142-226 can substitute for its MHV counterpart after one blind cell passage.  (A)  
Top:  Schematic of predicted secondary structures within the 5’-proximal 250-nt of the MHV and BCoV 
genomes showing long stem-loops III and IV and position of the MHV 30-nt unstructured region.  Bottom:  
Selected regions of the 30-nt from MHV and 32-nt from BCoV being tested in the MHV background are 
shown.  (B)  Plaque phenotypes shown with the corresponding mutant chimera.  (C)  Growth kinetics of 
the B174-226/M chimera as compared to that of wt MHV.  DBT cells were infected with virus at a MOI of 0.01 
PFU/cell and virus titers at the indicated times post infection were determined by plaque assays on L2 cells.  
The number depicted at each time point is the average of three independent experiments.  (D)  Northern 
analysis showing the RNA patterns for wt MHV and the B142-226/M chimera.  Cultures of DBT cells were 
mock-infected or infected with MOI of 0.01 PFU/cell, and intracellular RNA was extracted at 20 hours post 
infection.  The Northern analysis used a 32P-radiolabeled probe specific for the 3’ UTR as described in the 
Materials and Methods.  gRNA, genomic RNA; sgRNA, subgenomic RNA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
mutations
moi = 0.01
0
1
2
3
4
5
6
7
8
0 4 8 12 16 20 24 28 32
Hours Post Infection
lo
g 
PF
U
/m
L
wt MHV
M/B(174-226)
MHV-A59
1
A B
zzz
5’
I
II
III
3’
209
IV
wt MHV
B142-226/M
C
wt MHV
lethal
155 170 225
B174-226/M
mutations
lethal
B142-226/M
B1-158/M B1-173/M B1-226/M
D
m
oc
k
wt
MH
V
B
17
4-
22
6 /M
gRNA
sgRNA2
sgRNA3
sgRNA4
sgRNA5
sgRNA6
sgRNA7
1 2 3
140
B1-158/M
B1-173/M
B1-226/M
B174-226/M
141 173 2261581
30-nt
wt MHV
B174-226/M
lo
g 
PF
U
/m
L
the BCoV and MHV long SLIV structures and 5’-terminal nsp1 aa sequence differences of 
MSKINK and MAKMGK, respectively.  It also indicates that the 5’-terminal 16-nt of the 
nsp1 ORF act as part of the cis-acting SLIV RNA. 
     A surprising number of variations in stem-loop IV structure are tolerated, 
although replication is impaired.  Additional experiments demonstrated that deviations 
from intact wt-like BCoV or MHV SLIV structures were tolerated for virus replication, but 
a wt-like structure is important for robust growth.  To examine the structural features of the 
long SLIV that are important for virus replication, eight chimeric constructs with various 
combinations of long SLIV components were tested.  Four independent trials were made 
for each construct and the results of one trial for each are shown (Fig. 2.4).  (i) Using 
chimeric SLIV constructs in which the left side (B177-192/M) or the right side (B207-224/M) of 
the entire stem is made with BCoV sequence (thus replacing the homologous sequence in 
the MHV SLIV as defined by the alignment in Fig. 2.1 C), mixed plaque sizes were 
obtained (Fig. 2.4 A and B).  However, for these, two blind cell passages were required 
before plaques appeared.  Sequence analyses of selected plaque-purified populations 
revealed that from the left-side chimera (B177-192/M), two populations of progeny with 
deletions were found, one (plaque 1) with a deletion of nt 173 through 190 (counting from 
MHV nt 171, M171, at the base of the chimeric SLIV) and another (plaque 2) with a 
deletion of nt 174 through 178 (Fig. 2.4 A).  From the right-side chimera (B207-224/M), the 
progeny carried a deletion of nt 184 through 203 that included the terminal loop (Fig. 2.4 B, 
plaque 1).  (ii) Using chimeric constructs in which the stem of only the lower half of SLIV 
(B177-187, 214-224/M), or the lower half of the left side (B177-187/M), or lower half of the right 
side (B214-224/M) was made BCoV-like, wt-like plaques were obtained immediately after 
transfection (Fig. 2.4 C), and only sequences that matched those of the input chimeras were 
found (Fig. 2.4 C).  (iii) Using chimeric constructs in which the stem of only the lower 
fourth of SLIV (B177-180, 222-224/M), or lower fourth of the left side (B177-180/M), or lower 
fourth of the right side (B222-224/M) was made BCoV-like, wt-like plaques were obtained 
immediately after transfection (Fig. 2.4 D), and only sequences that matched those of the 
input chimeras were found (Fig. 2.4 D).  Taken together, these data show that there is 
tolerance for variation in SLIV structure, but that optimal virus replication in the chimera  
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FIG. 2.4.  A variety of SLIV structures are tolerated for virus replication.  Wild-type bases for the long 
SLIV in BCoV that differ from MHV according to the alignment in Fig. 2.1 C are noted by arrows.  The 
AUG start codon for ORF 1 is boxed.  (A)  Results for a chimera in which the upstream-half of SLIV is 
made BCoV-like in the MHV background.  The genome sequence of two individually plaque-purified 
progeny isolates show one 18-nt upstream deletion pattern and one 5-nt upstream deletion pattern.  (B)  
Results for a chimera in which the downstream-half of SLIV is made BCoV-like in the MHV background.  
The genomic sequence of the plaque-purified progeny isolate shows a 20-nt deleted upstream region that 
includes the terminal loop.  (C)  Results for chimeras in which the lower half of SLIV, or the upstream or 
downstream parts of the lower half of SLIV, are made BCoV-like in the MHV background.  The progeny of 
these chimeras were viable but debilitated, and they retained the parental BCoV sequences.  (D)  Results for 
chimeras in which the lower fourth of SLIV, or the upstream or downstream parts of the lower fourth of SLIV, 
are made BCoV-like in the MHV background.  The progeny of these chimeras were viable but debilitated, 
and they retained the parental BCoV sequences. 
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takes place with an intact wt BCoV or wt MHV SLIV.  In light of this, it is curious that 
B1-210/M in which only the lower part of the SLIV mismatched was not viable (Fig. 2.2 A 
and B).  It is possible that the lower part of the stem is more critical for SLIV function. 
     The BCoV 32-nt region upstream of the long stem-loop IV (nt 142-173) behaves 
as a coronavirus subgroup 2a-specific cis-replication domain.  Given that chimeras 
containing the BCoV SLs I & II and SLIII domains together (B1-141/M), or the long BCoV 
SLIV domain alone (B174-226/M), but not those containing the BCoV unstructured 32-nt 
domain (B1-226/M or B142-226/M), were immediately functional in the MHV background for 
virus replication (Fig. 2.2 and Fig. 2.3), it was postulated that the BCoV 32-nt domain 
(corresponding to a 30-nt domain in the MHV 5’ UTR) is an unstructured cis-replication 
RNA element that might be coronavirus subgroup 2a-specific.  To examine this hypothesis, 
chimeras were made to separately examine each of two subdomains in the 32-nt 
unstructured region.  For this, chimeras B1-158/M which extends the BCoV sequence in the 
viable B1-141/M chimera 17 nt into the 32-nt domain, and B1-173/M which extends completely 
through the BCoV 32-nt domain, were tested (Fig. 2.3 A and B).  The 17-nt extension in 
B1-158/M enabled replication, but only after two blind cell passages, and the plaques were 
heterogeneous in size (Fig. 2.3 B).  Sequence analyses of isolated plaques revealed a 
mixed population of mutations mapping at nt 55, 145, and 147, the latter two of which were 
within the 17-nt extension (data not shown).  These results suggested that the mutations 
were compensatory and enabled the replication.  For chimera B1-173/M, no viable virus was 
obtained immediately or after three blind cell passages (Fig. 2.3 B).  This pattern was 
consistent with results from B1-226/M which showed no viable progeny after three blind 
passages of transfected cells (Fig. 2.3 B).  To examine the compatibility of the BCoV 32-nt 
region alone in the MHV background, reciprocal 5’ UTR constructs were tested in which 
the BCoV 32-nt domain was the only BCoV sequence within the MHV background, 
(B142-173/M, or for brevity, B32-nt/M), and two in which the MHV 30-nt domain within the 
BCoV 5’ UTR or 16-nt-extended BCoV 5’ UTR with partial nsp1 cistron was placed in the 
MHV background (B1-210, M30-nt/M and B1-226, M30-nt/M) (Fig. 2.5 B).  After transfection with 
the B32-nt/M chimera, viable virus yielding heterogeneous-size plaques (Fig. 2.5 C) appeared 
after two blind cell passages, thus conforming to the above patterns with the BCoV 32-nt  
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FIG. 2.5.  Detrimental effects of the BCoV 32-nt unstructured region in the MHV background.  (A)  
Alignment of the 32-nt unstructured region among group 2a coronaviruses.  Identical nucleotides are shaded.  
Abbreviations: MHV, mouse hepatitis virus (strains -A59, -JHM, and -2); CoV-HKU1, human coronavirus- 
HKU1; ECoV, equine coronavirus; BCoV, bovine coronavirus (strains -Mebus and -ENT); HCoV-OC43, 
human coronavirus-OC43; HECoV-4408, human enteric coronavirus-4408; PHEV, porcine hemagglutinating 
encephalomyelitis virus;  Calf-Giraffe CoV, calf-giraffe coronavirus; Antelope CoV, sable antelope 
coronavirus.  (B)  Diagram depicting chimeric constructions.  (C)  Plaque phenotypes of the chimeric 
constructs.   (D)  Growth kinetics at MOI of 0.01 PFU/cell of the B1-226, M30-nt/M chimera relative to that of 
the wt.  The number depicted at each time point is the average of three independent experiments.  (E)  
Northern analysis for viral RNA synthesis of wt and the B1-226, M30-nt/M chimera was done as described for Fig. 
2.3.  gRNA: genomic RNA.  sgRNA: subgenomic RNA. 
domain in the MHV background.  For chimera B1-210, M30-nt/M, no viable virus was 
obtained immediately or after three blind cell passages (Fig. 2.5 C).  This result was 
consistent with the idea that a “long” SLIV is critically preferred for viral replication.  On 
the other hand, after transfection with B1-226, M30-nt/M, medium-size plaques formed within 
48 h after electroporation of genomic RNA (Fig. 2.5 B) and a final replication titer 100-fold 
lower than wt MHV (Fig. 2.5 C) was obtained.  Northern blot analysis of viral RNAs from 
infected cells shows that sgmRNAs are made in the same relative proportions as with wt 
MHV but are less abundant (Fig. 2.5 D).  These results indicate that the 32-nt unstructured 
region in BCoV is not immediately compatible with the MHV background and thus support 
the idea that the unstructured region may be a subgroup 2a-specific cis-replication element.  
Interestingly, an alignment of ~30-nt homologous sequences within the unstructured regions 
among twelve group 2a coronaviruses were examined (Fig. 2.5 A).  The results show that 
sequences in this region can be classified as MHV-like, BCoV-like, or intermediate.  This 
result is consistent with the notion that this region represents a subgroup 2a-specific 
cis-acting region.  
     Disrupting the lower stem of SLV within the nsp1 cistron blocks BCoV DI RNA 
replication but does not block MHV genome replication.  The structures of several 
coronavirus DI RNAs have shown that the most 5’-terminal region of the nsp1 ORF is 
present in each of them (15).  Group 3 coronaviruses do not have an apparent nsp1 cistron, 
however their 5’ UTR is long suggesting an equivalent cis-replication element could be 
located within the 5’ UTR.  Early experiments with the BCoV DI RNA suggested that both 
the 5’-partial nsp1 ORF and the N gene were required in cis for replication (23).  However 
it could not be determined whether it is the product of translation, or the act of translation 
itself, that is required in cis.  Therefore, to determine whether the Mfold-predicted SLV and 
SLVI behaved as cis-replication elements in the BCoV DI RNA, mutants that had disrupted 
and then restored the stem-loops were examined for replication.  Disruption in both 
stem-loops blocked BCoV DI RNA replication (19, 55). 
     In MHV, SLV and SLVI are predicted by Mfold but only SLV allowed the design of 
silent mutations to disrupt and then restore stem structure, and these were tested (Fig. 2.6).  
None of the mutations significantly disrupted MHV genome replication or virus production  
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FIG. 2.6.  Disruption of the lower helix of stem-loop V in the nsp1 coding region does not disable MHV 
replication.  (A)  Mfold-predicted structures of stem-loops V and VI in the nsp1 coding region.  Mutations 
in the lower helix of stem-loop V in the nsp1 coding region, analogous to those in stem-loop V of the BCoV 
nsp1 coding region that disabled BCoV DI RNA replication (19), are shown.  (B)  Growth kinetics for 
MHV containing wt stem-loop V (wt MHV), and helix-disrupting mutations separately in the left side (mutant 
Lt) and right side (mutant Rt) of the lower helix, and a combination of left and right mutations (mutant Lt/Rt) 
that restore the helix structure.   
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(Fig. 2.6 A and B).  These results together suggest SLV may not be a cis-replication 
element in the MHV genome, at least as determined by disruption of the base of the 
stem-loop.   
 
DISCUSSION 
     In this study we asked whether the BCoV 5’ UTR would function in the context of the 
MHV genome and support virus replication.  It was anticipated that it would since the two 
viruses are phylogenetically closely related and the BCoV DI RNA has been shown to 
replicate in the presence of MHV helper virus indicating the two share replication signals.  
Surprisingly, a precise replacement of the 209-nt MHV 5’ UTR with the 210-nt BCoV 5’ 
UTR was not functional in the MHV genome.  By replacing individual homologous 
regions in the MHV 5’ UTR with cis-acting domains in the BCoV 5’ UTR (as defined by DI 
RNA replication studies), it was learned that whereas domain I (comprised of SLs I and II), 
and domain II (comprised of SLIII) worked well despite sequence differences of 37 and 
36%, respectively, (i) SLIV (domain IV) with a nt sequence difference of 33% was 
functional only after it had been extended into the nsp1 coding region by 16 nt (to form a 
“long” SLIV), and (ii) a relatively unstructured 32-nt region (domain III) between SLs III 
and IV showing a nt difference of 40% yielded a viable virus only after two blind cell 
passages. 
     The first conclusion from this study is that an RNA sequence is identified within the 
5’-terminal 16-nt region of ORF 1 that functions as part of a cis-acting RNA signal, SLIV, 
for virus replication.  The idea that part of the nsp1 coding region could provide an 
important cis-replication function had been hinted at since a 5’-terminal portion of the nsp1 
cistron was found as a part of coronavirus DI RNAs (with the exception of group III 
coronaviruses which have no nsp1 cistron) (14, 142), and this part of the nsp1 cistron was 
found to be necessary for DI RNA replication in the BCoV DI RNA (23).  More recently, 
SLs V and VI in the BCoV DI RNA, as higher-order RNA structures, have been shown to 
behave as cis-replication elements (19, 55).  In addition, in MHV, mutations in the 5’- 
terminal region of the nsp1 cistron have been shown to be detrimental to MHV replication 
(17), but whether these were the result of RNA structural changes or protein changes were 
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not determined.  The presence of the nsp1 start codon in the downstream terminal portion 
of SLIV leaves open the possibility that SLIV may function as a riboswitch for regulation of 
ORF 1 translation or other function in RNA replication.  SLIV could also play a role in 
initiation of negative-strand RNA synthesis by interacting with proteins that in turn engage 
the 3’ UTR to initiate formation of the replication complex.  Or, since SLIV mirrors the 
negative-strand which harbors the initiation site for new positive-strand RNA synthesis for 
generating new genomes, it could be that structural changes are impairing this step.   
     Whether SLIV interacts in any way with SLV or SLVI in the nsp1 cistron to regulate 
some aspect of replication remains to be seen.  Certainly it is puzzling that SLV functions 
as a cis-replication element in the DI RNA but not the intact genome.  It could be that the 
four point mutations as used in the current study were insufficient for disrupting SLV 
structure in the context of the whole genome, or that the genome has a mechanism for 
coping with this disruption. 
     The second major conclusion from the current study is that the relatively unstructured 
BCoV 32-nt domain III (30-nt in MHV) is a coronavirus subgroup 2a-specific cis- 
replication element.  This is supported by the fact that a chimeric MHV genome with 
BCoV domains I-II, III, and IV (the long SLIV version) and the 30-nt MHV domain III 
replicated immediately after transfection of the recombinant genome to yield MHV wt-like 
plaques (B1-226, M30-nt/M, Fig. 2.5).  That is, no blind cell passaging was required.  What 
the 30-nt unstructured region does for virus replication is not known at this time.  The fact 
that it appears to be tailored to different species within subgroup 2a viruses would suggest it 
has evolved with other viral elements.  Perhaps this explains why MHV supported the 
replication of BCoV DI RNA less well than did the other BCoV-like coronaviruses such as 
ECoV, HCV-OC43, and HCoV-4448 (169).  In an associated follow-up study to this one 
(Guan and Brian, to be submitted) we learned that reversion of mutations within the 32-nt 
region to become more MHV-like together with suppressor mutations within nsp1 suggest 
that the nsp1 protein interacts with the 32-nt region.  Also, in a separate study the binding 
of BCoV N to SLIII was found to be enhanced by the presence of its flanking 32-nt region 
suggesting that perhaps there is an interaction between the N protein and the 32-nt region 
(Guan and Brian, to be submitted). 
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     Thus, the structure at the lower stem of SLIV and the 32-nt unstructured region 
between SLIII and SLIV appear to be sites critical to coronavirus replication, and the 
mechanism of their function should be pursued in the interest of finding sites for designing 
inhibitors of coronavirus replication. 
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CHAPTER III.  GENETIC EVIDENCE FOR INTERACTION 
BETWEEN TWO 5’-TERMINAL GENOMIC CIS-REPLICATION 
ELEMENTS AND NONSTRUCTURAL PROTEIN 1 IN THE MOUSE 
HEPATITIS CORONAVIRUS 
 
INTRODUCTION 
     In a previous study (Chapter II), we exploited the ~35% nucleotide sequence 
divergence between the 5’ UTRs of the BCoV and MHV to identify the 5’-proximal 
cis-replication elements for replication in the MHV genome.  We learned that domain I in 
MHV (nt 1-82) which contains higher-order structures named SLI and SLII can be 
functionally replaced by its BCoV counterpart, as can domain II (nt 83-140) which contains 
SLIII, and domain IV (nt 171-225) which contains a long SLIV that extends into the nsp1 
cistron (Fig. 3.1).  In each of these substitutions, despite sequence differences of 36, 34, 
and 33%, respectively, the chimeric virus replicated for at least 3 passages without 
compensatory suppressor mutations being observed within the 5’-most 1000-nt and 3’-most 
500-nt of the genome.  Surprisingly, a domain III of 30-nt unstructured region in the MHV 
5’ UTR (nt 141-170) that maps between SLIII and SLIV could not be immediately 
functionally replaced by its BCoV counterpart, a 32-nt region (nt 142-173) in the BCoV 5’ 
UTR (Fig. 3.1).  However, the resulting chimeric B142-173/M genome (also called B32-nt/M) 
was observed to be viable (i.e., make plaques) after two blind cell passages.  In two out of 
three experimental attempts, there were no viable viruses after three blind cell passages. 
     The results yielding viable B32-nt/M virus suggested that there had been compensatory 
mutations in the chimeric genome that enabled replication of the chimera.  Here, we 
describe the analyses that found and identified three suppressor mutations that could each 
act alone to bring about wt-like plaques in the context of B32-nt/M background, but not 
without a simultaneous single change (a “reversion” at one of two sites) within the 
transplanted BCoV 32-nt element.  One of the suppressor mutations (C30U) mapped 
within SLI in the 5’ UTR, and two (A353U and A363G) mapped within the nsp1 coding 
region.  These experiments were done using the reverse genetics system for MHV-A59 
developed by the Ralph Baric laboratory at the University of North Carolina (175) which  
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FIG. 3.1.  Cis-replication elements in the MHV 5’ UTR.  The organization of the 31.3-kb MHV genome 
is shown at the bottom.  Above the genome is a detailed view of the current model of cis-replication RNA 
stem-loops (SLs) I, II, III, and IV within the MHV 5’ UTR.  These four SL structures can be functionally 
replaced by their counterpart in the BCoV 5’ UTR.  Open boxes at nt 99 and 210 identify AUG start codons 
for the short upstream ORF and ORF 1, respectively.  An open box at nt 123 identifies the UAG stop codon 
for the short upstream ORF.  A dashed box in the loop of SLII denotes the core signal within the 
transcription regulatory sequence (TRS-CS).  The putative SLI is comprised of SL1 and SL2 identified by 
NMR and proposed by Liu and colleagues (88).  The highlighted 30-nt region (nt 141-170) indicates a newly 
identified MHV-specific cis-replication element (identified in Chapter II) which cannot be readily replaced 
with the BCoV counterpart.  After replacing this element with the 32-nt BCoV counterpart (BCoV nt 
142-173), the BCoV/MHV chimera, named B32-nt/M, is viable only after appearance of suppressor mutations at 
other 5’-proximal sites in the MHV. 
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enabled reconstitution of B32-nt/M with each of the three suppressor mutations to 
demonstrate the sufficiency of each suppressor nucleotide (along with a commensurate 
single intra-BCoV 32-nt “reversion”) for generating a wt-like MHV virus.  The pattern of 
suppressor and reverting mutations, furthermore, provides evidence of a 3-way cross talk 
between site C30 in SLI, sites U160 and U166 in the 30-nt region, and A363 (the first base 
of a lysine codon) in the nsp1 coding region.  Genetic evidence also indicated that this 
cross talk is virus species-specific, for at least the BCoV and MHV members of group 2a 
coronaviruses, since a chimeric virus containing the entire BCoV 5’ UTR and nsp1 cistron 
within the MHV background had the phenotype of a wt MHV in cell culture.  No such 
chimera could be made between the SARS-CoV and MHV.  From these data, a model is 
proposed to show that the putative 3-way interaction acts as part of a switch that toggles 
between genome translation and initiation of negative-strand RNA synthesis on the genome. 
 
MATERIALS AND METHODS 
     Cells and viruses.  DBT cells, L2 cells, and BHK-MHVR cells were grown in 
media and conditions as described in Chapters II. 
     Sequence alignment and GenBank accession numbers.   The nsp1 coding 
sequences of group 2a coronaviruses and SARS-CoV were translated by computer to amino 
acid sequences using Vector NTI Suite 8 (Invitrogen).  The 5’ UTR nucleotide sequence 
and nsp1 amino acids alignments, and phylogenetic tree construction, were performed by 
using the neighbor-joining method available with CLUSTAL X 1.83 in 1,000 bootstrap 
trials.  The generated phylogenetic tree was viewed by TreeView (Win32) 1.6.6.  Putative 
intrinsically disordered region and potential RNA binding residues within the BCoV and 
MHV nsp1s were predicted with Disembl (http://dis.embl.de) (86) and BindN programs 
(http://bioinformatics.ksu.edu/bindn) (162), respectively .  GenBank Accession Numbers 
for the sequences studied here are as follows: NC_001846 for MHV-A59, NC_006852 for 
MHV-JHM, AF201929 for MHV-2, NC_006577 for CoV-HKU1, NC_010327 for ECoV, 
U00735 for BCoV-Mebus, NC_003045 for BCoV-ENT, NC_005147 for HCoV-OC43, 
FJ415324 for HECoV-4408, NC_007732 for PHEV, EF424624 for Calf-Giraffe CoV, 
EF424621 for Antelope CoV, and NC_004718 for SARS-CoV-Toronto. 
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     Plasmid construction for mutations in fragment A of the infectious clone for 
MHV-A59.  The general strategy to generate chimeric and mutated MHV-A59 infectious 
clone was as described in Chapter II.  Site-directed mutagenesis was made by overlap PCR 
with the primers shown in Table 3.1.  Briefly, to make fragment A for rec1 infectious clone, 
a PCR was done with the primers MHV-C30U(-) and A59-ScaI in the presence of B32-nt/M 
and wt-MHV DNA template.  To make rec2, the first PCR was done with the primers 
T7startMHV and MHV-A353T(+), and the second PCR was done with the primers 
MHV-A353T(-) and A59-ScaI, wherein both PCR reactions the A fragment for B32-nt/M 
assembly was used as the amplification DNA template.  PCR fragments were 
chromatographically purified and used in a third PCR with the primers A59-ScaI and 
T7startMHV.  Same procedure was used for constructing other recombinant clones except: 
to make rec3, primers MHV-A363G(-) and MHV-A363G(+) were used; to make rec4, 
primers MHV-C30U(-), MHV-A353T(+), and MHV-A353T(-) were used; to make rec5, 
primers MHV-C30U(-), MHV-A363G(+), and MHV-A363G(-) were used.  To make 
mutated and chimeric clones, similar PCR strategy was used with designated primers and 
cognate DNA templates.  The mutated and chimeric plasmid A then was used to create a 
recombinant virus with fragment B through G in the MHV-A59 reverse genetics system.  It 
should be noted that in the case of replacing MHV nsp1 with SARS-CoV counterpart, 
additional synonymous mutations by primer-mediated PCR were made to eliminate Esp3 I 
and Sca I restriction sites appearing at nt 330 and 582, respectively, in order to enable the 
assembly of a full-length SARS-CoV/MHV chimera. 
     Assembly of the full-length MHV-A59 infectious recombinant virus RNA.  
Assembly of full-length MHV-A59 infectious recombinant construct was carried out as 
described in Chapter II. 
     Characterization of viral mutants by RT-PCR, viral RNA sequence analyses, and 
growth kinetics measurement.  Analyses of plaque morphology and genome sequencing 
of recovered progeny viruses were carried out as described in Chapter II. 
     Northern blot analysis of viral RNAs.  Northern blot assays were performed as 
described in Chapter II. 
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 TABLE 3.1.  Oligonucleotides used in Chapter III 
Oligonucleotidea Polarityb Sequence (5’Æ3’)c Binding region (nt) 
T7startMHV + gtcggcctcttaatacgactcactatagTATAAGAGTGATTGGCGTCCG T7 promoter MHV 1-21 
T7startBCoV + gtcggcctcttaatacgactcactataggattgtgagcgatttgc T7 promoter BCoV 1-17 
A59-Sca I - CGCCTTGCAGGAGTACTTACCCTTC MHV 899-923 
MHV-C30U (-) + GAGTGATTGGCGTCCGTACGTACCTTCTCAAC MHV 6-37 
MHV-A353U (-) + CGCAAGAACCGAATGTTAAAGG MHV 340-361 
MHV-A353U (+) - CCTTTAACATTCGGTTCTTGCG MHV 340-361 
MHV-A363G (-) + GGAGAAACTTTGGTTAATCACGTG MHV 360-383 
MHV-A363G (+) - CACGTGATTAACCAAAGTTTCTCC MHV 360-383 
MHV-U160A+U166G(-) + CGTTCTCAGCCAGGGACGTGTCC MHV 153-175 
MHV-U160A+U166G(+) - GGACACGTCCCTGGCTGAGAACG MHV 153-175 
BCoV (225-244) (-) + GGGcaaatacggtctcgaactac MHV 221-223 BCoV 222-244 
BCoV (225-244) (+) - gtagttcgagaccgtatttgCCC MHV 221-223 BCoV 222-244 
T7start-SARS (-) + gtcggcctcttaatacgactcactatagatattaggtttttacctacccagg SARS-CoV 1-24 
SARS-ScaI (+) - CGCCTTGCAGGAGTACTTACCCTTCGGgactgcacctccattgagctcac 
MHV 897-923 
SARS-CoV 
788-810 
SARS-330 mu (-) + gtccttcaggttagggatgtgctagtgcg SARS-CoV 322-350 
SARS-330 mu (+) - cgcactagcacatccctaacctgaaggac SARS-CoV 322-350 
SARS-582 mu (-) + ggtataacactgggggtgctcgtgccac SARS-CoV 565-592 
SARS-582 mu (+) - gtggcacgagcacccccagtgttatacc SARS-CoV 565-592 
MHV-TRS1 (-) + cctcgatctcttgtagatctAATCTAATCTAAACTTTAtttaaaatctgtgtagctgtcg 
MHV 58-75 
SARS-CoV 
38-57, 73-94 
MHV-TRS1 (+) - cgacagctacacagattttaaaTAAAGTTTAGATTAGATTagatctacaagagatcgagg 
MHV 58-75 
SARS-CoV 
38-57, 73-94 
MHV-TRS2 (-) + gtagatctgttctctaaacgaacAATCTAATCTAAACTTTAtttaaaatctgtgtagctgtcg 
MHV 58-75 
SARS-CoV 
50-72, 73-94 
MHV-TRS2 (+) - cgacagctacacagattttaaaTAAAGTTTAGATTAGATTgttcgtttagagaacagatctac 
MHV 58-75 
SARS-CoV 
50-72, 73-94 
MS-nsp1 (-) + ATGGCAAAGATGGGCAAATACatggagagccttgttcttggtgtc 
MHV 210-230 
SARS-CoV 
265-288 
MS-nsp1 (+) - gacaccaagaacaaggctctccatGTATTTGCCCATCTTTGCCAT 
MHV 210-230 
SARS-CoV 
265-288 
SM-nsp1 (-) + gggtgtgaccgaaaggtaagATGGCAAAGATGGGCAAATAC 
MHV 210-230 
SARS-CoV 
245-264 
SM-nsp1 (+) - GTATTTGCCCATCTTTGCCATcttacctttcggtcacaccc 
MHV 210-230 
SARS-CoV 
245-264 
MHV-1094(+) - CGATCAACGTGCCAAGCCACAAGG MHV 1094-1117 
DI3(+) - cgggatccgtcgacacgcgtttttttttttttttttttt Poly(A) 
MHV-leader(-) + TATAAGAGTGATTGGCGTCCG MHV 1-21 
MHV(605-623)(+) - GTTACACAGGCAGACGCGC MHV 605-623 
MHV(261-284)(-) + CCATGGATGCTTCCGAACGCATCG MHV 261-284 
MHV(30811-30830)(-) + GGATGGTGGTGCAGATGTGG MHV 30811-30830 
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         TABLE 3.1.  Continued. 
Oligonucleotidea Polarityb Sequence (5’Æ3’)c Binding region (nt) 
MHV-NPol(A)(+) - ttttttttttttttttttttttttttACACATTAGAGTC MHV 31019-31033 
T7MHV-NATG(-) + gtaatacgactcactatagATGTCTTTTGTTCCTGGGC MHV 29669-29687 
MHV(31094-31122)(+) - CAGCAAGACATCCATTCTGATAGAGAGTG MHV 31094-31122 
 
 
a The positive and negative symbols in the oligonucleotide names indicate the polarity of the nucleic acids to    
  which the oligonucleotides anneal. 
b Polarity of the oligonucleotide relative to the positive-strand viral genome. 
c Lower-case bases represent non-MHV sequences.  Capitalized bases represent MHV sequences.        
  Bold-capitalized bases denote mutated changes. 
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RESULTS 
     Genetic analysis of phenotypic revertants of a MHV chimera harboring the 
poorly compatible 32-nt unstructured region from the BCoV 5’ UTR identify three 
potential second site suppressor mutations and two potential intra-BCoV 32-nt 
“revertant” mutations.  In Chapter II it was demonstrated that a 30-nt unstructured 
region mapping between SLIII and SLIV within the 5’ UTR of MHV behaved as a 
species-specific cis-acting replication element since the 32-nt homologous region from 
BCoV was essentially incompatible with the MHV genome as shown with the chimeric 
construct B32-nt/M (Fig. 3.1).  The chimeric B32-nt/M genome after transfection was found 
to be nonviable in two experiments, but in a third, it was debilitated for growth and 
genetically unstable during the earliest stages of virus recovery (Fig. 3.2).  The recovered 
virus from blind cell passage 2 exhibited heterogeneous plaque sizes that ranged from very 
small to nearly wt-like (large, ~2.5 mm diameter) (Fig. 3.2 A).  The mutations observed 
within the 5’-terminal 1000-nt from small and large plaque isolates was analyzed at virus 
passages 1, 6 and 10 and the results are summarized in Fig. 3.3 A.  Details of mutations 
that arose at given times are shown for the S3 isolate as an example in Fig. 3.3 B.  
Sequence analyses of the serially-passaged, plaque-purified viruses that had developed a 
stable large plaque size and wt-like growth kinetics showed a commensurate acquisition of 
either one or both of two sets of mutations.  (i) Development of a wt-like phenotype 
correlated with the acquisition of one or more of three possible “suppressor” mutations, one 
within SLI (C30U) and two within the nsp 1 coding region (A353U and A363G).  
(Possibilities mapping outside the 5’-terminal 1000-nt of the genome may exist, but as 
shown in this study, any of the three identified here can cause a reverted phenotype.)  (ii) 
Development of a wt-like phenotype correlated with the acquisition of one or both of two 
possible “reverting” mutations within the transplanted 32-nt region from BCoV (A162U and 
G168U) (Fig. 3.3).  This series of observations led us to hypothesize that “suppressor” 
mutations outside of the 32-nt transplanted region, and/or possibly “revertant” mutations 
within the 32-nt region, or some combination of both, had arisen to enable the reverted 
phenotype.  These mutations also might, upon further analysis, reveal specific RNA-RNA 
interactions within the 5’ UTR, and/or between the 5’ UTR and the nsp1 coding region or  
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FIG. 3.2.  Severely impaired growth of the BCoV/MHV chimera (B142-173/M; also named B32-nt/M) is 
restored to wild-type levels through 1-10 viral passages.  (A)  Chimera B32-nt/M exhibits heterogeneity in 
plaque size but becomes uniform and wt-like through 10 viral passages.  At the center-top is a picture of the 
plaques from recovered B32-nt/M viruses after blind cell passage 2.  Note the heterogeneity in plaque size as 
compared to the uniformly large size of the wt MHV plaques (top-right).  Shown below are the plaques 
obtained from three small-plaque isolates (S1, S2, and S3), two large-plaque isolates (L1 and L2), and a wt 
control, when plated at viral passages 1, 6, and 10.  (B)  The B32-nt/M chimera initially displays growth 
defects but wt-like growth rates appear after a few viral passages.  Multiple-cycle growth kinetics of 
small-plaque (S1, S2, and S3) and large-plaque (L1 and L2) isolates were compared to that of wt virus.  DBT 
cells were inoculated with passage-1, passage-6, and passage-10 viruses, respectively, at an MOI of 0.01 
PFU/cell.  Supernatants were obtained at the indicated time points post infection and virus titers were 
determined by plaque assays on L2 cells.  The number depicted at each time point is the average of three 
independent experiments.   
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FIG. 3.3.  Putative suppressor mutations found in the 5’ UTR and nsp1 coding regions after serial 
passaging of B142-173/M (B32-nt/M).  (A)  Summary of sequencing results of RT-PCR products from viral 
passages 1, 6, and 10 of small- and large-plaque isolates.  At the top is a depiction of the 5’-proximal 
genomic region in which the potential repressor mutations were found.  Beneath this depiction is a table 
showing the nucleotide changes in comparison with the original chimera sequences.  The loci of nucleotide 
changes are boxed with arrows.  Mutations arising over time are marked with superscript “mix” according to 
the sequencing data shown in panel (B).  (B)  Sequencing results for viral passages 1, 6, and 10 of the S3 
isolate are shown for the SLI region, the BCoV 32-nt region, and the nsp1 coding region.  The nucleotides 
shown are complementary to the sequencing data because of the downstream primers used for automated 
sequencing.  The loci of the completed and ongoing mutations are indicated by arrows.  Foci with clearly 
mutated or mixed nucleotides are boxed. 
B
VP1
VP6
VP10
A G T T T T T C C T T T A A C T T T C
A G T T T Y T C C T T T A A C T T T C
A G T T T Y T C C T T T A A C T T T C
3’UCAAAgAGGAAAUUGAAAG 5’
A363G
350368
nsp1
C G T C C C T G G C W G A A A G C T G T T A A C A G C A G A A A
C G T C C C T G G C A G A A A G C T G T T A A C A G C A G A A A
C G T C M C T G G C W G A A A S C T G T T A A C A G C A G A A A
3’GCAGuGACCGuCUUUgGACAAUUGUCGUCUUU 5’
A162UG168U C157G
172 141
BCoV 32 nt
T T G A G A A G G T A C G T
T T G A G A A G G T A C G T
T T G A G A A G G T A C G T
3’AACUCUuCCAUGCA 5’
C30U
36 23
SLI
S3
coding region product (i.e., either as RNA-RNA or RNA-protein interactions) that are 
important for virus replication. 
     While it is possible that the reversions within the transplanted BCoV 32-nt region 
alone would suffice to give rise to wt-like (revertant) phenotypes in the context of the 
B32-nt/M background, we chose here to first analyze the three potential suppressor mutations 
(the one in SLI and the two in the nsp1 coding region) (Fig. 3.3 A) in the B32-nt/M 
background for sufficiency to cause a reversion to a wt-like phenotype.                  
     Any one of the three potential suppressor mutations in the 5’-terminal genomic 
region is sufficient to cause a MHV wt-like phenotype in the B32-nt/M background, but 
(usually) not without a simultaneous reversion of G168U within the BCoV 32-nt region.  
To test whether any one of the three potential second-site suppressor mutations C30U, 
A353U, or A363G (Fig. 3.3 A) are authentic suppressors, genome reconstructions were 
made that tested each individually in the B32-nt/M background (Fig. 3.4 A, B and C).  In 
contrast to the slow development of plaques following transfection with the B32-nt/M 
genomic RNA in the original experiment (Fig. 3.2), B32-nt/M genomic RNA recombinants 
harboring the single putative suppressors C30U (rec1), A353U (rec2), or A363G (rec3) 
developed near wt-like plaques within 24-36 h post electroporation (Fig. 3.4 B).  These 
results demonstrated an immediate suppressor function for each of the potential suppressor 
mutations.  Cells electroporated with double putative suppressor mutations, C30U and 
A353U (rec4), and C30U and A363G (rec5), also showed rapid development of wt-like 
plaques in the electroporated cells (Fig. 3.4 B).  Within the first virus passage of recovered 
recombinants rec 1-5, plaques were nearly uniform in size and only slightly smaller than wt 
plaques.  Growth curves similar to wt were found for rec 1, 3 and 5, but for rec 2, the 
growth rate lagged that of wt, and for both rec 2 and 4, the final titer reached was 
approximately ten-fold lower than for wt (Fig. 3.4 C).  Interestingly, for each of rec 1-5, 
the potential revertant G168U was also present in plaques isolated from virus passage 1, 
indicating this was possibly a simultaneous change enabling rapid recovery (Fig. 3.4 D).  
In rec1, C144U was also found, and in rec3 and rec4, the potential reversion A162U was 
also found.  From these results, i.e., from the fact that there was an apparent simultaneous 
selection of the intra-BCoV 32-nt A162U and/or G168U reversions, it cannot be determined  
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FIG. 3.4.  Identification of suppressor mutations by reconstituting viable viruses harboring revertant 
mutations.  (A)  Structures of recombinant and mutant viruses in comparison with wt MHV.  
Recombinants rec1, rec2, and rec3 were generated in the context of the B142-173/M (B32-nt/M) backbone with 
additional mutations C30U, A353U, and A363U.  These three mutations were second-site mutations found 
from revertants of plaque isolates described in Fig. 3.3.  Synergetic suppression effects were examined by 
constructing the recombinants rec4 and rec5 harboring the C30U mutation along with A353U and A363U, 
respectively, in the presence of BCoV 32-nt.  In contrast, mutants, mut1, mut2, and mut3, respectively, 
contain mutations of C30U, A353U, and A363U, in the MHV background.  (B)  Shown are the plaque 
phenotypes of recovered recombinant and mutant viruses, compared with that of the wt MHV.  (C)  Growth 
kinetics of the constructed recombinants, rec1 through rec5, compared to that of wt.  DBT cells were 
inoculated with passage-1 viruses at an MOI of 0.01 PFU/cell as described in the Materials and methods.  
Data shown are the averages of three independent experiments.  (D)  Sequencing results of the BCoV 32-nt 
from RT-PCR products of recombinants from passage-1 of rec1 through rec5 as described in the legend for 
Fig. 3.3. 
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whether or not each of the potential suppressor mutations alone (C30U, A353U, or A363G) 
was sufficient to cause a reverted phenotype.   
     To ask the inverse question, that is, do any of the three potential suppressor mutations 
(C30U, A353U, and A363G) alone in the wt MHV background cause a detrimental effect on 
virus growth (that might have been neutralized by the simultaneous intra-BCoV 32-nt 
mutations), each mutation was placed into the wt MHV background, forming mut1, mut2 
and mut3, and tested (Fig. 3.4 A).  Interestingly, of the three, only the intra-nsp1 ORF 
mutation, A363G (which causes a K52E mutation, a charge change from the basic lysine at 
amino acid 52 in nsp1 to a glutamic acid), showed a detrimental effect that was manifested 
by very small plaques that appeared after one blind cell passage of the electroporated cells 
(Fig. 3.4 B).  This result suggests there may be an interaction between the 30-nt element in 
the MHV genome and nt 363 in the nsp 1 coding region, or the nsp1 protein itself.  No 
other mutations were found in the 5’-terminal 1000-nt of recovered virus. 
 A severe detrimental effect resulting from placement of the third suppressor 
mutation (A363G) alone into the wt MHV background enabled demonstration of a 
three-way interaction between SLI, the 30-nt element, and the nsp1 coding region (or 
the nsp1 protein).  The severely detrimental effect of the A363G (K52E) mutation in 
mut3 enabled a more detailed examination of potential genetic cross talk between SLI, the 
MHV 30-nt region, and the nsp1 coding region (or nsp1 protein).  For this, the A363G 
mutation was tested for restoration of the wt-like phenotype in the MHV background in 
combination with the C30U mutation in SLI alone, with the paired U160A and U166G 
mutations (homologous to the BCoV 32-nt element at these sites) alone, and with both the 
C30U, U160A, and U166G mutations together (Fig. 3.5). 
     To test for cross talk between A363G in the nsp1 coding region and C30U in SLI, 
both mutations were placed into the wt MHV background to form mut5 (Fig. 3.5 A) and the 
recombinant genomic RNA was tested for replication by electroporation into cells.  
Remarkably, mut5 demonstrated wt-like MHV plaques immediately after transfection (Fig. 
3.5 C), and wt-like growth kinetics at virus passage 1 (Fig. 3.5 B), whereas the A363G 
mutant alone demonstrated very small plaques and growth kinetics with a final titer at 
104-105-fold lower than mut5 or wt (Fig. 3.5 B and C).  This result demonstrated that these  
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FIG. 3.5.  Genetic cross talk between the 5’ UTR and nsp1 in the MHV genome.  (A)  Shown are 
diagrams indicating the construction of mutants as compared to wt MHV and mut3 described in Fig. 3.4.  (B)  
Growth kinetics of the recovered mutants, mut3 through mut5, and their comparison with that of wt MHV.  
(C)  Plaque phenotypes of recovered mutants and their comparison with those of wt MHV.  The severely 
impaired growth of mut3 (with the A363G mutation) is restored to nearly wt growth by the simultaneous 
introduction of C30U to SLI (mut5), or BCoV counterparts U160A and U166G to the MHV 30-nt region 
(mut4), or both (mut6). 
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two mutated sites together enabled wt-like virus and suggested there was some form of 
cross talk between these two elements, either directly (as RNA-RNA) or indirectly (as 
RNA-protein). 
     To test for cross talk between the A363G in the nsp1 coding region and the 
(BCoV-like) U160A and U166G in the 30-nt region, all three mutations were 
simultaneously placed into the MHV background to form mut4 and tested for replication by 
electroporation into cells.  Remarkably, as with mut5, mut4 demonstrated wt-like plaques 
immediately after transfection (Fig. 3.5 C), and wt-like growth kinetics were demonstrated 
at virus passage 1 (Fig. 3.5 B).  This result suggested that A363G was selected in the 
B32-nt/M chimera to accommodate the A162 and the G168 in the BCoV 32-nt region, and 
therefore strengthens the notion that there is an interaction between the nsp1 coding region 
(or Nsp1 protein) and the 30-nt element.   
     To test whether all three mutants function mutually to yield a wt-like phenotype, all 
were used together to make mut6 (Fig. 3.5 A).  As demonstrated in Fig. 3.5 C, wt-like 
plaques were formed, and in Fig. 3.5.B, wt-like growth kinetics resulted.  These results 
together, therefore, support the hypothesis that there is a 3-way interaction between SLI, the 
30-nt region, and nsp1 coding region (or the nsp1 protein).   
     The BCoV 5’ UTR and entire BCoV nsp1 cistron function together in the MHV 
background to yield wt-like MHV.  The notion that there is a necessary virus 
species-specific cross talk between group 2a coronavirus 5’ UTRs and nsp1 cistrons (or, 
more likely, their nsp1 proteins) for virus replication was strengthened by the results from 
four other chimeric constructs that tested the compatibility between the 5’ UTR and nsp 1 
coding region.  Since we had previously shown (Chapter II) that a functional SLIV extends 
16-nt into the nsp1 cistron, we tested whether the entire BCoV 5’ UTR along with the 
extended 16-nt in the context of the MHV background was viable.  For this, construct 
B1-226/M was tested and it was nonviable even after three blind cell passages from three 
separate electroporation attempts (Fig. 3.6 A and B).  Likewise, a chimera with the entire 
MHV 5’ UTR through 16-nt into the nsp1 cistron along with the remaining nsp1 cistron of 
BCoV in the MHV background, B227-906/M, was nonviable (Fig. 3.6 A and B).  These 
results are consistent with the idea that the 5’ UTR and nsp 1 cistron have to be compatible  
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FIG. 3.6.  Functional exchangeability of the 5’ UTR-nsp1 regions in the viral genome between BCoV 
and MHV.  (A)  Specific interaction between the poorly compatible region within the 5’ UTR and nsp1 of 
BCoV and MHV.  Shown is the schematic of testing the interaction between 5’ UTR and nsp1 by replacing 
MHV sequences (solid line) with BCoV counterparts (dashed line) in the reverse genetics system of MHV.  
Note that the 5’ 16-nt of nsp1 from either BCoV or MHV is along with its cognate 5’ UTR to maintain the 
integrity of long-SLIV as described in the Chapter II.  (B)  Plaque phenotypes of lethal or viable chimeric 
viruses.  (C)  Indistinguishable growth kinetics of the chimera with entire BCoV 5’ UTR and nsp1 relative 
to that of wt MHV.  Multiple-cycle growth kinetics at an MOI of 0.01 PFU/cell of the chimeric viruses were 
compared to that of wt.  Data shown are average of three independent experiments.  (D)  Northern analysis 
for viral RNA synthesis of wt and the chimeric viruses.  Cultures of DBT cells were mock-infected or 
infected with an MOI of 0.01, and intracellular RNA was extracted at 20 hours post infection.  The Northern 
analysis used a 32P-radiolabeled probe specific for the 3’ UTR as described in the Materials and methods.  
gRNA: genomic RNA.  sgRNA: subgenomic RNA.  
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throughout (presumably to enable the 3-way interaction described above).  The results 
with three more chimeras support this conclusion as well.  In the first, a chimera with the 
BCoV 5’ UTR extended 16-nt into the nsp1 cistron and containing the MHV 30-nt element 
in the MHV background, B1-226, M 30-nt/M, was tested, and it was viable but debilitated, 
giving rise to medium-size plaques and growth kinetics that lagged wt MHV and reached a 
final titer 100-fold lower than wt MHV (Fig. 3.6 A, B and C).  In the second, a chimera 
with the MHV 5’ UTR extending 16-nt into the nsp1 cistron and containing the BCoV 32-nt 
element and a BCoV nsp1 cistron, B32-nt, 227-906/M, was tested, and its behavior essentially 
mimicked that of B1-226, M 30-nt/M (Fig. 3.6 A, B and C).  That is, it replicated but was 
somewhat debilitated (Fig. 3.6 A, B and C).  In the third construct, B1-906/M, the entire 
BCoV 5’-terminal sequence through the nsp1 codon was placed into the MHV background 
and was viable and indistinguishable from wt MHV (Fig. 3.6 A, B and C).  Thus, the 
BCoV 5’ UTR and adjacent nsp1 cistron function together in the MHV background to 
support the replication of a wt-like MHV.  This result is fully consistent with the notion 
that there is virus species-specific cross talk between the 5’ UTR region and the nsp1 coding 
region, or the nsp1 protein itself, for wt-like replication. 
     The 5’ UTR and adjacent nsp1 cistron of the group 2b SARS-CoV in the MHV 
background does not support chimera replication.  While it has been previously 
demonstrated that the SARS-CoV 3’ UTR was able to functionally replace the MHV 3’ 
UTR (51), the same was not true for the 5’ UTR (71).  It was shown, however, that some 
putative cis-acting elements from the SARS-CoV 5’ UTR can function in the MHV genome 
(71).  It was also shown in the same study that a SARS-CoV transcription regulatory 
sequence (TRS) (i.e., the RdRp template-switching signal) in the SARS-CoV SL3 (nt 58-72) 
cannot support MHV replication (71).  Our repeat of these experiments utilizing two 
different strategies for introducing the MHV TRS into the SARS-CoV 5’ UTR in chimeras 
S5’UTR-1/M and S5’UTR-2/M yielded lethal viruses (Fig. 3.7).  Nor did replacement of the 
MHV nsp 1 cistron with the SARS-CoV cistron in chimera S265-804/M yield a viable virus 
(Fig. 3.7).  
     To apply the lesson learned above with the BCoV and MHV chimeras, namely, that 
the cognate 5’ UTR and nsp1 cistron from one virus (e.g., BCoV) can function together to  
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FIG. 3.7.  Functional inexchangeability of the 5’ UTR-nsp1 domains in the viral genome between 
SARS-CoV and MHV.  The diagrams illustrate the construction of MHV chimeras whose 5’ UTR and/or 
nsp1 fragments (solid lines) were replaced with their SARS-CoV counterparts (hatched lines) in the reverse 
genetics system of MHV.  Lengths are proportional to the genetic distance.  To enable TRS-dependent 
transcription in the MHV background, the chimeras bearing SARS-CoV 5’ UTR also contained the 
MHV-TRS as indicated.  The carboxyl-terminal 18 amino acids of MHV were also fused with SARS-CoV 
nsp1 to enable proteolytic cleavage of nsp1 from the polyprotein by the MHV papain-like cysteine protease.  
MHV-TRS: MHV transcription regulatory sequence (5’ AATCTAATCTAAACTTTA 3’). 
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yield a viable chimera with another virus (e.g., MHV), we tested just such chimeras 
between the SARS-CoV and MHV.  Two chimeras were made, both with a MHV TRS to 
make leader fusion compatible but with different lengths of TRS-containing flanking 
sequence, however both constructs were nonviable (Fig. 3.7).  Thus, while some 
cis-replication elements in the 5’ UTR of SARS-CoV are compatible in the MHV 
background, e.g., stem-loops 1, 2 and 3, the specific 5’ UTR-nsp1 interaction was not 
functionally conservative between group 2a and 2b coronaviruses, at least by the analytic 
method used here. 
 
DISCUSSION 
     In this study we attempted to determine how it is that a 32-nt region of the BCoV 5’ 
UTR mapping between SLIII and SLIV (nt 142-173) cannot readily replace its 30-nt 
counterpart in the MHV 5’ UTR (nt 141-170) in the MHV background while the three 
remaining 5’ UTR structures in BCoV (SLI and SLII [together], SLIII, and [a long form of] 
SLIV) function immediately in the MHV background to yield viable chimeric viruses with 
near wt-like MHV properties (Chapter II).  We learned that a BCoV142-173/MHV chimera 
(also called B32-nt/M chimera), after first appearing nonviable in the electroporated cells and 
in the first cell passage post-transfection, grew poorly with mixed plaque sizes after a 
second blind cell passage.  After further virus passaging (i.e., virus passages 2 through 10), 
progeny viruses became more like MHV wt.  That is, plaques became large and growth 
kinetics mimicked that of wt MHV.  Genome sequence analyses of the 5’-terminal 1000-nt 
and 3’-terminal 500-nt at virus passage 6 and 10, furthermore, identified three potential 
suppressor mutations outside of the transplanted BCoV 32-nt region, and two potential 
“revertant” mutations within the transplanted 32-nt region.  While suppressor mutations 
could have occurred anywhere within the 32-kb genome, reconstruction experiments in 
which the suppressor mutations were placed back into the MHV genome along with the 
BCoV-specific 32-nt sites, revealed that one or more combinations of suppressor and 
revertant mutations found within the 5’-terminal 400-nt alone were sufficient for phenotypic 
reversion of the chimera to a MHV wt-like virus.  These results indicated that these 
probably are the only mutations causing the reverted phenotype.  Furthermore, a study of 
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the suppressor and reversion mutations led us to conclude that there are 2- and 3-way 
interactions between nt 30 in the SLI, nt 160 and/or nt 166 in the 30-nt region within the 5’ 
UTR, and aa 52, encoded by nt 363-365, within the nsp1 cistron, that are necessary for virus 
replication. 
     To our knowledge, this is the first demonstration of a functional role for nsp1 in the 
behavior of viral genomic RNA.  In earlier studies, we had shown that nsp1 is an RNA 
binding protein that binds cis-replication elements in both the 5’-terminal and 3’-terminal 
regions of the genome (55) (see Appendix), and in studies in other laboratories it has been 
shown that nsp1 in MHV and the SARS-CoV exerts profound effects on cellular mRNA 
stability and translational capability (69, 70, 189).  In the current study, we observed that 
the mutation at nt 363 (and possibly also at nt 353) within the nsp1 ORF behaved as a 
suppressor mutation enabling replication of the B32-nt/M chimera for BCoV.  We postulate, 
therefore, that this charged amino acid in the nsp1 protein is involved in a specific 
interaction with C30 in SLI and G168 in the 32-nt region to facilitate replication of the 
chimera.  That is, the charged amino acid is important for replication of MHV but not 
BCoV in this context.  
     The rationale for our hypothesis that the nsp1 protein (and not the encoding RNA) is 
acting in the 3-way interaction for regulation of replication as observed in this study is the 
following:  (i) A detailed analysis of this region of nsp1 described in Fig. 3.8 shows an 
amino-proximal pattern of charged amino acids that are different between the BCoV and 
MHV clades of subgroup 2a coronaviruses (Fig. 3.8 A).  These patterns, as well as the 
overall aa similarity of 58% between the two viruses, probably have an important influence 
on the folding of nsp1 and its interaction with RNA.  (The group 2 SARS-CoV, by 
comparison, a distant group 2b outlier, has yet a more remarkable difference [not shown]).  
The suppressor mutations K48N and K52E found in MHV nsp1 are both potential 
RNA-binding residues located in a predicted intrinsically disordered region (86).  They are, 
however, not conserved between MHV-like and BCoV-like viruses making them candidates 
for virus-specific RNA-protein interactions such as might be the case with nsp1 (Fig. 3.8 B).  
(ii) The charged amino acids within the amino-proximal half of nsp1 are vital for MHV 
genome replication as documented in studies from Brockway et al. (17).  This is  
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FIG. 3.8.  Phylogenetic relationships of 5’ UTR nucleotides and nsp1 amino acids among group 2a 
coronaviruses.  (A)  Alignments of amino acids 1 through 83 of nsp1 of group 2a coronaviruses.  At the 
top is the diagram of putative secondary structure of MHV-A59 nsp1 as derived from the nuclear magnetic 
resonance data of the homologous region of SARS-CoV nsp1 reported by Almeida et al. (3).  Loci of the 
revertant mutations, K48N and K52E, in nsp1 are shown.  Beneath this is nsp1 amino acids alignment of 
group 2a coronaviruses.  Potential intrinsically disordered regions in nsp1 of MHV and BCoV predicted by 
Disembl (86) are shown on top with dashed rectangles.  Potential RNA-binding residues predicted by BindN 
(162) for MHV and BCoV are shown in “+” and “Δ”, respectively.  The tentative clade classification of 
group 2a coronaviruses is noted at the right.  Amino acids identical across all group 2a coronaviruses are 
highlighted in black.  Amino acids conserved in BCoV-like but are similar in MHV-like and intermediate 
group 2a coronaviruses are highlighted in gray.  Mutations made in MHV-A59 nsp1 by Brockway et al. (17) 
that are detrimental (open asterisk) or lethal (solid asterisk) for viral replication are shown.  Regions in the 
proteins coinciding with the coding regions harboring SLV and SLVI are underlined with grid rectangles.  (B)  
Phylogenetic analysis of 5’ UTR nucleotides and nsp1 amino acids of group 2a coronaviruses and SARS-CoV.  
The trees were constructed by the neighbor-joining method and bootstrap values calculated from 1,000 trees 
are shown.  Putative clades designated as MHV-like, BCoV-like, or intermediate as describe in Chapter II are 
shown.  Abbreviations for coronaviruses are as follows: MHV, mouse hepatitis virus (strains -A59, -JHM, 
and -2); CoV-HKU1, human coronavirus-HKU1; ECoV, equine coronavirus; BCoV, bovine coronavirus 
(strains -Mebus and -ENT); HCoV-OC43, human coronavirus-OC43; HECoV-4408, human enteric 
coronavirus-4408; PHEV, porcine hemagglutinating encephalomyelitis virus; Calf-Giraffe CoV, calf-giraffe 
coronavirus; Antelope CoV, sable antelope coronavirus; SARS-CoV, severe acute respiratory syndrome 
coronavirus. 
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specifically true for residues conserved among all group 2a coronaviruses known at the time 
including K3, K6, H57, R64, E69, R78, and D79 which were crucial or essential for viral 
replication (Fig. 3.8 A) (17).  The K48 and K52 residues were not included in this set of 
analyses since they do not exist in the genomes of BCoV-like viruses (17).  (iii) None of 
the nt point suppressor (and revertant) mutations encountered in the present study caused 
more than a trivial disruption of the corresponding RNA sequence as evaluated by Mfold 
predictions.  Nor could any base-pairing between nsp1 coding sequence at these sites and 
5’ UTR sites be found by inspection.  (iv) The BCoV nsp1 has been previously shown to 
be an RNA-binding protein that interacts specifically with 5’ UTR cis-acting RNA elements 
(55).  (v) The two amino residues, K48 and K52 belong to an intrinsically disordered 
domain (IDD) based on bioinformatic predictions (90) and on homologous alignment with 
NMR-determined SARS-CoV nsp1 structure (Fig. 3.8 A) (3).  Many of the IDD containing 
proteins undergo induced folding, i.e., disorder-to-order transition, upon binding to their 
physiological partners, including DNA, RNA and proteins (167). 
     The precise 3-way interactions proposed here for regulatory function are difficult to 
envision in a precise way.  Of special interest is the interaction between SLI (C30) and 
nsp1.  It is not clear how the C30U mutation located within SLI relieves the problem 
caused by the downstream long-ranged BCoV 32-nt substitution because no apparent RNA 
base-pairing can be identified.  The C30U mutation, however, did enable replication of the 
chimeric genome (Fig. 3.3) and it was able to rescue the severe growth defect resulting from 
the A363G (K52E) mutation in nsp1 (Fig. 3.5).  Thus, we speculate that the 5’ UTR-nsp1 
interaction is tri-partite among SLI, 30-nt and nsp1 and that the cross talk between SLI and 
30-nt RNAs is probably mediated by a protein bridge involving nsp1 and possibly other 
RNA structures and/or other viral or cellular proteins.  Hence, we envision that the 
substitution of BCoV 32-nt forces a slightly different conformation of the nsp1 protein that 
leads to an SLI mutation (C30U) and/or nsp1 interactions as the result of mutations such as 
K48N and K52E.  This idea is consistent with the fact that the C30U mutation, in the 
context of wt 5’ UTR, did not cause a detectable effect on the viral phenotype in the MHV 
background (Fig. 3.4).  It is also possible that the BCoV 32-nt element in the MHV 
background interferes with the folding of the entire 5’ UTR cis-acting structures such that 
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mutations within the SLI and/or nsp1 are required to regain their functional activities.  A 
related observation is that placement of the BCoV 5’ UTR and nsp1 in the MHV 
background enabled the chimera to replicate as efficiently as wt MHV (Fig. 3.7).  Further 
mutational analysis will be needed to precisely define the nsp1-5’ UTR interactions 
identified in this study. 
     What is the biological significance of 5’ UTR-nsp1 interaction?  Given that the 
coronavirus genomic RNAs are capped and polyadenylated, and that many precedents exist 
that describe translation regulation through the binding of regulatory proteins to 5’-proximal 
elements, it is reasonable to speculate that nsp1, an early protein in coronavirus replication, 
regulates genome translation in a similar fashion.  For positive-strand RNA viruses that 
replicate in the cytoplasm, there is a need for a mechanism to inhibit genome translation at 
some point since translation (requiring a 5’Æ3’ movement of ribosome) and negative- 
strand RNA synthesis from the genome template for genome replication (requiring a 3’Æ5’ 
movement of the viral RdRp) cannot simultaneously occur on the same molecule.  A 
model is proposed here for such a role for coronavirus nsp1 and is illustrated in Fig. 3.9.  
The proposed model combines some features of a mechanism proposed by Zust et al. (190) 
for initiating negative-strand RNA synthesis on the coronavirus genome.  Consistent with 
models for translation of eukaryotic mRNAs and positive-stand RNA virus genomes (5, 6, 
48, 57), efficient translation would probably be facilitated by circularization of the RNA 
template through a PABP1-eIF4G-eIF4E protein bridge (Fig. 3.9 A).  The 5’-3’-end 
bridging model for coronavirus genomic RNA is supported by data showing a minimum 
length requirement for the 3’ poly(A) tail that matches that for PABP1 binding and efficient 
DI RNA replication (64, 83, 143, 185).  In the model proposed by Zust et al. for initiating 
coronavirus negative-strand synthesis, an essential 3’-terminal cis-acting bulged stem-loop 
forms a thermodynamically stable interaction with an upstream intra-pseudoknot loop 
sequence to prevent the pseudoknot formation in order to support the 5’-3’-end bridging and 
genome translation at the appropriate time (Fig. 3.9 A).  According to their model, once 
genome translation is completed, viral proteins signal a 3’ end change wherein a 
supercomplex is formed to initiate negative-strand RNA synthesis (Fig. 3.8 B).  We 
postulate that nsp1 is one of these signaling proteins.  We envision that nsp1 interacts with  
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FIG. 3.9.  Hypothetical model for a switch from translation to initiation of negative-strand RNA 
synthesis during coronavirus replication.  (A)  Upon cell entry after infection, the translation of 
positive-strand viral genome utilizes host cap-dependent machinery and a circularization resulting from a 
bridging by proteins of eIF4E, eIF4G and PABP.  This step is based on the widely-supported translation 
model of most eukaryotic mRNAs.  At this stage, formation of the pseudoknot (PK) is prohibited by closure 
of the bottom segment of the 3’-terminal bulged stem-loop through base-pairing between the PK loop and the 
3’ end of the genome.  (B)  After translation and processing of the coronavirus polyproteins pp1a and pp1ab, 
viral nsp1 binds the 5’ UTR to exclude initiation factors and down-regulates genome translation.  The 5’ end 
translation-silencing signal is then transduced to the 3’ end by protein-protein interaction between nsp1, nsp7 
and nsp10, thus recruiting nsp8 and nsp9 to bind the stem formed by the PK loop and the 3’ end.  
Negative-strand RNA synthesis is then initiated by the primase activity of nsp8, then allowing the PK to form.  
(C)  Once PK formation is achieved, the main RNA synthesizing enzyme, RdRp (nsp12), along with other 
replication-related nonstructural proteins from the translation of ORF 1 join the giant protein complex and 
carry out elongation of the negative-strand primer.  Not shown are possible roles played by other viral and 
cellular factors.  eIF: eukaryotic initiation factor; PABP, poly(A) binding protein. 
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the 5’ UTR and with the nsp7-nsp10 complex (18) which in turn accompanies nsp8 (a 
primase) and nsp9 (another RNA-binding protein) to bind the stem formed between the 
pseudoknot loop 2 and the extreme 3’ end of the genome (190).  The nsps7-8-9-10 
complex is a postulated pre-replication complex required for synthesis of an oligonucleotide 
primer by nsp8 which is later used by the primer-dependent RdRp (or nsp12) to complete 
negative-strand RNA synthesis (36, 41, 66, 68, 120, 148, 149, 180, 190).  Following 
primer synthesis, the pseudoknot takes shape and recruits the RdRp and other viral proteins, 
and a mature replication complex is established which then elongates the negative-strand 
antigenome (Fig. 3.9 C).  It should be noted that the viral protein N (113, 151, 182, 184, 
186) and cellular proteins such as PTB (65, 81), hnRNP A1 (64), and chaperones (109, 110, 
176, 177), shown previously to interact with 5’ and 3’-terminal cis-replication elements, are 
not depicted here but are highly likely participants in the process. 
     In a final note, many intrinsically disordered proteins fold flexibly and bind different 
targets depending on physiological conditions and intracellular locations, and in some cases 
play key roles in the assembly of supercomplexes (40).  These properties may describe the 
multi-functional nsp1 which we postulate is playing key roles as a regulatory protein in viral 
genome translation and replication.  This postulate arises from the genetic evidence 
obtained in this study.  We anticipate that our model will facilitate further studies on the 
mechanisms governing coronavirus RNA translation and replication. 
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CHAPTER IV.  STEM-LOOP III IN THE 5’ UTR, IDENTIFIED 
PREVIOUSLY AS A CIS-REPLICATION ELEMENT FOR BCOV DI 
RNA, IS NOT ESSENTIAL FOR REPLICATION OF THE MOUSE 
HEPATITIS CORONAVIRUS GENOME 
 
INTRODUCTION 
     Primary sequences and higher-order structures in the 5’ and 3’ UTRs of coronaviruses 
have been shown to function as cis-acting elements for replication of either a helper virus- 
dependent DI RNA replicon, or for replication of the full-length viral genome.  The 
terminal genomic cis-replication RNA signals have been best characterized in the group 2 
coronaviruses through studies using the BCoV (for which only a DI RNA replicon has been 
studied since a reverse genetics system is not yet available), the MHV (for which both a DI 
RNA replicon and a reverse genetics system for the full-length viral genome are available), 
and the SARS-CoV (for which a DI RNA replicon is not available, and a reverse genetics 
system is available) (15, 97). 
     To date, from several studies with BCoV and MHV that have been carried out in 
different laboratories, and from Chapters II and III above, an overall configuration of the 
cis-replication elements within the 5’ UTR of the group 2a coronaviruses (BCoV and MHV) 
can be summarized as depicted in Fig. 4.1.  The 5’ UTR cis-replication elements are four 
highly structured stem-loops (SLs) named I (comprised of the two smaller SL 1 and 2), II, 
III, and IV, and a relatively unstructured segment of 30 nt in MHV (32 nt in BCoV) that 
shows virus species-specific replication properties (Chapters II and III).  At this time it is 
not known precisely what each cis-acting element does.  The 5’ UTR RNA replication 
signals could be regulating genome translation and/or the subsequent steps of genomic and 
subgenomic RNA syntheses.  The regulation involving any of these steps presumably 
requires an interaction with trans-acting viral and/or cellular proteins.  It should be noted 
that the initial studies used to identify the coronavirus 5’ UTR cis-replication signals utilized 
exclusively the DI RNA systems which have the advantage of identifying cis-acting signals 
independent from any trans-acting signaling function.  That is, the cis-acting activity can 
be evaluated independently from any alternative function (such as encoding a trans-acting 
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FIG. 4.1.  Cis-replication SLIII in the MHV 5’ UTR.  The organization of the 31.3-kb MHV genome is 
shown at the bottom.  Above the genome is a current model for the four cis-replication RNA stem-loop 
structures I, II, III, and IV in the MHV 5’ UTR.  Distances as drawn are proportional to the distances in the 
nucleotide sequence.  Solid circles indicate the AUG start codon for ORF 1.  The enlarged section is a 
detailed view of nt 83-140 which are comparable to BCoV nt 85-141 (variant bases in the BCoV sequence are 
identified by arrows).  Note that this region contains the SLIII structure as defined in earlier studies (122) as 
well as flanking sequences of 14-nt upstream and 26-nt downstream.  The start and stop codons for the 
SLIII-associated intra-5’ UTR ORF are boxed.  The plaque phenotypes of wild type (wt) and chimeric MHV 
B85-141/M are displayed at the right.  
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protein) for the same genetic element (19).  Making a distinction between a cis and a trans 
function for a given genetic element is difficult when using only the viral genome and a 
reverse genetics system.  Therefore, DI RNA analyses are still the method of choice for 
identifying viral cis-replication elements. 
     The identity of the BCoV 5’-proximal SLIII as a higher-order cis-replication element 
was determined by enzymatic probing and by mutation analysis (122).  The structure of 
the stem was shown to be required for DI RNA accumulation through mutation experiments 
that disrupted its structure and concurrently destroyed its replicating ability and then 
compensatory mutations that restored its base-paired structure and concurrently restored its 
replicating ability (122).  In addition, a SLIII-associated intra-5’ UTR AUG-initiated short 
upstream ORF (uORF) was shown to be strongly preferred by the BCoV DI RNA for 
optimal replicating ability (122).  Consistent with these apparent requirement for DI RNA 
replication, SLIII, along with its associated uORF, appears highly conserved among group 2 
coronaviruses and to be similarly conserved in coronavirus groups 1 and 3 implying an 
important biological function (122).  Further studies also showed that seven host proteins 
of unknown identity as well as three unidentified viral proteins of 55, 38, and 22 kDa from 
BCoV-infected cells could be UV-crosslinked to the SLIII probe, suggesting that these 
proteins may be trans-acting factors for SLIII function (S. Raman, PhD dissertation, 2003).  
These experimentally determined properties together suggested that SLIII is a crucial 
cis-replication element for coronavirus DI RNA replication and therefore probably is also 
required for coronavirus genome replication. 
     Here, to establish the functional importance of SLIII and its associated short uORF 
for MHV replication, a set of mutation experiments on SLIII in the context of the MHV 
genome was carried out with the use of a reverse genetics system.  It was learned, 
surprisingly, that several structural mutations of SLIII and even deletion of a large portion 
of SLIII, including deletion of the associated short uORF, and eventually deletion of the 
entire long form of SLIII, are tolerated by MHV for virus replication.  The results of this 
study raise new questions about the role of SLIII in coronavirus replication and lead us to 
speculate on how its function could be (at least partially) determined. 
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MATERIALS AND METHODS 
     Cells and viruses.  DBT cells, L2 cells, and BHK-MHVR cells were grown in 
media and conditions as described in Chapters II and III. 
     Plasmid constructions for mutations in fragment A of the infectious clone for 
MHV-A59.  The general strategy to generate mutated or truncated MHV-A59 infectious 
clone was as described in Chapters II and III.  Site-directed mutagenesis was made by 
overlap PCR with the primers shown in Table 4.1.  Briefly, to make B85-141/M-loopC, the 
first PCR was done with the primers G106C-G108C(-) and A59-ScaI, and the second PCR 
was done with the primers G106C-G108C(+) and T7startMHV, wherein both PCR reactions 
the A fragment for B85-141/M assembly was used as the amplification DNA template.  PCR 
fragments were chromatographically purified and used in a third PCR with the primers 
A59-ScaI and T7startMHV.  The other SLIII-associated mutants were established 
following the same PCR scheme except for the use of different designated primers.  To 
make B85-141/M-loopA, primers G106A-G108A(-) and G106A-G108A(+) were used; for 
B85-141/M-loopU, primers G106T-G108T(-) and G106T-G108T(+) were used; for 
B85-141/M-stemL, primers BCoV SL3-2L(-) and BCoV SL3-2L(+) were used; for 
B85-141/M-stemR, primers BCoV SL3-2R(-) and BCoV SL3-2R(+) were used; for 
B85-141/M-stemLR, primers BCoV SL3-2LR(-) and BCoV SL3-2LR(+) were used; for 
MHVΔ96-115, primers MHV(96-115)del(-) and MHV(96-115)del(+) were used; for 
MHVΔ91-120, primers MHV(91-120)del(-) and MHV(91-120)del(+) were used; for 
MHVΔ80-130, primers MHV(80-130)del(-) and MHV(80-130)del (+) were used; and for 
MHVΔ75-138, MHV(75-138)del(-) and MHV(75-138)del(+) were used. 
     Assembly of the full-length MHV-A59 infectious recombinant virus RNA.  
Assembly of full-length MHV-A59 infectious recombinant construct was carried out as 
described in Chapters II and III. 
   Characterization of viral mutants by RT-PCR, viral RNA sequence analyses, and 
growth kinetics measurement.  Analyses of plaque morphology and genome sequencing 
of recovered progeny viruses were carried out as described in Chapters II and III. 
     Northern blot analysis of viral RNAs.  Northern blot assays were performed as 
described in Chapters II and III. 
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 TABLE 4.1.  Oligonucleotides used in Chapter IV 
Oligonucleotidea Polarityb Sequence (5’Æ3’)c Binding region (nt) 
T7startMHV + gtcggcctcttaatacgactcactatagTATAAGAGTGATTGGCGTCCG T7 promoter MHV 1-21 
A59-Sca I - CGCCTTGCAGGAGTACTTACCCTTC MHV 899-923 
A59-BCoV(85-141)(-) + cttgtgggcgtagatttttcatagtggtgtctatattcaTTCCTTGACTTTCGTTCTCTGC 
MHV 141-162 
BCoV 103-141 
A59-BCoV(85-141)(+) - ctatgaaaaatctacgcccacaagcatagaatacagggagtgCCGTTTATAAAGTTTAGATTAG 
MHV 61-82 
BCoV 85-126 
G106C-G108C(-) + gtattctatgcttCtCggcgtaga BCoV 93-116 
G106C-G108C(+) - tctacgccGaGaagcatagaatac BCoV 93-116 
G106A-G108A(-) + gtattctatgcttAtAggcgtaga BCoV 93-116 
G106A-G108A(+) - tctacgccTaTaagcatagaatac BCoV 93-116 
G106T-G108T(-) + gtattctatgcttTtTggcgtaga BCoV 93-116 
G106T-G108T(+) - tctacgccAaAaagcatagaatac BCoV 93-116 
BCoV SL3-2L(-) + gtatAGAatgGGtgtgggcgtagatttttcatagtggtgtc BCoV 93-133 
BCoV SL3-2L(+) - gacaccactatgaaaaatctacgcccacaCCcatTCTatac BCoV 93-133 
BCoV SL3-2R(-) + gtattctatgcttgtgUCcgtUCUtttttcatagtggtgtc BCoV 93-133 
BCoV SL3-2R(+) - gacaccactatgaaaaaAGAacgGAcacaagcatagaatac BCoV 93-133 
BCoV SL3-2LR(-) + gtatAGAatgGGtgtgUCcgtUCUtttttcatagtggtgtc BCoV 93-133 
BCoV SL3-2LR(+) - gacaccactatgaaaaaAGAacgGGcacaCCcatTCTatac BCoV 93-133 
MHV(96-115)del(-) + CGGCACTTCCTGCGTGCTTGTCATAGTGCTGAC MHV 80-95, 116-132 
MHV(96-115)del(+) - GTCAGCACTATGACAAGCACGCAGGAAGTGCCG MHV 80-95, 116-132 
MHV(91-120)del(-) + CTTTATAAACGGCACTTCCTCATAGTGCTGACATTTGTAG MHV 71-90, 121-140 
MHV(91-120)del(+) - CTACAAATGTCAGCACTATGAGGAAGTGCCGTTTATAAAG MHV 71-90, 121-140 
MHV(80-130)del(-) + GTTTAAATCTAATCTAAACTTTATAAAACATTTGTAGTTCCTTGACTTTCG 
MHV 53-79, 
131-154 
MHV(80-130)del(+) - CGAAAGTCAAGGAACTACAAATGTTTTATAAAGTTTAGATTAGATTTAAAC 
MHV 53-79, 
131-154 
MHV(75-138)del(-) + GTAGTTTAAATCTAATCTAAACTTTAGTTCCTTGACTTTCGTTCTC 
MHV 50-74, 
139-159 
MHV(75-138)del(+) - GAGAACGAAAGTCAAGGAACTAAAGTTTAGATTAGATTTAAACTAC 
MHV 50-74, 
139-159 
MHV-1094(+) - CGATCAACGTGCCAAGCCACAAGG MHV 1094-1117 
DI3(+) - cgggatccgtcgacacgcgtttttttttttttttttttt Poly(A) 
MHV-leader(-) + TATAAGAGTGATTGGCGTCCG MHV 1-21 
MHV(605-623)(+) - GTTACACAGGCAGACGCGC MHV 605-623 
MHV(261-284)(-) + CCATGGATGCTTCCGAACGCATCG MHV 261-284 
MHV(30811-30830)(-) + GGATGGTGGTGCAGATGTGG MHV 30811-30830 
MHV-NPol(A)(+) - ttttttttttttttttttttttttttACACATTAGAGTC MHV 31019-31033 
T7MHV-NATG(-) + gtaatacgactcactatagATGTCTTTTGTTCCTGGGC MHV 29669-29687 
MHV(31094-31122)(+) - CAGCAAGACATCCATTCTGATAGAGAGTG MHV 31094-31122 
a The positive and negative symbols in the oligonucleotide names indicate the polarity of the nucleic acids to     
  which the oligonucleotides anneal. 
b Polarity of the oligonucleotide relative to the positive-strand viral genome. 
c Lower-case bases represent non-MHV sequences.  Capitalized bases represent MHV sequences. 
  Bold-capitalized bases denote mutated changes. 
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RESULTS 
     A wild-type-like loop sequence and a wild-type-like stem integrity of the “short” 
SLIII are not required for MHV replication.  Experiments described in Chapter II 
demonstrated that the wt BCoV short SLIII with flanking sequences (nt 85-141), differing 
by ~30% in nt sequence from wt MHV counterpart (nt 83-140) (Fig. 4.1), when used to 
construct a B85-141/M chimera enabled the chimera to make nearly MHV wt-like plaques, 
and to have nearly wt-like growth kinetics, although the final virus titer of the chimera is 
approximately tenfold less than that of wt.  This demonstrated that some variation in SLIII 
structure was tolerated for MHV virus replication.  To further explore the structural 
requirements for SLIII function, the B85-141/M chimera was used as a starting point and 
further mutations were made to alter the loop and stem (Fig. 4.2), and effect of these on 
virus replication were studied.  Since loops (terminal and internal) and bulges within an 
RNA helix structure are known to be sites for protein binding (101), we first sought the 
effects of changes in these for virus growth and began with an analysis of the SLIII terminal 
tetraloop.  Tetraloops are secondary structural motifs that stabilize hairpins in a variety of 
RNAs (106).  Among all currently identified group 2a coronaviruses, the consensus 
sequence for the SLIII tetraloop is YGYG, where Y stands for any pyrimidine (27, 122).  
This conservation in sequence suggests the second and fourth guanines probably play a role 
in the function of the tetraloop and they were therefore selected for mutation analysis.  
Mutants B85-141/ M-loopC, B85-141/M-loopA, and B85-141/M-loopU in which both guanines in 
the tetraloop were changed to cytosines, adenines, and uracils, respectively, were made and 
tested (Fig. 4.2 A).  In vitro-prepared mutant genomic RNAs were electroporated into host 
cells and the character of progeny viruses, if any, were monitored.  To our surprise, all 
three mutants were viable and none were impaired with respect to plaque size or progeny 
titers (~1×107 PFU/ml) when compared to those of B85-141/M (Fig. 4.2 A).  This indicated 
that the character of the two tetraloop bases, despite their conservation among known group 
2a coronaviruses, is not critical for SLIII function in virus replication. 
     We next tested the group 2a-conserved features of the SLIII helix.  By site-directed 
mutagenesis three mutants were created for testing (Fig. 4.2 B).  In mutant B85-141/M- 
stemL, five of the eight bases in the left arm were changed leaving only the SLIII-associated 
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FIG. 4.2.  Stem and loop mutants of BCoV SLIII in the MHV genome.  For each mutant, highlighted 
nucleotides in black are those that were changed from the chimera B85-141/M.  The start codon for the 
SLIII-associated intra-5’ UTR ORF is boxed.  Plaque phenotypes are shown below the depiction of mutants.   
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AUG codon intact and altering the second amino acid (LÆG) in the putative 8-aa short 
peptide derived from the intra-5’ UTR uORF.  In mutant B85-141/M-stemR, five of the eight 
bases in the right arm were changed that maintained the CGU base pairing with the AUG 
start codon in the left arm and altered two amino acids (GÆS and DÆL) in the putative 
8-aa peptide product.  In mutant of B85-141/M-stemLR, the entire stem structure was 
replaced with one that used a different set of bases yielding a stem with the same free 
energy as B85-141/M, and yielded a peptide differing by three amino acids (LÆG, GÆS, and 
DÆL) from B85-141/M.  For each mutant, infectious RNA was prepared and electroporated 
into host cells and the progeny were evaluated.  Surprisingly, each mutant yielded progeny 
virus with plaque sizes that were indistinguishable from those of B85-141/M (Fig. 4.2 B).  
That is, they were essentially MHV wt-like.  These results suggested that the integrity of 
SLIII is not necessary for MHV replication in cell culture.  Thus, the wt-like plaques and 
growth phenotypes of the six short SLIII mutants led us to hypothesize that the principal 
role of SLIII may be to supply a platform for the intra-5’ UTR short ORF which may play a 
biological role during infection, but is not in itself required for virus replication in cell 
culture. 
     A deleted “short” SLIII mutant virus is viable and is only mildly debilitated.  
To further examine the required features of SLIII for MHV replication, we chose to evaluate 
a “long” form of SLIII that had been previously suggested by alternative Mfold-predictions 
(Fig. 4.3 A).  Interestingly, the long form of SLIII is consistent with a model predicted by 
other algorithms as well (88) and seems to be a structure phylogenetically conserved among 
all known coronaviruses (27).  The long SLIII in MHV contains two central small loops 
separated by a helix of three base pairs with a seven base-paired helix both above and below 
the two central loops.  The upper-most helix and the terminal tetraloop comprise the entire 
short SLIII evaluated above (Fig. 4.3 A).  The long SLIII of BCoV has a large (16-nt) 
central loop with an eight base-paired stem above and a five base-paired helix below the 
loop.  The upper stem and terminal tetraloop here also comprise the entire short SLIII in 
BCoV (Fig. 4.3 A).  For both MHV and BCoV, the existence of the long SLIII remains to 
be established by structure probing. 
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FIG. 4.3.  Predicted alternative “long” secondary structure for MHV and BCoV SLIII.   (A)  At left 
is the Mfold-predicted wild-type (wt) “long” structure for MHV SLIII along with its adjacent upstream SLII.  
At right is the predicted “long” BCoV counterpart.   The previously-described “short” SLIII shown to be 
required for BCoV DI RNA replication is highlighted in gray.  The heptameric UCUAAAC template- 
switching signal (also called the transcription regulatory sequence or TRS) for transcription initiation is shown 
in the loop of SLII and is boxed with a dashed line.  The start and stop codons for the SLIII-associated 
intra-5’ UTR ORF are boxed.  (B)  MHV SLIII truncation mutations tested for replication in MHV.  
Nucleotides are numbered according to the wt MHV sequence from the first base at the 5’ end of the genome.  
Plaque phenotypes are shown below the respective mutant with their names given at the top. 
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     To establish whether the long SLIII in MHV plays a role in viral replication, 
truncation and deletion mutations of it in the genetic background of the wt MHV genome 
were constructed and tested (Fig. 4.3 B).  In the first mutation, the upper part of the long 
SLIII, that is, the part comprising the entire short SLIII, was precisely removed to form 
MHVΔ96-115.  Remarkably, this mutant was viable and immediately after electroporation of 
the mutated genome formed plaques nearly wt MHV in size (Fig. 4.3 B).   
     A phenotype characterization of this surprising mutant was done by first establishing 
single-cycle and multiple-cycle growth curves of MHVΔ96-115 progeny (Fig. 4.4 A).  Under 
both conditions of growth, the growth rate of MHVΔ96-115 lagged slightly behind that of wt 
MHV and the maximal titer reached was approximately tenfold less than that of wt MHV.  
A Northern blot analysis of viral RNAs from infected cells, furthermore, revealed that the 
MHVΔ96-115 produced the same set of sgmRNA species and in the same relative proportions 
as wt MHV (Fig. 4.4 B).  These results indicated that the RNA sequence making up the 
entire structure of the short SLIII is not required for MHV replication in cell culture or for 
the generation of wt MHV plaques. 
     A deleted “long” SLIII mutant virus is viable, but is greatly debilitated.  We 
next evaluated the requirement for the remaining part of the long SLIII (i.e., the part without 
the short SLIII component) for MHV replication.  For this, a second mutant of wt MHV, 
MHVΔ91-120, was made and tested in which nt 91-120 was deleted.  Nucleotides 91-120 
comprise all of the short SLIII and all of the top bulge and central stem in the long SLIII 
(Fig. 4.3 B).  Surprisingly, again, MHVΔ91-120 replicated and formed plaques 
indistinguishable from wt MHV immediately after electroporation of the mutant genomic 
RNA (Fig. 4.3 B).  Growth curves of this mutant have not yet been done; however, 
Northern blot analysis of viral RNAs from infected cells shows that sgmRNAs are made in 
the same relative proportions as with wt MHV but are far less abundant (Fig. 4.4 B).  Thus, 
MHV without nt 91-120 can replicate, but viral growth is slightly more debilitated than 
virus just missing the short SLIII. 
     In the next mutant evaluated, the entire full-length of the long stem-loop, nt 80-130,    
was precisely deleted from the wt MHV genome to form mutant MHVΔ80-130.  Most 
surprisingly, this mutant too was viable after electroporation of the mutated genomic RNA 
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FIG. 4.4.  Growth of MHV SLIII truncation mutants in cell culture.  (A)  Growth of the truncation 
mutant MHVΔ96-115 relative to that of wild-type (wt) MHV.  DBT cells were infected with wt MHV or MHVΔ
96-115 at an MOI of 0.01 PFU/cell (left) or 5.0 PFU/cell (right).  At the indicated times postinfection, aliquots 
of medium were removed and infectious titers were determined on mouse L2 cells.  Open and solid symbols 
represent results from two independent experiments.  (B)  RNA synthesis of SLIII truncation mutants in cell 
culture relative to that of wt MHV.  Northern analyses for viral RNA synthesis of wt and the SLIII truncation 
mutants.  Cultures of DBT cells were mock-infected or infected with MOI of 0.01 PFU/cell, and intracellular 
RNA was extracted at 24 hours post infection.  The Northern analysis used a 32P-radiolabeled probe specific 
for the 3’ UTR as described in the Materials and Methods.  gRNA, genomic RNA; sgRNA, subgenomic 
RNA.  
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and the plaques generated, albeit after a long recovery period after transfection, were large 
and indistinguishable from wt plaques.  A Northern blot analysis of viral RNAs from cells 
infected with progeny of MHVΔ80-130 revealed that sgmRNA species were produced in the 
same relative proportions as from wt MHV (Fig. 4.4 B).  In addition, a sequence analysis 
of the genomic 5’-proximal 1000-nt region in the recovered virus showed two mutations, 
U33A and C37U (data not shown).  These two nucleotide changes may be functioning as 
suppressor mutations and their further analyses might reveal a mechanistic feature of long 
SLIII function. 
     Finally, an extensive deletion mutation that removed nt 75-138 which included some 
upstream and some downstream flanking sequences of the long SLIII and formed mutant 
MHVΔ75-138 was found to be lethal.  The results with MHVΔ75-138, therefore, indicate an 
essential role for at least part of this region of the genome for virus replication.   
 
DISCUSSION 
     In this study, we have shown that the MHV genome is capable of tolerating a wide 
variety of mutations in the SLIII region (Figs. 4.1 and 4.2).  More strikingly, we found that 
both the “short” (nt 96-115) and “long” (nt 80-130) forms of SLIII, along with the SLIII- 
associated 24-nt uORF, can be completely removed without killing virus replication in cell 
culture (Figs. 4.3 and 4.4).   
     These findings differ considerably from those our laboratory reported earlier for the 
replication of BCoV DI RNA (122).  This apparent discrepancy points out some 
fundamental differences between the replication requirements for DI RNAs and viral 
genomes that are not fully understood but that have been noted before (50, 55).  Namely, 
these differences might reflect the fact that successful competition by the DI RNA for the 
helper virus replication machinery might require the DI RNAs to be more sensitive to 
alternations in structure in order to achieve replication fitness (55).  In the virus genome, 
removal of short SLIII significantly impaired viral replication efficiency as observed in 
kinetic assays (Fig. 4.4 A), suggesting that in this context SLIII may act as a modulator of 
RNA synthesis rather than an essential element, per se.  That is, its function might differ to 
suit a particular set of physiological circumstances.  Interestingly, a similar observation 
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was reported earlier by S. Goebel et al. (50) for the HVR in the MHV 3’ UTR which acts as 
a cis-acting element for DI RNA replication.  In a DI RNA, this region is required for 
replication (89), whereas it is not required for replication in the full-length genome.  In the 
mouse host, however, deletion of the HVR from the genome led to a dramatic attenuation of 
virulence (50).  This finding also established that some genetic elements are responsible 
for tissue tropism which determines the site of virus replication and associated virulence.  
Indeed, it is known that diseases and clinical symptoms caused by MHV infection vary 
greatly depending on the strain, dose, and mode of the inoculation of the virus, as well as 
the genetic background, age, and immune status of the mouse host (33, 56, 118).  Thus, it 
is possible that SLIII may also play a critical role in pathogenesis.  This, then, calls for 
further mouse infectivity studies to determine the potential roles of SLIII RNA element in 
pathogenesis. 
     It remains to be determined whether the SLIII-associated short uORF benefits the 
replication of the viral genome.  Mutagenesis studies in the group 2a BCoV DI RNA 
showed that the short uORF or its product may act to enhance replication through a 
cis-acting influence on translation although its upstream area does not contain highly 
favorable Kozak sequences (23, 122, 157).  Several short uORFs have also been shown to 
affect the translation of downstream ORFs in eukaryotic and viral RNAs through a variety 
of mechanisms under a range of pathological condition (80, 107).  It would seem possible 
that the SLIII-associated intra-5’ UTR uORF behaves similarly in the coronavirus genome.  
In this regard, translational analysis of the genome ORF 1 in the absence of the uORF is 
needed to determine the uORF’s importance for virus replication in cell culture and the 
animal host, and to determine the pathogenic consequences of its removal. 
     If the SLIII really plays an important, but not essential, role in viral RNA synthesis, 
then its function may be that of a regulatory element that could be functioning at any of 
several steps leading to RNA replication.  As such, it is reasonable to speculate that its 
function (s) will be mediated by trans-acting factors, based on precedents in other 
positive-strand RNA viruses (6, 48, 57).  In this regard, both host and viral proteins should 
be considered candidate factors for binding the positive- and/or negative-strand of SLIII.  
This hypothesis is consistent with an earlier finding in our laboratory that translation 
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efficiency of a reporter gene attached to the genomic 5’ UTR of BCoV differs between 
infected and uninfected cells (133).  It is also consistent with the fact that seven unknown 
cellular proteins and three viral proteins of 55, 38, and 22 kDa bind the positive-strand 
BCoV SLIII as determined by a UV-crosslinking assay (S. Raman, PhD dissertation, 2003).  
In addition, a preliminary study with purified BCoV N and nsp1 proteins showed that these 
interact with SLIII (see Appendix) suggesting their potential roles as SLIII trans-acting 
factors.  Since N has also been shown to be enhancing RNA replication in transfection 
studies (154), its association with SLIII in connection with this behavior needs to be 
studied. 
     From experiments described here it was not established whether SLIII functions as a 
structure in the “short” or “long” form.  However, from the preliminary evidence of 
potential suppressor mutations in SLI for replicating mutants lacking the long-SLIII (Fig. 
4.3) it is possible that the flanking areas of long-SLIII may be involved in an interaction 
with SLI.  This inference is consistent with what we learned from studies described in 
Chapter III wherein the relatively unstructured hypervariable 30-nt (nt 141-170) just 
downstream of the long SLIII specifically interacts with SLI and the nsp1 coding region (or 
possibly nsp1 itself) as demonstrated by genetic evidence.  It is also conceivable that the 
long-SLIII itself may be one constituent of a giant interactive complex, and removal of it 
would potentially reshape the complex thereby leading to the unexpected suppressor 
mutations within SLI. 
     The dispensability of the SLIII element in the MHV genome for virus replication 
raises the question of just what is the minimal 5’ UTR requirement for virus replication in 
cell culture.  Answering a similar question regarding the 3’ UTR led to an experimental 
shortening of a functional MHV 3’ UTR (50, 190).  A systematic analysis of the minimal 
structural requirements for 5’ end may help to define the 5’-proximal mechanisms involved 
in genome translation, genome replication, and genome-directed discontinuous transcription 
steps that generate the leader-containing sgmRNAs.  
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CHAPTER V.  FUTURE DIRECTIONS 
INTRODUCTION 
     After the SARS epidemic in 2003, world-wide interest was stimulated to identify new 
coronaviruses from a variety of hosts that might have served as reservoirs for the origin of 
the SARS-CoV via interspecies virus jumping and recombination.  Significant research 
effort around the world was also boosted to depict coronavirus replication mechanisms and 
coronavirus RNA and protein functions with the hope of developing new anti-coronaviral 
therapeutic agents, and to characterize host immune response with the hope of developing 
effective new vaccines.  Yet many details of coronavirus replication mechanisms remain 
largely unknown. 
     In this dissertation, two model group 2a coronaviruses, BCoV and MHV, have been 
investigated to examine their 5’-terminal cis-acting RNA signals for viral genome 
replication.  The results led to the surprising findings that (i) part of the 5’-proximal RNA 
signaling structure lies within the nsp1 coding region (Chapter II), (ii) a species-specific 
interaction between sites within the 5’ UTR and nsp1 occurs (Chapter III), and (iii) a large 
part of 5’ UTR-mapping SLIII, formerly thought of as a critical cis-replication structure, can 
be deleted without killing the virus (Chapter IV).  The second of these discoveries has 
opened up the possibility that such interactions may occur in other if not all coronaviruses.  
It also suggests a potential mechanism by which a transition between genome translation 
and negative-strand RNA synthesis might be regulated.  Understanding this mechanism in 
detail might identify a target for antiviral drug design that could be broadly effective against 
coronaviruses. 
 
TO IDENTIFY OTHER VIRAL FACTORS THAT INTERACT WITH 5’ 
GENOMIC RNA CIS-REPLICATION ELEMENTS  
     In our substitution experiments (Chapters II and III) and deletion experiments 
(Chapter IV), the genomic RNA sequences of recovered viruses were only confirmed for the 
5’-terminal 1000 nt and the 3’-terminal 500 nt mainly based on the fact that these 
components appear in all characterized coronavirus DI RNAs, and they therefore must be 
essential for replication (15).  To explore the possibility that suppressor mutations might 
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exist elsewhere in the genome, whole genome sequencing should be done to find them.  
Finding them might identify other viral proteins that contribute to suppression of 
debilitating mutations.  Because of the large genome size, however, this has not been 
feasible for all of the engineered viruses.  Particular interests should focus on the 
phenotypic revertants of the B32-nt/M chimera and the MHVΔ80-130 mutant whose behavior 
led to the finding of 5’ UTR-nsp1 interactions and nonessential nature of SLIII, respectively.  
Once nucleotide changes are probed, reconstruction experiments could be done to establish 
the authenticity of putative suppressor mutations.  Further structural and biochemical 
analyses would likely arise from the identification of novel viral factors.  An alternative 
method for finding other viral trans-acting factors that interact with the 5’ UTR might be 
affinity purification wherein the entire 5’ UTR RNA from different constructs would be 
biotin-labeled and used for streptavidin bead pull-down of intracellular proteins extracted 
from virus-infected cells at different times postinfection.  The purified proteins could then 
be identified by mass spectrometry and sequencing (125).  Given that the 5’ UTR likely 
behaves as a unit for replication based on our results, attention would be given to the intact 
5’ UTR instead of individual cis-acting RNA elements.  Confirmation of the 5’ UTR- 
bound viral proteins could then be done by using electrophoretic mobility shift assays 
(EMSAs) along with purified proteins.  Mapping of the putative viral proteins on the 5’ 
UTR would then need to be done to understand their function. 
 
TO IDENTIFY THE FUNCTIONAL DEFECT ARISING FROM THE 
EXCHANGE OF THE INCOMPATIBLE SPECIES-SPECIFIC 32 (30)-NT 
5’ UTR SEGMENT BETWEEN BCOV AND MHV 
     From genetic evidence described in Chapter III, a species-specific interaction 
between 5’ UTR and nsp1 was shown to be necessary for virus replication.  The precise 
nature and function of this interaction, however, remains to be elucidated.  To learn these, 
some of the lethal chimeras, such as B1-226/M and B227-906/M (Fig. 3.7), might be useful.  
First attempt could be addressed to their effects on translation.  It is known that the capped 
infectious RNAs prepared in vitro must undergo translation immediately after transfection 
into host cells in order to synthesize the replicase proteins needed to initiate replication.  
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Therefore, it should be tested whether the 5’-end replication structures identified in the 
dissertation and elsewhere are regulators of translation.  To establish the capability of these 
lethal constructs to support translation, in vitro translation could be employed by using the 
rabbit reticulocyte lysate along with radiolabeling and SDS-PAGE analysis.  The study 
could then be expanded to in vivo system by evaluating translational consequences driven 
by 5’-terminal cis-replication elements fused with reporter gene.  Another way to examine 
the defects of these mutants is the coupled in vitro translation-replication assays, which has 
been shown to be quite successful in distinguishing viral genome replication from genome 
translation under the same experimental system (20).  This strategy can be joined with 
two-cycle ribonuclease (RNase) protection assay for specifically detecting negative-strand 
RNAs (114).  Furthermore, it might also be enormously rewarding to establish an in vitro 
replication system whereby active MHV replication complexes are isolated from MHV- 
infected cell lysates and used to assay viral RNA synthesis.  This system would also serve 
as a framework for further investigation of the coronaviral replication cycle.  Given that a 
similar system has been demonstrated for SARS-CoV (158), development of the in vitro 
MHV replication machinery would certainly facilitate the progress on understanding the 
modulation of virus replication. 
 
TO CHARACTERIZE THE 5’ UTR-NSP1 INTERACTION 
     The evidence described in Chapter III suggested specific interactions between SLI, 
the hypervariable 30-nt region between SLIII and SLIV, and the nsp1 which has been partly 
proven for BCoV as shown in the Appendix.  However, it is unknown how SLI and the 
30-nt region interact or how this interaction is affected by nsp1 binding.  A number of 
analytical procedures are available for characterizing RNA-protein complexes that could be 
used.  In-line probing and nuclear magnetic resonance (NMR) are two such techniques.  
The in-line probing assay relies on structure-dependent spontaneous cleavage of RNA and 
has been shown useful for finding altered structure or altered RNA orientation after ligand 
binding (102, 124).  Comparing the in-line probing profiles of the MHV or BCoV 5’ UTR 
in the presence and absence of nsp1 might give hints about the structural changes of 5’ UTR 
as a function of binding.  NMR analysis of the nsp1-5’ UTR complex is an alternative way 
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to map and characterize the interactive sites at high-resolution.  Both methods can be 
employed with the nsp1 mutant (K52E) that is detrimental for viral replication (Chapter III).  
In addition, the 5’ UTR may function as a tertiary RNA structure which is a structure that is 
poorly understood at present.  Current algorithms for predictions of RNA tertiary 
conformations are available but are not accurate (136).  A comprehensive effort will be 
needed to understand the structure/function relationship of the 5’ UTR and nsp1 binding. 
 
TO EXPLORE THE POSSIBILITY AND MEANS OF 5’-3’-END CROSS 
TALK OF THE VIRAL GENOME 
     Genome circularization as a function of viral and cellular factors may be a common 
feature of positive-strand RNA viruses.  Circularization potentially provides several 
advantages to the virus for its replication including coordination of translation and genome 
replication, coordination of transcription and genome replication, coordination of viral 
macromolecules for intracellular trafficking of viral components, and controlling viral 
genome integrity (stability) (44, 48, 57, 179).  To further test our proposed model of an 
nsp1-mediated molecular switch between genome translation and negative-strand RNA 
synthesis, several fundamental questions should be studied.  First, does translation and 
replication occur at the same template simultaneously?  This would not be expected since 
the ribosome travels in the 5’Æ3’ direction and the RdRp travels in the 3’Æ5’ direction.  
To answer this question, the genome template can be analyzed for its ability to synthesize 
RNAs by purified viral RdRp in the presence or absence of translation inhibitor.  Besides, 
translation and RNA synthesis likely take place at different intracellular compartments, 
meaning that the positive-strand template would be guided to the double membrane vesicle 
after protein synthesis (158).  With regard to this presumption, is nsp1 involved in the 
events of translation shut-off and genome trafficking?  An extended question is progeny 
RNAs after genome replication still capable of serving as templates for translation in vivo, 
or they are all packaged into virions and exit the host cells?  Are there any 5’-3’-end cross 
talks during the course of viral infection?  What roles the end-to-end communications 
might play?  Future experiments addressed to these issues could bring us closer to 
understanding how viral translation and replication are regulated in infected cells. 
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EXPRESSION AND PURIFICATION OF BCOV NUCLEOCAPSID 
PROTEIN USING SUMO-FUSIONS 
     Other than its structural role in the virion, the coronaviral nucleocapsid protein (N) 
has been shown to have regulatory significance in viral RNA and protein syntheses (97).  
Giving that N was found to specifically bind the TRS, a template-switching signal, at the 3’ 
end of leader-encoding RNA, it has been proposed that N participates in viral transcription 
(i.e., production of sgmRNAs) either in a direct or regulatory manner (9, 146, 154).  N has 
also been proven to enhance the efficiency of viral replication after transfection of the 
full-length synthetically-produced RNA genome (during reverse genetics studies) (1, 131, 
132, 175).  Likewise, a correlation has been found between the affinity of N binding to the 
leader sequence on sgmRNAs and the translational efficiency of these and other mRNAs 
(experimentally constructed) (150, 151).  Although N has been known to perform these 
several non-structural functions, the mechanism by which it does so remains to be 
determined.  To begin to characterize the interaction between N and viral RNAs, we 
systematically sought the binding of E. coli-expressed BCoV N to the known putative 
cis-replication RNA elements located at the 5’ and 3’ termini of BCoV genome. 
     To prepare BCoV N for electrophoretic mobility shift assay (EMSA), the pET SUMO 
Protein Expression System (Invitrogen) was utilized for high-level expression of 
recombinant N in E. coli and cleavage of native proteins (Fig. A.1).  The small ubiquitin- 
related modifier (SUMO) is a protein that functions in post-translational modification 
(SUMOylation) by covalent attachment to other proteins (59).  SUMOylation is reversible 
through the action of specific deconjugating enzymes, i.e., SUMO proteases.  It has been 
demonstrated that fusion of SUMO at the N-terminus of other proteins can lead to enhanced 
solubility of the modified proteins (96, 187, 188).  This property makes SUMO a useful 
tag for expression of recombinant proteins.  In addition, cleavage by SUMO protease can 
result in the production of native proteins without extra conjugated moieties.  Accordingly, 
expression of a construct encoding the SUMO-N utilized the pET SUMO plasmid as the 
backbone (Fig. A.1 A).  The pET SUMO vector also bears an N-terminal 6×His tag which 
enables rapid purification of expressed SUMO-N by Ni-NTA affinity chromatography. 
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FIG. A.1.  Expression and purification of BCoV N protein by SUMO-fusion in E. coli.  (A)  Map and 
features of pET SUMO vector for expression of SUMO-N fusion protein in E. coli.  (B)  The procedure for 
purification of BCoV N expressed with SUMO-fusion system in E. coli and cleavage of 6x His-SUMO-tagged 
protein.  (C)  Aliquots of the samples from various steps of the purification procedure were resolved by 
12% SDS-PAGE and stained with Coomassie blue.  The migration positions of molecular weight markers, 
SUMO-N, and N resulting from final protease cleavage are as indicated. 
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     The procedure for purifying BCoV N is illustrated in Fig. A.2 B.  SDS-PAGE and 
Coomassie blue staining were used to evaluate the effectiveness of the purification steps and 
the cleavage of the SUMO-N fusion protein (Fig. A.2 C).  Briefly, BL21 (DE3) E. coli 
cells transformed with pSUMO-N was inoculated 5 ml of LB medium containing 50 g/ml 
kanamycin and cells were grown at 37 °C overnight with shaking at 250 rpm.  The 
overnight culture was transferred into 500 ml fresh LB medium to permit exponential 
growth until ~0.6 OD600.  Protein expression was induced with 1 mM IPTG (isopropyl-β- 
D-thiogalactopyranoside) and cells were incubated for another 20 h at 20 °C with shaking at 
200 rpm.  The E. coli cells were harvested by centrifugation at 5,000 × g for 20 min at 4 °C, 
flash frozen in liquid N2, and resuspended by probe sonication (3 × 10 sec bursts, on ice) in 
lysis buffer (PBS containing 200 mM NaCl, 10 mM imidazole, 5% glycerol, 1% Triton 
X-100, 1mg/ml lysozyme, 1 mM PMSF [phenylmethanesulphonylfluoride], 25 U/ml 
Benzonase endonuclease [Novagen], and 1× EDTA-free Complete Protease Inhibitor 
[Roche], pH 7.8) at 3 ml per 1 g of cells.  The lysed cells were centrifuged at 20,000 × g 
for 30 min at 4 °C, and supernatant was collected as the soluble fraction.  The soluble 
fraction was incubated with ~2 ml Ni-NTA superflow resin (Qiagen) for 2 h at 4 °C on an 
orbital shaker.  The mixture was loaded onto a Poly-Prep chromatography column 
(Bio-Rad) and the samples of flow-through containing unbound proteins were collected.  
The resin was extensively washed with ~50-100 ml of wash buffer (lysis buffer containing 
20 mM imidazole) at 4 °C until OD280 value reached the base line (UV value = 0).  The 
SUMO-N fusion protein was eluted with 4 ml elution buffer (PBS containing 200 mM NaCl, 
300 mm imidazole, pH 7.8) where different fractions were checked on SDS-PAGE and 
pooled.  The purified SUMO-N was dialyzed and concentrated with YM-30 membranes 
(30 kDa cutoff, Millipore) against PBS at 4 °C to remove high salt and imidazole.  
Cleavage of SUMO by SUMO protease and recovery of native BCoV N by reloading onto a 
column with Ni-NTA resin were achieved in accordance with the manufacturer’s protocol 
(Invitrogen and Qiagen).  The concentration of final eluted BCoV N was determined using 
the Bradford color-reaction assay (Bio-Rad) measured spectrophotometrically at 595 nm 
with bovine serum albumin as a standard.  Purified BCoV N samples were stored at -80 °C 
after glycerol was added to 10%. 
 109
BCOV N BINDS CIS-REPLICATION STRUCTURES IN THE 5’ UTR 
     To determine the binding capability of purified E. coli-expressed BCoV N protein to 
terminal cis-replication RNA elements, N protein was systematically incubated with 32P- 
labeled RNA probes that included the three 5’ UTR-located elements, SLI-SLII [(+) 1-98 nt], 
SLIII [(+) 69-182 nt], SLIV [(+) 152-262 nt], the nsp1-cistron-located SLV-SLVI [(+) 231- 
364 nt], and the two 3’ UTR-located elements, the BSL-PK [(+) 291-159 nt] and the HVR 
[(+) 162-1 nt] (Fig. A.2 A).  To make the RNA probes for EMSAs, primers bordering the 
respective elements that had incorporated the EcoRI and HindIII restriction enzyme sites for 
directional ligation into EcoRI/HindIII-digested pGEM3Zf(-) vector (Promega) were used 
for PCR amplification.  To synthesize and radiolabel RNA probes, 2 μg of Hind III- 
digested plasmid DNA was transcribed in a 50-μl reaction mixture containing 40 U of T7 
RNA polymerase (Promega), 0.5 mM rNTP mixture of ATP, GTP, and CTP, 120 μCi of 
[α32P]UTP (3,000 Ci/mmole) (MP Biomedicals), 100 mM DTT, 0.1 μg/μl acetylated BSA, 
and 1 U/μl RNasin (Promega) at 37 °C for 2 h.  The mixture was then treated with 2.5 U of 
RQ1 RNase-free DNase (Promega) at 37 °C for 30 min, and probes were purified by 
electrophoresis on a 6%-polyacrylamide-7M urea gel.  RNA visualized by autoradiography 
was eluted from the excised gel band overnight at 4 °C in elution buffer (1 mM EDTA, 0.5 
M ammonium acetate) and ethanol precipitated.  Cerenkov counts were determined by 
scintillation counting in water.  RNA probes were quantified spectrophotometrically. 
     The procedure for EMSA was as described by Andino et al. (6) and modified by 
Silvera et al. (138).  Briefly, ~4 × 104 cpm of α32P-labeled RNA probe (2-5 ng) was 
incubated in a 20-μl binding reaction mixture containing 5 mM HEPES (pH 7.9), 40 mM 
KCl, 2 mM MgCl2, 4% glycerol, 2 mM DTT, 0.25 μg/μl heparin, 0.5 μg/μl yeast tRNA, 1 
U/μl RNasin (Promega), 1× EDTA-free Complete Protease Inhibitor (Roche), and indicated 
amounts of N protein.  The mixture was pre-incubated without probe at 30 °C for 10 min, 
followed by additional 10 min incubation after probe was added.  Two μl of 50% glycerol 
was added, and then mixtures were electrophoretically separated on a 6% nondenaturing 
polyacrylamide gel at 4 °C for 4 h using 0.5× TBE (45 mM Tris-borate and 1 mM EDTA) as 
running buffer.  Gels were dried and exposed to Kodak XAR-5 film, and the radiolabeled 
bands were visualized by autoradiography and quantified by phosphor imaging. 
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FIG. A.2.  RNA structures in the BCoV genome tested for BCoV N binding.  (A)  The organization of 
the BCoV genome is shown at the top.  Below this is a schematic diagram of the current model for the BCoV 
5’ and 3’ terminal cis-replication RNA secondary structures required for BCoV DI RNA replication.  Six 
stem-loops (SL I-VI) and three higher-order structures are depicted.  Solid circles at nt 210 denote the AUG 
start codon for ORF 1 whose coding sequence is depicted by a thickened line.  The stop codon UAA for the 
N-gene preceding the 3’ UTR is boxed.  All nt numbering is from the first base at the 5’ and 3’ ends of the 
genome, respectively.  Shown below the RNA structures are the RNA segments (solid lines) used as 
32P-labeled probes in the EMSAs.  BSL, bulged stem-loop; PK, pseudoknot; HVR, 3’ hypervariable region.  
(B)  EMSA results when purified BCoV N protein mixes with the respective probes indicated at the top of 
each gel.  Arrows identify the positions of free RNA probes.  Brackets [C] identify the shifted probe as the 
result of an N protein:RNA complex. 
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     In the EMSA experiments, N was not found to bind the RNA probes encompassing 
the 5’-proximal SLIV [(+) 152-262 nt] and the SLV-SLVI [(+) 231-364 nt], or the 
3’-proximal BSL-PK [(+) 291-159 nt] and HVR [(+) 162-1 nt] (Fig. A.2 B).  By contrast, 
N bound weakly to the RNA probe harboring the 5’-proximal SLI-SLII [(+) 1-98 nt] and 
strongly bound to the probe bearing the SLIII [(+) 69-182 nt] (which contained the extended 
flanking sequences of 15 nt upstream and 53 nt downstream).  The weak interaction 
between N and SLI-SLII is consistent with previous observations showing this same 
interaction by co-immunoprecipitation and by Northwestern blotting analysis (9, 146).  
The EMSA results, therefore, are consistent with the hypothesis that this interaction plays a 
role in the discontinuous RNA transcription event (i.e., RdRp template switching event) 
since the UCUAAAC template switching signal is within the loop of SLII.  In addition, 
this is the first report of a direct interaction between any coronaviral protein and SLIII.  
The binding of SLIII shown here confirms and extends earlier observations from our 
laboratory (S. Raman, PhD dissertation, 2003) that an unknown viral protein of 55 kDa 
(similar in molecular weight to N and therefore presumed to be N) in BCoV-infected cell 
was UV-crosslinked to the SLIII RNA probe, (+) 69-182 nt, and supershifted in an EMSA 
with antiserum to N.  Taken together, these results indicated N may function to regulate 
RNA synthesis or translation of the genome through its interaction with 5’ cis-replication 
SLI, SLII, or SLIII, or some combination of these, but not through the binding of the 
5’-proximal SLIV, SLV, and SLVI, or the 3’-proximal RNA cis-replication elements. 
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BCOV N BINDS SLIII WITH SPECIFICITY AND MICROMOLAR 
AFFINITY 
     To determine the binding specificity of BCoV N to the SLIII and its flanking 
sequences [nt 69 to182 in the 5’ UTR; the probe: (+) 69-182 nt], EMSAs were carried out 
following the procedure described for Fig. A.2 except that specific or non-specific RNA 
competitors, as indicated, was incubated in the binding reaction mixture for 10 min at 30 °C 
prior to the addition of the labeled probe (Fig. A.3 A-B).  Figure A.3 B, lane 1, shows that 
the (+) 69-182 nt probe migrates as upper and lower bands, presumably representing two 
folded forms of the molecule.  Lanes 2-4 show a positive correlation between increasing 
amounts of N in the reaction and a greater abundance of the shifted bands.  Lanes 5-7 
show a complete inhibition of probe shifting with 5, 10, and 15 μg of unlabeled probe, 
representing 2500, 5000, and 7500 molar excess over labeled probe, respectively, whereas 
no inhibition was seen with 5, 10, and 15 µg of yeast tRNA (lanes 8-10).  These results 
demonstrate a specific binding of BCoV N to the SLIII-bearing probe. 
     To determine the binding affinity of N to the SLIII-bearing probe, (+) 69-182 nt, 
EMSA was carried out in which serial dilutions of N were added to a constant nanomolar 
amount of the probe (Fig. A.3 C).  Lane 1 shows the two migrating forms of the free probe 
as observed in Fig. A.3 B.  Lanes 2-9 show the band-shifting complexes with increasing 
concentrations of N.  From these results it appears that complex 1 resulted from N binding 
to the lower-migrating form of the probe with a Kd (dissociation constant) of ~0.2 μM.  
This result suggests a single N-binding site on the lower-migrating form of the probe.  
Surprisingly, multiple shifted bands (complexes 2-4) were observed in the mobility shifting 
that apparently arose from the upper-migrating form of the probe, suggesting sequential 
loading of N onto the RNA probe as the amounts of N increased, perhaps reflecting 
cooperative binding.  The binding affinities of N to these multiple sites were not 
determined.  To verify the correlation between the two folded forms of the free probe and 
corresponding shifted bands, the RNA probe was heated to 95 °C for 5 min and snap-cooled 
on ice in an attempt to generate a single secondary structure for the probe.  The EMSA 
procedure was then carried out as described for Fig. A.3 C with this treated probe (Fig. A.3 
D) (31).  Interestingly, after the heatÆsnap-cool treatment, the upper-migrating form of 
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FIG. A.3.  EMSA of purified BCoV N protein binding to the positive-strand RNA probe, (+) 69-182 nt.  
(A)  Schematic identification of cis-replication stem-loops I-IV in the BCoV 5’ UTR.  Shown below the 
stem-loops is the RNA segment (solid line) used as the 32P-labeled probe in the EMSA described in panels B, 
C, and D.  2.5 nM of 32P-labeled probe was used in each reaction for the EMSA.  (B)  Lane 1, probe alone 
showing the upper and lower migrating forms; lanes 2-4, shifted bands into lower [C1] and upper [C2] 
complexes that form with the indicated amounts of N; lanes 5-7, competition of N binding with 5, 10, and 15 
µg of unlabeled probe; lanes 8-10, competition of N binding with 5, 10, and 15 µg of yeast tRNA over and 
above the initial yeast tRNA in the binding buffer present in all lanes.  (C)  Lane 1, probe alone showing the 
upper and lower migrating forms; lanes 2-9, shifted bands into lower [C1] and upper [C2-C4] complexes that 
form with the indicated amounts of N.  (D)  The same experiment as described in panel (C) except that the 
32P-labeled probe was heated and then snap-cooled (95 °C, 5 min, then 4 °C, 10 min) before adding to the 
probe reaction mixture.  Lane 1, probe alone showing a single migrating form; lanes 2-10, a shifted band [C] 
identifying the complex that forms with the indicated amounts of N.  In panels B, C, and D, arrows indicate 
the positions of free probes. 
free probe disappeared (Fig. A.3 D, lane 1), suggesting the formation of the upper-migrating 
form of the probe had occurred gradually in the buffered conditions during overnight elution 
at 4 °C from the denaturing gel during probe preparation.  As anticipated, lanes 2-10 show 
only a single shifted band, identifying a Kd value of ~0.2 μM.  These results indicate that 
indeed the single and fastest migrating RNA:protein complex resulted from the lower- 
migrating form of the RNA probe. 
     To confirm the binding specificity of N to the SLIII proper, two analyses were carried 
out that were based on the EMSA procedure (Fig. A.4).  First, the radiolabeled probe 
nearly representing the SLIII, (+) 85-126 nt, was used for EMSA along with specific and 
non-specific competitors (Fig. A.4 B).  Lane 1 shows the probe migrating as a single band 
even without the heatÆsnap-cool treatment, indicating a spontaneous tendency for the 
probe to yield a single secondary structure.  Lanes 2-4 show far less quantitative shifting of 
the probe [than the probe of (+) 69-182 nt, Fig. A.3] with increasing concentrations of N, 
thus binding affinity could not be determined in this experiment.  Lanes 5-7, however, 
show that shifted band with 0.75 μM N was completely inhibited by the addition of 4, 8, 
and 12 μg of unlabeled probe, whereas lanes 8-10 show no inhibition of binding with 4, 8, 
12 μg of yeast tRNA.  These results show weaker but still specific binding of N to the (+) 
85-126 nt probe as compared to the (+) 69-182 nt probe.  In the second approach, binding 
of N to the heatÆsnap-cooled (+) 69-182 nt probe was evaluated by adding competitors of 
SLIII and flanking sequences, respectively (Fig. A.4 C).  The RNA segments used as a 
32P-labeled probe, (+) 69-182 nt, or unlabeled competitor, (+) 85-126 nt and (+) 127-182 nt, 
were depicted along with putative 5’ UTR cis-acting stem-loop structures in Fig. A.4 A.  
Figure A.4 C, lane 1, shows the migration of a single band of free (+) 69-182 nt probe after 
heatÆsnap-cool treatment as demonstrated in Fig. A.3 D, and thereby a single shifted band 
was observed with the addition of N as shown in lanes 2-4.  Significantly, lanes 5-7 show 
the shifted band with 0.2 μM of N was completely inhibited by the addition of 80, 160, and 
240 ng, respectively, of unlabeled (+) 85-126 nt probe.  Yet the competitions were not seen 
in lanes 8-10 where 80, 160, and 240 ng of unlabeled (+) 127-182 nt probe was added, 
respectively.  Neither was the competition observed with the addition of 0.4, 0.8, and 1.6 
μg yeast tRNA as shown in lanes 11-13.  Taken together, these results show that whereas  
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FIG. A.4.  EMSA of purified BCoV N binding to the positive-strand RNA probe, (+) 85-126 nt.  (A)  
Schematic identification of cis-replication stem-loops I-IV in the BCoV 5’ UTR.  Shown below the 
stem-loops are the RNA segments (solid lines) used as 32P-labeled probes in the EMSAs described in panels B 
and C.  (B)  5 nM of 32P-labeled probe, (+) 85-126 nt, was used in each reaction for the EMSA.  Lane 1, 
probe alone showing a single migrating form; lanes 2-4, a shifted band [C] that forms with the indicated 
amounts of N protein; lanes 5-7, N binding in the presence of 4, 8, and 12 µg unlabeled probe, (+) 85-126 nt; 
lanes 8-10, N binding in the presence of 4, 8, and 12 µg yeast tRNA over and above the initial yeast tRNA in 
the binding buffer present in all lanes.  (C)  10 nM of 32P-labeled probe, (+) 69-182 nt, was heated and 
snap-cooled, and used in each reaction for the EMSA.  Lane 1, probe alone showing a single migrating form; 
lanes 2-4, a shifted band [C] that forms with the indicated amounts of N; lanes 5-7, N binding in the presence 
of 80, 160, and 240 ng of unlabeled probe, (+) 85-126 nt; lanes 8-10, N binding in the presence of 80, 160 and 
240 ng of unlabeled probe, (+) 127-182 nt; lanes 11-13, N binding in the presence of 0.4, 0.8, and 1.6 µg of 
yeast tRNA over and above the initial yeast tRNA in the binding buffer present in all lanes.  In panels B and 
C, arrows indicate the positions of free probes.  
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SLIII per se is a specific target for N protein binding, the presence of its extended flanking 
sequences probably contributes to increase the binding affinity and/or permit the folding of 
an alternative higher-order structure of SLIII. 
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BCOV NSP1 BINDS SLIII AND ITS FLANKING SEQUENCES WITH 
SPECIFICITY AND MICROMOLAR AFFINITY 
     In an early collaborative set of experiments with Kortney Gustin (PhD, 2008) and 
others in the laboratory, binding of BCoV nsp1 to BCoV 5’ UTR cis-replication elements 
was studied (55).  Here, is a detailed description of that piece of work.  In retrospect, 
since MHV nsp1 in more recent experiments has been shown by genetic evidence to 
specifically interact with its homologous 5’ UTR (Chapter III), these experiments have 
become even more important.  To determine whether BCoV nsp1 binds the putative 
5’-proximal cis-replication elements within the BCoV 5’ UTR, same experimental scheme 
was employed.  First, a similar procedure as described for BCoV N was utilized to 
construct, express, and purify recombinant BCoV nsp1 protein from E. coli expression 
system (55).  Secondly, in cooperation with lab colleagues, we have learned that BCoV 
nsp1 is an RNA-binding protein that weakly binds 5’-terminal SLI-SLII and SLIV, 
moderately binds 3’-terminal BSL-PK, and strongly binds the SLIII with its extended 
flanking sequence (55).  These data indicates that nsp1 may function with these 
cis-replication elements by using a variety of binding sites and affinities. 
     Having learned that BCoV nsp1 causes a strong band shifting in the (+) 69-182 nt 
probe representing SLIII with its extended flanking sequences (55), we aimed to establish 
both its specificity and affinity of binding.  To determine the binding specificity and 
affinity of nsp1 to the probe (+) 69-182 nt, EMSAs were used following the procedure 
described for N binding.  Figure A.5 B, lane 1, shows that the SLIII-bearing probe, (+) 
69-182 nt, migrates as upper and lower bands, representing two presumably different folded 
forms.  Lane 2-4 shows a positive correlation between an increasing amount of nsp1 in the 
reaction and a greater abundance of the shifted bands.  Two separately shifted bands were 
found, presumably arising from the binding of nsp1 to the upper- and lower-migrating 
forms of the free probe, respectively.  In contrast to the multiple shifted complexes from 
the binding of N to the upper-migrating form of the probe, nsp1 appeared to form only a 
single shifted complex from both forms of the probe, suggesting a single nsp1-binding site 
or multiple binding sites with very strong cooperativity.  In addition, lane 2 shows 
approximately 50% of the lower-migrating form and all of the upper-migrating form of the  
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FIG. A.5.  EMSA of purified BCoV nsp1 binding to the positive-strand probes, (+) 69-182 nt and (+) 
85-126 nt.  (A)  Schematic identification of cis-replication stem-loops I-IV in the BCoV 5’ UTR.  Shown 
below the stem-loops are the RNA segments (solid lines) used as 32P-labeled probes in the EMSAs shown in 
panels B, C, and D.  (B)  2.5 nM of 32P-labeled probe, (+) 69-182 nt, was used in each reaction for the 
EMSA.  Lane 1, probe alone showing upper and lower migrating forms; lanes 2-4, shifted bands into lower 
[C1] and upper [C2] complexes that form with the indicated amounts of nsp1; lanes 5-7, competition of nsp1 
binding with 5, 10, and 15 µg of unlabeled probe; lanes 8-10, competition of nsp1 binding with 5, 10, and 15 
µg of yeast tRNA over and above the tRNA in the binding buffer present in all lanes.  (C)  5 nM of 
32P-labeled probe, (+) 85-126 nt, was used in each reaction for the EMSA.  Lane 1, probe alone showing a 
single migrating form; lanes 2-4, a shifted band [C] that forms with the indicated amounts of nsp1; lanes 5-7, 
competition of nsp1 binding with 4, 8, and 12 µg of unlabeled probe, (+) 85-126 nt; lanes 8-10, competition of 
nsp1 binding with 4, 8, and 12 µg of yeast tRNA over and above the initial yeast tRNA in the binding buffer 
present in all lanes.  (D)  10 nM of 32P-labeled probe, (+) 69-182 nt, was heated and snap-cooled, and used 
in each reaction for the EMSA.  Lane 1, probe alone showing a single migrating form; lanes 2-4, a shifted 
band [C] that forms with the indicated amounts of nsp1; lanes 5-7, competition of nsp1 binding with 80, 160, 
and 240 ng of unlabeled probe, (+) 85-126 nt; lanes 8-10, competition of nsp1 binding with 80, 160 and 240 
ng of unlabeled probe, (+) 127-182 nt; lanes 11-13, competition of nsp1 binding with 0.4, 0.8, and 1.6 µg of 
yeast tRNA over and above the tRNA in the binding buffer present in all lanes.  Arrows indicate the positions 
of free probes.  
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probe fully shifting positions with 2.5 μM nsp1, indicating a Kd of ~2.5 μM for nsp1 
binding.  Lanes 5-7 show a complete inhibition of probe (+) 69-182 nt shifting with 5, 10, 
and 15 μg of unlabeled probe, representing 2500, 5000, and 7500 molar excess over labeled 
probe, respectively, whereas no inhibition was seen with 5, 10 and 15 μg of yeast tRNA.  
These results together show specific binding of nsp1 to the SLIII-bearing probe (+) 69-182 
nt. 
     To confirm the binding specificity of nsp1 to the SLIII proper, a probe which harbors 
only the SLIII was also used and the results were compared to SLIII with the longer 
flanking sequences.  Two EMSAs were carried out (Fig. A.5 C and D).  First, a probe 
nearly representing the SLIII per se, (+) 85-126 nt, was used for the EMSA along with 
specific (unlabeled probe RNA) and non-specific (yeast tRNA) competitors (Fig. A.5 C).  
Lane 1 shows the probe (+) 85-126 nt migrating as a single band even without heatÆsnap- 
cool treatment, indicating a tendency of this SLIII structure to readily form spontaneously.  
Lanes 2-4 show far less quantitative shifting of the probe to an upper band with increasing 
amounts of nsp1 than was seen with the longer flanking regions (Fig. A.5 B).  Thus, a 
binding affinity could not be determined by these experiments.  Lanes 5-7, however, show 
that a shifted band with 2.5 μM nsp1 was completely inhibited by the addition of 4, 8, and 
12 μg, respectively, of unlabeled (+) 85-126 nt probe, whereas lanes 8-10 show no 
inhibition of binding with 4, 8, 12 μg of yeast tRNA.  These results show weaker but still 
specific binding of nsp1 to the SLIII per se.  In the second approach, binding of nsp1 to the 
heatÆsnap-cooled (+) 69-182 nt probe (with the longer flanking regions) was sought in the 
presence of three potential competitors: unlabeled SLIII [(+) 69-182 nt], unlabeled 55-nt 
RNA region between SLIII and SLIV representing no stem-loop [(+) 127-182 nt], and 
unlabeled yeast tRNA (Fig. A.5 A and D).  Figure A.5 D, lane 1, shows the migration of a 
single band of free (+) 69-182 nt probe after heatÆsnap-cool treatment as demonstrated in 
Figs. A.3 D and A.4 C, and therefore only a single shifted band were observed with the 
addition of nsp1 as shown in lanes 2-4.  Lanes 5-7 show a weak shifted band with 1.6 μM 
nsp1 that was essentially all competed out by the addition of 240 ng competitor of SLIII 
RNA probe (+) 85-126 nt, as shown in lane 7.  Little or no competition was seen in lanes 
8-10 with 80, 160, and 240 ng of unlabeled nonstructured RNA probe (+) 127-182 nt, or in 
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lanes 11-13 with 0.4, 0.8, and 1.6 μg of yeast tRNA.  Taken together, these results show 
that whereas SLIII per se is likely a specific target for nsp1 binding, the presence of its 
extended flanking sequences probably contribute to an increase of the binding affinity 
and/or permit the folding of an alternative higher-order structure of SLIII that enhances 
binding. 
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BCOV N AND NSP1 BIND THE NEGATIVE-STRAND COUNTERPART 
OF SLIII 
     The functional importance of the negative-strand counterparts of genomic and 
subgenomic RNAs of coronaviruses is much less understood.  One widely supported idea 
for the role of negative-strand RNA in coronaviruses life cycle is that template switching 
takes place from an internal site on the positive-strand genome to a site near the 5’ end of 
the genome during the generation of negative-strand RNAs to produce a subgenomic 
mRNA-length negative strand from which the positive-strand subgenomic RNA are 
synthesized (130).  It is also speculated that the coronavirus genome 5'-proximal end is a 
partially double-stranded structure that, as a double-stranded structure, facilitates the 
template switching step (168, 170).  The functional activities of the negative-strands are 
probably also achieved through interactions with cellular and viral proteins.  To date, 
however, only cellular proteins hnRNP A1, SYNCRIP and PTB have been shown to bind 
the negative-strand counterparts of 5’ UTR and 3’ UTR of MHV genome (30, 46, 65, 181). 
     Having shown that BCoV N and nsp1 specifically bind the SLIII with high affinity 
and behaves in a potentially multiple site-binding manner, we sought to examine the 
binding capacity of N and nsp1 to the negative-strand of SLIII with the same experimental 
approach (Fig. A.6).  The plasmids for generating the positive-strand probes for EMSAs 
were used to make the RNA probes of negative-strand counterparts except the DNA 
template was digested with EcoRI (not HindIII) followed by in vitro RNA transcription with 
SP6 RNA polymerase (not T7 RNA polymerase).  EMSAs were done following the same 
procedure described above for binding positive-strand RNA.  Figure A.6 B, lane 1, shows 
that the probe, (-) 69-182 nt, migrates similarly to its positive-strand counterpart in that it 
migrates as upper and lower bands, probably representing two folded forms of the probe.  
The structure of the predicted negative-strand of SLIII has not yet been examined by 
structure probing.  Lanes 2-4 show a positive correlation between increasing amounts of N 
and shifted bands.  Interestingly, the shifted bands appeared to result from only the 
upper-migrating but not from the lower-migrating form of the probe, suggesting a certain 
structure of the negative-strand probe is a prerequisite for N binding.  In addition, shifted 
band with 0.75 μM of N was completely inhibited by the addition of unlabeled probe, (-)  
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FIG. A.6.  EMSA of purified BCoV N binding to the negative-strand probes, (-) 69-182 nt and (-) 85-126 
nt.  (A)  Schematic identification of cis-replication stem-loops in the BCoV genomic 5’ UTR.  Shown 
below the stem-loops are the RNA segments (broken lines) used as negative-strand 32P-labeled probes for the 
EMSAs described in panels B, C, and D.  (B)  2.5 nM of 32P-labeled probe, (–) 69-182 nt, was used in each 
reaction for the EMSA.  Lane 1, probe alone showing upper and lower migrating forms; lanes 2-4, a shifted 
band [C] that forms with indicated amounts of N; lanes 5-7, competition of N binding with 0.5, 1, and 1.5 µg 
of unlabeled probe, (–) 69-182 nt; lanes 8-10, competition of N binding with 4, 8, and 12 µg of yeast tRNA 
over and above the tRNA in the binding buffer present in all lanes.  (C)  The same experiment as shown in 
panel (B) except that the 32P-labeled probe was heated and snap-cooled (95 °C, 5 min then 4 °C, 10 min) 
before adding to the reaction mixture.  Lane 1, probe alone showing migration of a single form; lanes 2-6, no 
shifted bands observed under the conditions described for panel B.  (D)  5 nM of 32P-labeled probe, (–) 
85-126 nt, was used in each reaction for the EMSA.  Lane 1, probe alone showing a single migrating form; 
lanes 2-4, a shifted band [C] that forms with the indicated amounts of N; lanes 5-7, competition of N binding 
with 1.5, 3, and 4.5 µg of unlabeled probe, (–) 85-126 nt; lanes 8-10, competition of N binding with 4, 8, and 
12 µg of yeast tRNA over and above the tRNA in the binding buffer present in all lanes.  In panels B, C, and 
D, arrows indicate the positions of free probes.  
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69-182 nt (lanes 5-7), but not by yeast tRNA (lanes 8-10), indicating a specific interaction 
between N protein and the negative-strand RNA region of SLIII.  The shifted band of the 
(-) 69-182 nt probe disappeared once the probe had been heatÆsnap-cooled, indicating that 
the upper-migrating form of the probe for N binding can only occur after it has properly 
re-folded (after the urea treatment) to a native structure under the overnight elution 
conditions at 4 °C in buffered solution (Fig. A.6 C). 
     To confirm the binding specificity of N to the negative-strand form of SLIII RNA and 
not its flanking sequences, a similar strategy was designed but for a probe that represented 
the negative-strand form of SLIII proper, (-) 85-126 nt (Fig. A.6.A).  This probe was used 
for the EMSA along with putative specific and non-specific competitors (Fig. A.6 D).  
Lane 1 shows the (-) 85-126 nt probe migrating as a single band without the heatÆsnap- 
cool treatment, indicating a tendency for the negative-strand SLIII structure to maintain a 
single folded form.  Lanes 2-4 show that very little shifting of the probe occurs, far less 
quantitative, with increasing concentration of nsp1, yet the shifted band with 0.75 μM N 
was clearly inhibited by unlabeled (-) 85-126 nt probe (lanes 5-7) but not inhibited by yeast 
tRNA (lanes 8-10).  Taken together, these results show a much weaker but still specific 
binding of N to the negative-strand form of SLIII per se, whereas its extended downstream 
flanking sequences greatly enhanced this binding affinity.  It is possible that N binds this 
negative-strand RNA, i.e., the RNA between SLIII and SLIV, with significant affinity.  
Inasmuch as this sequence in the positive-strand represents an important 32-nt unstructured 
RNA for nsp1 binding (Chapter III), further studies should be done on it in the MHV 
reverse genetics system. 
     To determine if BCoV nsp1 also binds the negative-strand counterpart of SLIII, 
similar EMSAs were carried out with the same probes described for Fig. A.6 (Fig. A.7).  
Interestingly, shifted bands were observed not only with the upper-migrating form of (-) 
69-182 nt probe with the long flanking regions, but also the lower-migrating form of the 
probe (Fig. A.7 B, lanes 2-4).  Both shifted bands were specifically inhibited by unlabeled 
(-) 69-182 nt RNA (lanes 5-7) but not by yeast tRNA (lanes 8-10).  EMSA was also carried 
out with SLIII proper (-) 85-126 nt probe (Fig. A.7 C).  In this experiment shifted bands 
were observed (lanes 2-4), although far less than quantitative, and binding was shown to be  
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FIG. A.7.  EMSA of purified BCoV nsp1 binding to the negative-strand RNA probes, (-) 69-182 nt and 
(-) 85-126 nt.  (A)  Schematic identification of cis-replication stem-loops in the BCoV 5’ UTR.  Shown 
below the stem-loops are the RNA segments (broken lines) used as negative-strand 32P-labeled probes for the 
EMSAs described in panels B and C.  (B)  2.5 nM of 32P-labeled probe, (-) 69-182 nt, was used in each 
reaction for the EMSA.  Lane 1, probe alone showing upper and lower migrating forms; lanes 2-4, shifted 
bands identify the lower [C1] and upper [C2] complexes that formed with indicated amounts of nsp1; lanes 
5-7, competition of nsp1 binding with 0.5, 1, and 1.5 µg of unlabeled probe, (–) 69-182 nt; lanes 8-10, 
competition of nsp1 binding with 4, 8, and 12 µg of yeast tRNA over and above the tRNA in the binding 
buffer present in all lanes.  (C)  5 nM of 32P-labeled probe, (–) 85-126 nt, was used in each reaction for the 
EMSA.  Lane 1, probe alone showing a single migrating form; lanes 2-4, a shifted band [C] that forms with 
the indicated amounts of nsp1; lanes 5-7, competition of nsp1 binding with 1.5, 3, and 4.5 µg of unlabeled 
probe, (–) 85-126 nt; lanes 8-10, competition of nsp1 binding with 4, 8, and 12 µg of yeast tRNA over and 
above the tRNA in the binding buffer present in all lanes.  In panels B and C, arrows indicate the positions of 
free probes.  
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specific as evidenced by inhibition of binding with unlabeled (-) 85-126 nt probe (lanes 5-7) 
but not with yeast tRNAs (lanes 8-10).  These results together indicate that negative-strand 
SLIII per se is also a specific binding target for nsp1 binding, and suggests that the extended 
flanking sequence contributes to the binding.  Enhanced binding by the flanking sequence 
could be a function of direct binding to the flanking sequence, or altered capacity of SLIII 
binding due to altered folding.  Whether interplay between N and nsp1 is cooperative or 
competitive for the binding of SLIII-bearing negative-strand RNA and its flanking sequence 
remains to be determined. 
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THERE IS NO DETECTABLE RNA-RNA INTERACTION BETWEEN 
THE 5’ AND 3’ UTRS OF BCOV BASED ON A GEL-SHIFT ASSAY 
     Accumulative evidence has pointed to a hypothesis that RNA genomic circularization 
through a protein-protein bridge or RNA-RNA cross talk may be a general replication 
mechanism for positive-strand RNA viruses (4, 57, 127).  The long-range interaction 
between the 5’ and 3’ ends of viral genome has been implicated in the regulation of 
translation, initiation of negative-strand RNA synthesis, and the switch between them (44, 
48, 161).  While several cellular and viral proteins have been proposed to function in 
coronaviruses as mediators of 5’-3’-end cross talk, based on their UTR-binding properties, 
terminal RNA-RNA interactions have never been experimentally ruled out.  To directly 
examine an RNA-RNA interaction between the termini of the BCoV genome, RNA binding 
assays were established as described by Alvarez et al. (4) who used the assay to examine the 
termini interaction of flavivirus genome.  32P-labeled RNA probes of the 3’ UTR-located 
BSL-PK structure [(+) 291-159 nt] and the HVR structure [(+) 162-1 nt] were obtained by 
in vitro transcription and were purified through 6% PAGE with 7M urea (Fig. A.8 A).  
Unlabeled RNA probes encompassing different 5’- and 3’-terminal cis-replication elements 
were prepared from the RiboMax kit (Promega) along with Bio-spin 6 column purification 
(Bio-Rad) and quantified spectrophotometrically (Fig. A.8 A).  Both labeled and unlabeled 
RNA samples were heat denatured at 85 °C for 5 min and slow-cooled to room temperature.  
Different unlabeled RNA probes were added to the binding mixture which contained 5mM 
HEPES, pH 7.9, 100mM KCl, 5mM MgCl2, 3.8% glycerol, 2.5 μg tRNA, and 32P-labeled 
RNA probe (0.4 nM, 13,000 cpm) in a final volume of 30 μl.  RNA:RNA complexes were 
analyzed by electrophoresis through native 6% polyacrylamide gels supplemented with 5% 
glycerol.  Gels were pre-run for 1 h at 4 °C at 150 V, and then mixtures were loaded with 
additional 2 μl 50% glycerol followed by electrophoresis at 4 °C for 4 h.  Gels were dried 
and visualized by autoradiography.  Non-detectable RNA-binding shifts were observed 
when four different RNA probes representing the 5’-terminal located cis-replication 
elements were analyzed for their binding ability to the 3’ UTR-located BSL-PK and HVR, 
respectively (Fig. A.8 B and C).  These results suggest the absence of a physical 
RNA-RNA contact between 5’ and 3’ ends of the BCoV genome.  This negative evidence  
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FIG. A.8.  Positive-strand RNA-RNA binding analysis between the BCoV 5’ and 3’ terminal 
cis-replication RNA elements.  (A)  A model of BCoV 5’ and 3’ terminal cis-replication RNA secondary 
structures identified for BCoV DI RNA replication.  Shown below the 3’ UTR RNA structures are two (+) 
RNA segments (mosaic lines) used as 32P-labeled probes.  Also shown are two (-) RNA segments (broken 
lines) used as respective unlabeled binder to each probe in the binding assays.  Shown below the 5’ terminal 
RNA structures are four unlabeled (+) RNAs (solid lines) tested for 5’-3’ RNA-RNA interaction.  (B) and (C)  
The RNA probes present in the binding assays are indicated at the top.  Binding assays were carried out with 
increasing amounts of unlabeled RNA (+) 1-98 nt (lanes 1-4), (+) 69-182 nt (lanes 5-8), (+) 152-262 nt (lanes 
9-12), (+) 231 to 364 nt (lanes 13-16), and respective negative-strand counterpart of each probe (lanes 17-20).  
Arrows indicate the positions of free RNA probes.  Shifted band in (B) and shifted bands in (C) showed the 
complexes [C] that form with the indicated amounts of RNAs. 
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is consistent with the fact that significant base-pairing between the 5’ and 3’ ends of 
coronavirus genome have not been found by inspection or by computer analysis.  However, 
it remains possible that RNA conformational changes arising from protein binding may lead 
to potential RNA-RNA interaction. 
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